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Thesis Summary 
 
Orally disintegrating tablets (ODTs) which are also referred to as orodispersible and 
fast disintegrating tablets, are solid oral dosage forms which upon placing on the 
tongue, disperse/disintegrate rapidly before being swallowed as a suspension or 
solution. ODTs are therefore easier and more convenient to administer than 
conventional tablets and are particularly beneficial for paediatric and geriatric patients, 
who generally have difficulty swallowing their medication.  
 
The work presented in this thesis involved the formulation and process development of 
ODTs, prepared using freeze-drying. Gelatin is one of the principal excipients used in 
the formulation of freeze-dried ODTs. One of the studies presented in this thesis 
investigated the potential modification of the properties of this excipient, in order to 
improve the performance of the tablets. As gelatin is derived from animal sources, a 
number of ethical issues surround its use as an excipient in pharmaceutical 
preparations. This was one of the motivations, Methocel™ and Kollicoat® IR were 
evaluated as binders as alternative materials to gelatin. Polyox™ was also evaluated as 
a binder together with its potential uses as a viscosity increasing and mucoadhesive 
agent to increase the retention of tablets in the mouth to encourage pre-gastric 
absorption of active pharmaceutical ingredients (APIs). The in vitro oral retention of 
freeze-dried ODT formulations was one property which was assessed in a design of 
experiments – factorial design study, which was carried out to further understand the 
role that formulation excipients have on the properties of the tablets. Finally, the novel 
approach of incorporating polymeric nanoparticles in freeze-dried ODTs was 
investigated, to study if the release profile of APIs could be modified, which could 
improve their therapeutic effect. 
 
The results from these studies demonstrated that the properties of gelatin-based 
formulations can be modified by adjusting pH and ionic strength. Adjustment of 
formulation pH has shown to significantly reduce tablet disintegration time. Evaluating 
Methocel™, in particular low viscosity grades, and Kollicoat® IR as binders has shown 
that these polymers can form tablets of satisfactory hardness and disintegration time. 
Investigating Polyox™ as an excipient in freeze-dried ODT formulations revealed that 
low viscosity grades appear suitable as binders whilst higher viscosity grades could 
potentially be utilised as viscosity increasing and mucoadhesive agents. The design of 
experiments – factorial design study revealed the influence of individual excipients in a 
formulation mix on resultant tablet properties and in vitro oral retention of APIs. Novel 
methods have been developed, which allows the incorporation of polymeric 
nanoparticles in situ in freeze-dried ODT formulations, which allows the modification of 
the release profile of APIs.  
 
Key words/phrases: lyophilisation, excipients, oral retention, nanoparticles, sustained 
release. 
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Figure 7.7 A comparison of the dissolution profile of piroxicam from nanoparticle-free 
(NP-Free, shown in blue) and nanoparticle-containing (NP, shown in red) tablets. Each 
formulation was tested three times, and the mean values ± standard deviation is 
shown.              208
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1.1 Oral Drug Delivery 
The oral route of drug administration is the most common route of delivering active 
pharmaceutical ingredients (APIs) to the human body (York, 2007). In comparison with 
other routes of drug administration, the oral route is considered the safest, simplest 
and most convenient (York, 2007). Additionally, delivering APIs via the oral route 
receives a high level of patient compliance, as well as being non-invasive (Mohammed 
et al. 2011). There are also some disadvantages related to the oral drug delivery route 
such as slower API absorption compared with APIs delivered parenterally and the 
destruction of certain APIs due to the harsh conditions of the stomach (acidic nature) 
and gastrointestinal enzymes (Ansel et al. 2011).  
 
Solutions, suspensions, tablets and capsules are examples of the most common oral 
drug delivery dosage forms. The vast majority of these dosage forms are swallowed 
which allows the APIs to be absorbed in the gastrointestinal tract (GIT) and enter 
systemic circulation, whilst a small minority exert a local therapeutic effect in the GIT 
(Ansel et al. 2011).  
 
1.1.1 Dosage Form Factors Which Influence API Bioavailability 
As mentioned, there are a wide range of delivery systems available for oral drug 
delivery and the dosage forms in which APIs are formulated have a tremendous 
influence on the bioavailability of the APIs (Mohammed et al. 2011) (Figure 1.1). 
Formulation of an API in the form of a suspension or capsule for example, influences 
the rate and extent that the API is absorbed and becomes available at the site of 
therapeutic action (Ashford, 2002a).  
 
APIs formulated as aqueous dosage forms display the highest bioavailability compared 
to other oral dosage forms (Mohammed et al. 2011). In an aqueous solution, the API is 
readily available for dissolution into the GIT contents which allows for swift absorption 
into systemic circulation (Mohammed et al. 2011).  
 
APIs formulated as aqueous suspensions are generally second in efficiency in terms of 
absorption, as the rate limiting factor is the dissolution of the API (Mohammed et al. 
2011). Following oral administration of APIs in the form of aqueous suspensions, the 
large surface area of the APIs in the gastrointestinal fluids allows efficient dissolution 
and subsequently absorption into systemic circulation (Mohammed et al. 2011). In 
terms of suspensions, a number of factors relating to the formulation can have a 
significant influence on the rate and extent of API absorption in the GIT including the 
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particle size of the API and the viscosity of the suspension formulation in the GIT 
(Ashford, 2002a). 
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Figure 1.1 Schematic illustration representing the different processes and the barriers 
encountered in oral drug delivery. 
 
Following solutions and suspensions dosage forms, APIs formulated as hard gelatin 
capsules are considered third in terms of efficiency of absorption of APIs. Following the 
administration of a hard gelatin capsule and its subsequent disintegration, as long as 
the formulation disperses sufficiently, the API will exhibit a large surface area in the 
GIT for dissolution (Mohammed et al. 2011). However, the surface area of the API is 
considered less than is the case encountered with suspension dosage forms, and 
hence why suspensions are considered second in efficiency behind solutions in terms 
of the efficiency of absorption of APIs (Ashford, 2002a). 
 
One formulation strategy to encourage the API to exhibit a large surface area following 
the administration and disintegration of a hard gelatin capsule is to include a 
hydrophilic excipient in the formulation (Mohammed et al. 2011). As encountered with 
suspension dosage forms, a number of formulation factors play a role on the rate and 
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extent of API absorption in the GIT, e.g. drug-excipient interactions and the packing 
density of the capsule formulation (Ashford, 2002a).  
 
Behind solutions, suspensions and hard gelatin capsules, tablets are considered fourth 
in terms of the efficiency of API absorption, as tablets undergo compression at high 
forces during preparation which results in a considerable decrease in surface area of 
the API (Mohammed et al. 2011). This has a significant influence on the bioavailability 
of an API, due to the challenging task of presenting a suspension of fine API particles 
in the GIT, following administration of a tablet (Ashford, 2002a).  
 
Following the oral administration of a tablet, it disintegrates into aggregates/granules, 
followed by deaggregation in order to form a suspension of fine API particles 
(Mohammed et al. 2011). Only then can the API dissolve before being absorbed 
systemically (Ashford, 2002a). Taking this into consideration it becomes apparent why 
tablets are considered fourth in terms of the efficiency of API absorption, as tablets 
need to undergo a number of steps/processes for the API to be able to be absorbed. 
As with suspensions and hard gelatin capsules dosage forms, a number of formulation 
factors are associated with tablets which influence API bioavailability, such as the 
nature and quantities of the formulation ingredients and the compaction pressures 
used to prepare the tablets (Ashford, 2002a). 
 
1.1.2 Physiological Factors of the Gastrointestinal Tract Which Influence API 
Bioavailability 
As discussed, the dosage form in which an API is formulated, together with the 
associated formulation factors play a tremendous role on the bioavailability of an API. 
Another group of factors which have a significant influence on the rate and extent of 
API absorption in the GIT is the physiology of the GIT. 
 
The surface areas of the gastrointestinal absorption sites exhibit substantial variability 
along the GIT (Mohammed et al. 2011). The regions of the small intestine generally 
possess the largest surface area and subsequently this is where maximum absorption 
of APIs occurs, in contrast, minimal API absorption occurs in the stomach and colon 
due to small surface areas (Mohammed et al. 2011). 
 
The pH of the GIT also influences API absorption and similarly to the surface areas of 
the gastrointestinal absorption sites, varies considerably along the GIT (pH 1.8 – 7.8) 
(Mohammed et al. 2011). pH influences API absorption as it effects the chemical 
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stability of APIs (Ashford, 2002b). The most acidic location is found in the stomach 
(due to the secretion of hydrochloric acid from parietal cells (Widmaier et al. 2011)) 
whilst more alkaline environments are encountered in the small and large intestines as 
a result of the secretion of bicarbonate into the lumen of these areas of the GIT 
(Ashford, 2002b).   
 
The fed or fast state can have a tremendous effect on the bioavailability of an API. 
When a person is in a fed condition, a reduction in gastric emptying rate can take 
place, which delays the therapeutic action of an API (Mohammed et al. 2011). 
Additionally, following the consumption of food, the secretion of gastric fluids and 
enzymes can be stimulated which can degrade some APIs or in some cases increase 
the bioavailability depending on the nature of the API and the food consumed (Ashford, 
2002b).  
 
The consumption of food can lead to a reduction in API bioavailability due to the 
complexation between an API and a component in the diet (Mohammed et al. 2011). A 
well-documented example is the complexation between tetracycline and calcium, 
which forms a non-absorbable complex (Ashford, 2002b). The consumption of food 
can also influence the viscosity of gastrointestinal contents and the blood flow to the 
liver, which can affect the absorption and bioavailability of APIs (Mohammed et al. 
2011).    
 
Aging is another physiological factor which can affect API absorption. Aging is 
generally linked to a reduction in gastric emptying rate along with influencing 
postprandial pH response, and a reduction in gastrointestinal transit times (Mohammed 
et al. 2011). 
 
Other physiological factors which can influence API absorption are gastric emptying 
rate, defined as the rate at which an API in solution leaves the stomach and enters the 
duodenum, and intestinal motility (Mohammed et al. 2011). There are two types of 
intestinal movements including propulsive and mixing forces. Propulsive forces allow 
for the movement of materials through the GIT and determine the residence time of the 
API/formulation in the small intestine before absorption. They have a direct relationship 
with the amount of drug absorbed as greater the intestinal motility, the shorter the time 
that an active drug ingredient or dosage form is present in the small intestine, and is 
available for absorption. Mixing movements in the GIT is significant in fed conditions 
when compared to fast conditions as the presence of food in the GIT dictates the rate 
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and extent of mixing of the dosage form with the contents. Mixing movements can 
increase active drug ingredient absorption and consequently bioavailability by 
increasing the interaction of active drug ingredients with the gastrointestinal 
membrane. They can also increase the rate of dissolution of active drug ingredients 
from solid oral dosage forms, such as tablets. 
 
As discussed, a number of parameters need to be taken into consideration when 
developing an oral drug delivery product (Table 1.1). An understanding of these factors 
will aid the development of a pharmaceutical product, which is effective and displays 
the required absorption/bioavailability. With an aging population, and the subsequent 
influence this has on the physiology of the GIT, which directly impacts API absorption, 
the development of future pharmaceutical products lies with formulations which will 
utilise the changes in GIT physiology in order to maximise the absorption of APIs.    
 
Table 1.1 Variations in physiological environment encountered throughout the entire 
length of the GIT. Table taken from Mohammed et al. (2011) 
1.1.3 Mechanisms and Transport Routes of API Absorption in the 
Gastrointestinal Tract 
When an active drug ingredient has undergone dissolution in the small intestine of the 
GIT, and is in a form suitable for absorption across the intestinal mucosa, a number of 
different routes and mechanisms exist for the drug candidate to be absorbed from the 
apical side of the intestinal mucosa into the systemic circulation for hepatic 
metabolism. These routes include; transcellular, paracellular, efflux and metabolism, as 
shown in Figure 1.2.  
 
The majority of active drug molecules follow the transcellular route, which is an 
example of a passive diffusion mechanism, in which drug molecules move down the 
concentration gradient, from a region of high concentration to a region of lower 
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concentration without the use of energy. The paracellular route, where the drug 
permeates between the tight junctions of the epithelial cells is another example of a 
passive diffusion mechanism, in which molecules transport between the epithelial cells 
of the intestinal mucosa, through water-filled pores. 
 
For API’s to undergo passive diffusion via the transcellular route, they require certain 
properties which relate to lipophilicity, polar surface area, hydrogen bonding potential, 
non-polar surface area and number of rotatable bonds. In contrast, for active drug 
ingredient molecules to undergo passive diffusion via the paracellular route, the 
molecules require certain properties which relate to molecular weight/volume, flexibility 
and charge, and are generally restricted to small polar compounds (molecular weight < 
250 g/mol) (Mohammed et al., 2011). 
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Figure 1.2 Flow chart summarising the various processes encountered in drug 
absorption from the GIT.  
 
Drug molecules can also cross the intestinal mucosa via active transport absorption 
routes and mechanisms, as shown in Figure 1.2. The drug molecules move against 
their concentration gradient, which is driven by adenosine triphosphate (ATP). In terms 
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of carrier mediated routes and mechanisms, the drug molecules require specific 
binding with the transporter proteins for permeation across the cells. Efflux and influx 
routes follow a similar principle to carrier mediated routes, in which an active drug 
ingredient molecule binds to a transporter/carrier. In the case of efflux, an active drug 
ingredient molecule enters the epithelial cell via the apical side, and binds to an efflux 
transporter, which transports the drug molecule back to the lumen of the small 
intestine. Whilst in the case of influx, an active drug ingredient molecule enters the 
epithelial cell via the apical side, and binds to an influx transporter, which transports 
the drug molecules to the basolateral side of the epithelial cell, for absorption into 
systemic circulation (Mohammed et al., 2011). 
 
Active drug ingredient molecules can be transported across the intestinal mucosa 
membrane via endocytosis, in which an active drug ingredient molecule fuses with the 
lipid membrane on the apical side of the membrane, and a membrane forms around 
the molecule. The molecule then travels through the cell and exits the cell by fusing 
with the lipid membrane on the basolateral side of the membrane. 
 
 
1.2 Swallowing Issues and Dysphagia related to Conventional Solid Oral Dosage 
Forms 
Of the various oral dosage forms available, tablets are considered the most common 
(Alderborn, 2007). Some of the reasons for the high acceptability of tablets include: 
 tablets exhibit superior chemical and physical stability, compared to liquid 
dosage forms  
 dose uniformity 
 low production cost 
 easy to handle, and can be modified in terms of their use and delivery of the 
API (Alderborn, 2007). 
 
Despite the numerous advantages of tablets as solid dosage forms, and the reasons 
why they are considered the most common form currently in use, a significant 
issue/disadvantage with tablets and other solid oral dosage forms exists. A number of 
people have difficulty swallowing their medications, e.g. it has been reported that 
around one third of patients in long term care facilities experience difficulties with 
swallowing solid oral dosage forms, and in general, it has been reported that up to one 
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third of people in all age groups experience swallowing difficulties during their lifetime 
(Stegemann et al. 2012).   
 
Additionally, it is expected that swallowing issues and dysphagia, which have a direct 
impact on oral medication administration and patient compliance, are becoming an 
increasing problem due to the aging population (Stegemann et al. 2012). 
 
Swallowing difficulties are not only related to aging (presbyphagia) but also to 
pathological conditions (dysphagia) (Stegemann et al. 2012). Examples of pathological 
conditions causing dysphagia include; central-nervous diseases such as Parkinson’s 
disease, musculoskeletal diseases such as osteoarthritis, metabolic diseases such as 
diabetes and finally oncological diseases such as oropharyngeal tumours (Stegemann 
et al. 2012). Additionally, certain APIs can induce dysphagia, such as the 
antipsychotic; haloperidol (Stegemann et al. 2012).  
 
In terms of the impact of the formulation of solid oral dosage forms on dysphagia, it has 
been identified that the; size, shape and surface texture of the dosage forms are the 
principle factors influencing swallowability (Kelly et al. 2010). In particular, it has been 
reported that patients report that bigger sized solid oral dosage forms and poorer 
quality of tablet coatings have led to non-compliance and possibly discontinuation of 
medication programs (Payot et al. 2011).    
 
To overcome the issues of dysphagia and difficulty in swallowing, a survey has shown 
that two thirds of the patients, who participated, dealt with this by opening capsules or 
crushing tablets before administering their medication, whilst two thirds of patients 
ceased their medication programs (Strachan and Greener, 2005). Modifying the solid 
oral dosage form, by opening capsules or crushing tablets can result in possible API 
instability and an alteration of the performance of the solid oral dosage form which has 
not been tested or authorised (Stegemann et al. 2012). These modifications of the 
stability of the API and the performance of the solid oral dosage form can possibly 
result in adverse effects or intoxication to/of the patients (Cornish, 2005). Additionally, 
another administration issue can become apparent, such as patients being exposed to 
poor tasting formulation ingredients (Kelly et al. 2009 and Kelly et al. 2010).  
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1.3 Orally Disintegrating Tablets (ODTs) and Their Advantages 
To overcome the issues of patients having difficulty swallowing their medication, in 
particular, medications in the form of solid oral dosage forms, a potential solution to 
this problem is orally disintegrating tablets (ODTs). ODTs which are also referred to as 
orodispersible and fast disintegrating tablets, are tablets which when placed in the 
mouth, disperse/disintegrate rapidly before being swallowed, due to the action of saliva 
(Council of Europe, 2002).  
 
ODTs are characterised as solid oral preparations that disintegrate rapidly in the oral 
cavity, with an in vitro disintegration time of approximately 30 seconds or less when 
based on the United States Pharmacopoeia (USP) disintegration test method (Food 
and Drug Administration (FDA), 2008). The distinct advantage of ODTs is that they are 
products which are designed to disintegrate or dissolve rapidly on contact with saliva, 
thus eliminating the need to chew the tablet, swallow an intact tablet, or take the tablet 
with liquids (FDA, 2008). 
 
ODTs are solid oral dosage forms, but as they disintegrate in the oral cavity, they 
perform as suspensions or solutions (based on the solubility of the API), which as 
discussed earlier, exhibit the most effective absorption of APIs. Consequently ODTs 
can provide a more rapid onset of therapeutic action, compared to tablets and 
capsules. 
 
One of the several advantages/benefits of ODTs as solid oral dosage form is that 
ODTs aid the administration of APIs to patients who experience swallowing difficulties 
or to those patients who have no access to water (Seager, 1998). ODTs therefore are 
a convenient dosage form not only as an alternative to conventional tablets/capsules, 
which some people find difficult to swallow, but also to patients who have no access to 
water/liquids, which is used to aid the administration of conventional tablets/capsules. 
 
Schwartz et al. (1995) reported in a study, which investigated the preference of 
patients to administer freeze-dried ODTs or conventional tablets of famotidine, that 
75% of the sample population revealed a preference for freeze-dried ODTs and the 
results from the study were consistent for younger (< 60 years old) and older (> 60 
years old) subjects.  
 
Clarke et al. (2003) reported in a study which investigated patient preference for 
administering either a lyophilised ODT or conventional tablet of selegiline (used in the 
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treatment of Parkinson’s disease), that 78% of the subjects preferred the ODT to their 
normal/conventional tablet, with 98% of the subjects reporting that they found the ODT 
easy to administer. Meanwhile, Clarke et al. (2003) highlighted the potential application 
of ODTs to patients suffering from certain conditions/diseases, by reporting that due to 
the ease of administration of ODTs, they can be particularly be applicable in conditions 
such as Parkinson’s disease, where the incidence of dysphagia is a common 
occurrence with patients (reportedly up to 82% of Parkinson’s disease patients may 
suffer from dysphagia) (Edwards et al. 1991, Kurihara et al. 1993, Leopold and Kagel 
1996 and Singer et al. 1992).  
 
Another advantage/benefit of ODT’s, is that they can improve the overall clinical 
performance of medications by reducing the incidence of medication non-compliance 
(Seager, 1998). As already discussed, a significant number of people who suffer with 
issues of dysphagia and swallowing difficulties cease to adhere to their medication 
programs (Strachan and Greener, 2005). ODTs therefore potentially have a significant 
application in addressing the issues of dysphagia and subsequent poor compliance 
with medication programs.  
 
Schwartz et al. (1995) reported that freeze-dried ODTs have the potential of improving 
compliance, when used as an alternative to tablets and other conventional dosage 
forms. In fact, in a recent study which compared the compliance rates of two oral 
delivery methods for the delivery of selegiline (used in the treatment of Parkinson’s 
disease); standard pill and an ODT formulation that achieved pre-gastric absorption, 
results showed a 98.5% compliance rate with the ODT formulation compared to 81% 
with the standard oral treatment in US Medicare patients (Hamlen and MacGregor, 
2011).   
 
Clarke et al. (2003) reported the potential for an ODT product to improve patient 
compliance for patients suffering from Parkinson’s disease, due to the ease of 
administration of ODTs, in particular for patients suffering from dysphagia. 
 
A third advantage/benefit of ODTs is that they can enhance the clinical effects of some 
APIs through pre-gastric absorption from the mouth, pharynx and/or oesophagus, 
which can lead to an increase in bioavailability and reduction in adverse drug reactions 
(if these reactions are caused by first-pass hepatic metabolism) (Seager, 1998). An 
example of a freeze-dried ODT product which demonstrates pre-gastric absorption 
(predominantly buccal) is Zelapar™, in which selegiline is the core therapeutic 
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candidate administered for the treatment of Parkinson’s disease (Kearney, 2003 and 
Clarke et al. 2003). Due to pre-gastric absorption, a 1.25 mg dose ODT has equivalent 
efficacy to a 10 mg dose conventional tablet, with the added advantage of a reduction 
in adverse drug reactions (Kearney, 2003 and Clarke et al. 2003). The 1.25 mg dose 
ODT showed greater than 90% reduction in plasma levels of the primary metabolites of 
selegiline (Kearney, 2003 and Clarke et al. 2003), which are pharmacologically active 
and associated with neurotoxicity (Brust, 1993) and cardiovascular toxicity (Pickar et 
al. 1981 and Churchyard et al. 1997).  
 
ODTs are also associated with certain drawbacks and disadvantages, e.g. generally, 
ODTs exhibit poorer mechanical properties than conventional tablets. Another 
disadvantage of ODTs is that taste-masking of poor-tasting excipients and/or APIs 
needs to be considered with ODT formulations, as these tablets disintegrate in the oral 
cavity. In addition, other factors which are applicable for consideration in the 
development of conventional tablets also apply to ODT. These include: 
physicochemical properties of the active drug ingredient in the gastrointestinal fluids, 
e.g. particles size, crystal form and chemical stability, nature and quantities of the 
diluent, binder and other excipients and conditions of storage.  
 
 
1.4 Technologies Used to Manufacture ODTs 
A number of technologies are used to manufacture ODTs, namely; freeze-drying 
(lyophilisation), moulding and conventional compression methods (Fu et al. 2004). 
More recently, novel technologies have emerged, which include tablet loading (Holm 
and Slot 2009), compression of pulverized components (Bauer and Rohrer 2007) and 
sublimation (Lee et al. 2002). 
 
In a review carried out by AlHusban et al. (2010a), which involved evaluating patents 
based on ODTs, published from 1999 to 2010, techniques used to prepare the ODTs 
were quantitatively analysed. Figure 1.3 shows the proportion of each technology 
applied to make the ODTs, which were detailed in the patents evaluated. Figure 1.3 
shows that 85% of the patents related to conventional tablet compression technologies 
(direct compression and granulation-compression) (AlHusban et al. 2010a). This could 
possibly be attributed to the low costs of performing conventional compression 
technologies, as standard equipment and materials are used. 2% of the patents were 
attributed to tablet loading and compression of pulverised components technologies, 
respectively, which are both new technologies used in the preparation of ODTs 
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(AlHusban et al. 2010a). Only 4% of the patents related to freeze-drying technologies, 
whilst 9% of the patents were attributed to tablet moulding technologies (AlHusban et 
al. 2010a). 
 
 
Figure 1.3 The various technologies used in the manufacture of ODTs in the period 
1999 to 2010. The results shown are the percentage of patents published from 1999 to 
2010, detailing the technology used to prepare ODTs. Figure adapted from AlHusban 
et al. (2010a).   
 
1.4.1 Conventional Compression Methods – Direct Compression and 
Granulation-Compression 
The use of direct compression to form ODTs, involves the mixing of carefully chosen 
excipients followed by compression at low forces in order to maximise the porosity of 
the tablets to encourage rapid disintegration of the tablets in the mouth.  
 
As mentioned, systematic investigation of the excipients combinations needs to be 
carried out for the successful development of ODTs, to ensure that the tablets display 
rapid disintegration, possess a pleasant mouth-feel and exhibit satisfactory mechanical 
properties (AlHusban et al. 2010a). 
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The excipients used to make directly compressed ODTs generally include a 
disintegrant e.g. starch or a combination of disintegrants, which promotes the swift 
disintegration of the tablets. In addition to this, a sugar alcohol, (mannitol is commonly 
used) is used due to its high water-soluble nature which with the disintegrants 
promotes the rapid disintegration of the tablets.  
 
Interestingly it has been reported that some formulations consist of water-insoluble 
excipients, such as microcrystalline cellulose (AlHusban et al. 2010a). The rationale for 
this was to utilise the repulsive forces between these excipients and the water-soluble 
excipients, as a means of promoting tablet disintegration (AlHusban et al. 2010a). In 
addition to the two principle excipients; disintegrants and highly water-soluble 
excipients, directly compressed ODT formulations also include supplementary 
excipients such as binders, glidants and flavouring agents. 
 
The use of conventional compression methods is not only limited to direct 
compression, but also extends to granulation, and the subsequent compression of the 
granules. The general approach of formulating these types of ODTs involves the 
mixing of highly water-soluble excipients and disintegrants (as discussed with the 
direct compression formulations), and the API, followed by granulation to form rapidly 
dispersible granules which are subsequently compressed to form ODTs (AlHusban et 
al. 2010a). Examples of other excipients used in these types of formulations, that differ 
from the standard excipients, are other hydrophilic materials such as amino acids 
(Ohta et al. 2004). Meanwhile, the use of effervescent agents such as sodium 
carbonate and malic acid (used in combination) has also been reported in order to 
encourage tablet disintegration (Ouali, 1998). 
 
In addition to the careful selection of excipients, another approach which has been 
reported with these types of ODTs is the development of innovative production 
methods in order to prepare ODTs via granulation (AlHusban et al. 2010a). E.g. 
Ramalho and Mulchande (2006) reported a method of mixing the API with pre-formed 
granules, which consisted of mannitol and maize starch gum, therefore omitting the 
API from the granulation process.  
 
The use of granulation to prepare ODTs has also been used to compress 
multiparticulates into ODTs, with the aim of masking bitter tasting APIs and protecting 
the APIs. An example of this approach has been reported by Mimura et al. (2009) in 
order to mask the taste of the bitter-tasting mitiglinide calcium hydrate, by coating the 
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API granules with the water insoluble polymer; ethyl acrylate-methyl-methacrylate 
copolymer. 
 
The method of coating APIs has also been applied to deliver acid-labile APIs in the 
form of ODTs, through the use of enteric coating. E.g. Shimizu et al. (2001) reported a 
multi-step method to prepare enteric coated pellets of lansoprazole. This involved 
coating a neutral core with the API and basic inorganic salt, followed by coating with a 
water-soluble polymer (such as hydroxypropyl methylcellulose), enteric coating and 
finally the application of a sugar-alcohol (mannitol). This approach allows the pellets to 
reach the small intestine, dissolve, and release the API. 
 
It has also been reported that ODTs prepared by conventional compression methods, 
undergo post-compression treatment in a bid to improve the physical and disintegration 
properties of the tablets. An example of this approach was reported by Uemura et al. 
(2009), in which an alcohol solvent was applied to the surface of the tablets, to dissolve 
the binder, and consequently form bridges between the granules. Following the 
evaporation of the alcohol, the binder-bridges solidified, which improved the physical 
properties of the tablets (Uemura et al. 2009). 
 
1.4.2 Tablet Moulding   
The use of moulding to manufacture ODTs, principally involves the use of water-
soluble ingredients (Fu et al. 2004). The manufacturing method involves moistening 
the powder mixture with a solvent, in which ethanol or water are commonly used, and 
then moulding the mixture into tablets under pressures which are lower than those 
used in conventional tablet compression methods (Fu et al. 2004). The solvent used 
during tablet manufacture, is ultimately removed by air-drying, and as the tablets are 
manufactured using pressures which are lower than those used in conventional tablet 
compression methods, the tablets have a high porosity, which subsequently enhances 
dissolution (Fu et al. 2004) and results in tablets which exhibit rapid disintegration. 
More recently, variations/modifications in the moulding manufacturing method have 
emerged, such as heat moulding and no-vacuum lyophilisation.  
 
An example of the use of heat moulding has been reported by Takaishi et al. (2005). 
The authors investigated the use of mannitol and erythritol (saccharides) which melt 
following heating, and form bridges between the formulation ingredients, with an 
ultimate objective of improving the physical properties of the tablets.  
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A significant development in the field of ODTs prepared by moulding was reported by 
Myers et al. (1999) who reported an apparatus which combined each step of the tablet 
preparation process; mixing, filling, tamping and curing. This development therefore 
improved the efficiency and convenience of preparing ODTs using the moulding 
method. 
 
1.4.3 Tablet Loading 
Holm and Slot (2009) recently reported a new method of preparing ODTs. The tablets 
prepared using this method usually consists of at least 60% of a sorbent material such 
as magnesium oxide and metal silicate such as sodium silicate. In addition a 
hydrophilic substance (e.g. glucose) and superdisintegrant (such as sodium 
carboxymethyl cellulose) were included in the formulation, together with a filler and 
binder.  
 
The formulation was compressed, followed by loading of the tablet with the API (in 
liquid form), which involved spraying the liquid onto the tablet, or placing the tablet in 
an excess of the liquid (which can be in the form of a suspension). The tablet loading 
method of preparing ODTs was claimed to be applicable for poorly water-soluble APIs. 
(Holm and Slot, 2009). 
 
1.4.4 Compression of Pulverised Components   
In addition to the tablet loading method, a novel new method of manufacturing ODTs 
has also been reported which involves compressing components which are in a 
pulverised form. It has been reported that tablets prepared using this method display a 
similar porous structure to the tablets prepared using freeze-drying. 
 
The formulation of tablets prepared using this method usually consist of a dry mixture 
of a binder such as acacia, API, filler, and other supplementary excipients such as a 
lubricant. Under high pressure, liquefied or compressed gases or gas mixtures, 
optionally in the presence of a low-boiling point solvent (e.g. methanol) is used to 
moisten the dry mixture. This is followed by the preparation of a mouldable plasticised 
mass, following the stirring and homogenisation of the mixture in an autoclave. Tablets 
are prepared by filling the wetted mixture in a mould under pressure, followed by 
decompression to produce the highly porous ODTs. (Bauer and Rohrer, 2007). 
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1.4.5 Freeze-Drying 
Freeze-drying, which is also known as lyophilisation, is the method which produces 
tablets that exhibit the most rapid disintegration and dissolution, due to their highly 
porous nature, that allows the rapid penetration of saliva into the porous matrix of the 
tablets. The proposed desired properties of freeze-dried ODTs are shown in Table 1.2.  
 
Table 1.2 Proposed desired properties for freeze-dried ODTs.  
Tablet Property Desired 
Value 
Tablet Hardness 12 N 
Tablet Disintegration Time 10 s 
In Vitro Oral Retention Time 100 s 
 
The process of freeze-drying generally consists of three steps, which include; freezing, 
primary drying and secondary drying. The first step, freezing, involves the transition of 
water from a liquid state to a frozen (solid) state, consequently, the solutes are 
separated from the ice.  
 
The primary drying step, which is also referred to as ice sublimation, involves the 
application of vacuum (a reduction in pressure) and an increase in shelf temperature. 
During this step, ice is transferred from a solid state to a vapour/gaseous state, due to 
sublimation. The final step of the freeze-drying process, secondary drying, is 
performed at an increased temperature and under vacuum, in order to remove water 
from the freeze concentrate. (Tang and Pikal, 2004) (Figure 1.4).  
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Figure 1.4 Graph demonstrating the triple point below which sublimation occurs. S in 
the diagram denotes solid phase, L represents liquid phase and G gaseous phase. The 
point at which all the three phases converge is referred as the triple point. 
(Polyparadigm, 2006). 
 
The particular advantages of freeze-drying are that the initial solution is frozen such 
that the final dry product is a network of solid occupying the same volume as the 
original solution. Thus the product is light and porous and readily soluble, which 
subsequently exhibits rapid disintegration in the oral cavity when in contact with saliva. 
(Aulton, 2002). 
 
Zydis® is a freeze-dried tablet-shaped ODT dosage form product, which has been in 
commercial production since 1986. Zydis® tablets are unique, as they spontaneously 
disintegrate in the mouth in seconds, due to their characteristic high porosity, produced 
by the freeze-drying process (Figure 1.5). The highly porous structure of the tablets, 
allows the rapid ingress of saliva, which subsequently quickly dissolves the soluble 
excipients, thus releasing the drug particles as a suspension or solution on the tongue. 
The suspension or solution is then swallowed, and the drug is absorbed in the 
conventional way. (Kearney 2003). Interestingly, human in vivo studies, using gamma 
scintigraphy, have shown that even when taken without water, the component 
materials of the formulation uniformly disperse over the mucosa and are subsequently 
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cleared efficiently from the buccal and oesophageal regions (Washington et al. 1989). 
This demonstrates the potential application of these dosage forms to encourage pre-
gastric absorption of APIs. 
 
Mixing
Binder, other 
excipients and 
active drug 
Filling in 
moulds or 
blisters
Solution, 
suspension or 
emulsion
Lyophilised ODTs
Freeze 
drying
Annealing
Freezing
Figure 1.5 Schematic illustration representing the various stages involved in the 
formulation of lyophilised ODTs. 
 
The formulation of Zydis® products, consist of a tablet matrix composed of materials 
that can be readily freeze-dried and also impart sufficient strength to allow easy 
removal from the packaging. The selected materials also have to be compatible with a 
wide range of APIs. Kearney (2003) reported that no single excipient had the ideal 
characteristics, but a suitable matrix structure was achieved by using the combination 
of a water-soluble polymer (e.g. gelatin) and a sugar alcohol (e.g. mannitol). 
  
The Zydis® formulating process requires an API to be dissolved or suspended in an 
aqueous solution of water-soluble structure formers. Gelatin and mannitol are the two 
most commonly used structural excipients, whilst other suitable structure formers such 
as starch and gums can also be used, depending on the properties of the APIs. A 
general rule with Zydis® products is that the best physical characteristics are achieved 
by using a mixture of a water-soluble polymer and a crystalline sugar-alcohol or amino 
acid, at a typical combined concentration of 10% w/w in the matrix solution. The 
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polymer component provides the strength and resilience, whilst the crystalline 
component provides the hardness and texture. (Kearney 2003). 
 
Lyoc™ is another freeze-dried ODT technology that involves preparing an oil-in-water 
emulsion which is subsequently freeze-dried in its final packaging (Lafon, 1986). It has 
been reported that Lyoc™ formulations require a large amount of an undissolved inert 
filler to increase the viscosity of the formulations to prevent in-homogeneity by 
sedimentation during freeze-drying. It was further reported that the incorporation of a 
large amount of an undissolved inert filler in the formulations, results in reducing tablet 
porosity and subsequently increasing tablet disintegration time. (Fu et al. 2004). 
 
QuickSolv® is an ODT technology, which involves dispersing or dissolving matrix 
forming agents and an API in water that is consequently accurately dosed into pre-
formed blisters. The formulation is then frozen, followed by immersion in a water 
miscible alcohol. The solidified/frozen matrix formulation is therefore exposed to the 
water miscible alcohol, to which the matrix components are insoluble in, and as a result 
water is removed yielding the matrix components and API. Residual water miscible 
alcohol may then be removed by placing the product in a vacuum chamber under 
reduced pressure. (Gole et al. 1993). 
 
LyoPan® is an additional freeze-drying technology used to manufacture ODTs. 
LyoPan® differs from other freeze-drying technologies, as the LyoPan® process utilises 
partial freeze-drying as not all of the formulation undergoes freeze-drying. The 
LyoPan® process involves the formulation existing as two components; a powdered 
component and an aqueous component. The powdered component is firstly dosed into 
the tablet mould followed by the aqueous component and as a result only a small 
volume of the formulation is frozen and dried in this partial or reduced freeze-drying 
process. The LyoPan® freeze-drying process has several distinct advantages, in 
particular; as the amount of water used by this process is considerably less than 
completely freeze-dried formulations, which consequently results in corresponding 
savings in production time and energy consumed, the freeze-drying time is significantly 
reduced. Additional advantages include; high doses of API can be incorporated in the 
tablets, the absorption properties of APIs can be controlled or adjusted by using pre-
processed pellets, e.g. pellets with intestinal soluble coatings, and finally taste-
improving components and/or sweeteners can be added to the formulations. (Bauer, 
2007). 
 
Chapter One: Introduction 
 
42 
 
Nanomelt®, a Nanocrystal™ technology, is another application used with freeze-dried 
ODTs, which is claimed to improve compound activity and final product characteristics. 
The fundamental principle, on which the technology is based, involves decreasing the 
particle size of the API, which increases its surface area that subsequently results in an 
increase in the dissolution rate of the API. The technology is used for poorly water-
soluble APIs. Nanocrystal™ particles are nano-sized drug substances, typically less 
than 1000 nm in diameter, which are produced by milling using a proprietary wet 
milling technique and are stabilized against agglomeration to create a suspension that 
behaves like a solution. In order to formulate the freeze-dried ODTs, Nanocrystal™ 
colloidal dispersions of API are combined with water soluble ingredients, which are 
filled into blisters and lyophilized. It is claimed that this approach is mainly used when 
formulating highly potent or hazardous materials, as it avoids a number of 
manufacturing steps, commonly encountered when formulating conventional tablets, 
such as granulation, blending and tableting which generate large amounts of 
aerosolised powder and possess a greater risk of toxicity through exposure. (Badgujar 
and Mundada, 2011).  
 
As discussed above, extensive research has been focussed on freeze-drying 
technology in order to develop ODT products. In addition to this, widespread research 
has focussed on the selection of excipients, in particular the polymeric binder and 
matrix supporting/disintegration enhancing agents used in freeze-dried ODT 
formulations, as identified by AlHusban et al. (2010a) in a review of recent research 
trends in the field of ODTs.   
 
As reported earlier, gelatin is one of the most commonly used excipients in the 
formulation of freeze-dried ODTs (Kearney, 2003). However, a significant 
disadvantage of using gelatin as an excipient in pharmaceutical products is that non-
adherence to medication programs can occur due to religious beliefs and/or dietary 
preferences (Sattar et al. 2004).  
 
Sattar et al. (2004) reported that patients stopped taking their medication when they 
discovered that gelatin was used as an excipient in their medication. The 
consequences of patients ceasing their medication programs can include worsening of 
clinical symptoms and relapse of their illness’. The long term effects of medication 
nonadherence due to religious beliefs can include increasing hospitalisation rates and 
healthcare costs, and possibly poor healthcare provider-patient relationships. (Sattar et 
al. 2004). 
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In a study reported by Vissamsetti et al. (2012) which involved investigating patient 
preferences to the origin of excipients in formulations, 40% of the patients responded 
that they had a dietary restriction which requires avoiding consumption of animal-
derived excipients. 
 
Other findings from the study by Vissamsetti et al. (2012), indicated that 150 (85.2%) of 
the 176 patients who preferred vegetarian only treatment stated that they would not 
take any oral medication which comprised of animal-derived excipients. However, 100 
(56.8%) of these would consume medications consisting of animal-derived excipients if 
no alternatives were available. Interestingly, only 36 (20.5%) of patients who preferred 
vegetarian medication would have specifically asked their doctor or pharmacist 
regarding the composition of their medication, to see if it conflicted with their dietetic 
restrictions. It was also reported in the study that 20% of the UK population might 
practice dietetic restriction due to religious reasons. (Vissamsetti et al. 2012). 
 
It has been reported that one approach for decreasing the inadvertent prescription of 
medications consisting of animal-derived excipients, is to modify pharmaceutical 
formulations so that only non-animal-derived excipients are used (Vissamsetti et al. 
2012). 
 
The ethical and formulation issues related to gelatin, were the rationale identified by Li 
et al. (2007) in order to identify alternatives to gelatin in the formulation of freeze-dried 
ODTs. Li et al. (2007) identified pullulan as an alternative to gelatin, with the added 
advantages of simpler formulation process steps and shorter freeze-drying time. 
Murray et al. (2003) also reported a gelatin-free freeze-dried ODT formulation using 
modified starches as alternatives to gelatin. Murray et al. (2003) claimed that higher 
concentrations of API could be used with formulations consisting of modified starches 
than with formulations consisting of gelatin. 
 
The use of alternative materials to gelatin has also been reported by Remon and 
Corveleyn (2000) and Johnson et al. (2002). Remon and Corveleyn (2000) reported 
the use of maltodextrin as matrix forming agents and water-soluble polymers such as 
xanthan gum, methylcellulose and hydroxypropyl methylcellulose as binding agents. 
Johnson et al. (2002) meanwhile reported the use of a wide range of polymeric 
materials derived from plant and synthetic origins as binding agents, e.g. acacia, agar 
and dextran. Johnson et al. (2002) additionally reported the use of sugar alcohols 
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and/or amino acids as matrix supporting/disintegration enhancing agents in the 
formulation of freeze-dried ODTs. 
 
Subsequent chapters of this thesis investigated other materials as alternatives to 
gelatin in the formulation of freeze-dried ODTs including Methocel™ (hydrophilic 
cellulose ethers) and Kollicoat® IR (polyvinyl alcohol-polyethylene glycol co-polymer). 
Additionally, Chapter 7 of this thesis investigated the novel approach of incorporating 
polymeric biodegradable nanoparticles in freeze-dried ODTs to develop sustained 
release formulations comprising of non-animal-derived excipients.  
 
 
1.5 Recent Trends and the Need for Further Developments in the Field of ODTs 
The field of ODTs has witnessed extensive developments over recent years. In relation 
to ODTs prepared by conventional compression methods (direct compression and 
granulation-compression), these technologies appear most extensively developed. 
This can possibly be attributed to the standard equipment used, low costs of preparing 
the tablets and the application of a wide range of excipients together with the ease at 
which these technologies can be adapted in terms of the methods used to prepare the 
tablets (AlHusban et al. 2010a). 
 
These technologies have seen recent developments in the selection of excipients used 
in the formulations. For instance, the use of water-insoluble excipients to promote 
tablet disintegration by utilising the repulsive forces between water-soluble and 
insoluble components is an innovative approach. There have also been developments 
relating to the granulation methods used to prepare the tablets. Additionally, 
developments in the taste-masking of APIs have enabled commercial exploitation of 
these technologies. This has allowed ODTs to be used to deliver acid-labile APIs, to 
maximise absorption in the small intestines and subsequently increase bioavailability. 
(AlHusban et al. 2010a). 
 
There have also been developments regarding improving the physical and 
disintegration properties of ODTs, through the application of post-compression 
treatments to the tablets. This demonstrates that development opportunities with ODTs 
not only exist with the formulation of the tablets but also post formulation compression 
of tablets. (AlHusban et al. 2010a).  
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The emergence of tablet loading and compression of pulverised components 
technologies, as novel methods of preparing ODTs, highlights the efforts made in this 
field to continue to develop the properties of the tablets. The tablet loading method 
claims to be applicable for poorly water-soluble APIs, whilst the compression of 
pulverised components method, is reported to prepare tablets which exhibit a similar 
porous structure to the tablets prepared using freeze-drying. (AlHusban et al. 2010a). 
 
Recent developments in ODTs prepared by freeze-drying have involved advancements 
with the technology itself, such as the LyoPan® technology, as discussed earlier. 
Additionally, developments have focussed on the selection of excipients which are 
suitable for being applied to freeze-dried ODT formulations, with particular emphasis 
on uncovering water-soluble polymeric binders which can be used as an alternative to 
gelatin. (AlHusban et al. 2010a). 
 
Despite the recent developments in the field of ODTs, one of the principal motivations 
for further work into this area is the aging population. It is widely acknowledged that the 
population in both developed and developing nations is aging, and the number of 
people aged 60 years or older, is projected to increase significantly over the next 38 
years, as shown in Figure 1.6. As discussed earlier aging is one factor which is related 
to difficulty in swallowing (Stegemann et al. 2012). Consequently, ODTs are 
particularly beneficial for geriatric patients, as they are convenient to administer. 
Figure 1.6 Projection of the number of people aged 60 years or over, in both 
developed and developing countries, from 1950-2050. Figure sourced from: United 
Nations Department of Economic and Social Affairs (2011). 
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The ability for elderly patients to administer their medication easily and conveniently is 
particularly important, as a significant number of elderly patients are prescribed 
multiple medications for a range of medical conditions. Consequently, these patients 
are expected to administer several medications, a number of times during a day. As a 
result, the potential for medication errors and nonadherence to medication programs is 
high. As discussed earlier, the consequences of medication nonadherence includes; 
worsening of clinical symptoms and increasing healthcare costs (Sattar et al. 2004). 
Additionally, it has been shown that patients comply better with an ODT tablet than 
with a conventional tablet (Hamlen and MacGregor, 2011), therefore ODTs appear as 
a logical method of improving patient compliance and reducing nonadherence to 
medication programs, especially in chronic long term medical conditions. 
 
 
1.6 Aims and Objectives of the Thesis 
Due to the aging population and the anticipated increase in the emergence, 
development and use of convenient dosage forms, such as ODTs, the research in this 
thesis aims to contribute to the formulation of ODTs prepared by freeze-drying. The 
principle aim in this thesis is to evaluate the application of novel commercially available 
polymers in the development of freeze dried ODTs together with investigating 
techniques to formulate APIs in a sustained release system that would disintegrate 
rapidly. It is anticipated that success of the above two strategies will have significant 
impact on the availability of ODT dosage forms that will have wider appeal to patient 
populations from diverse social and religious beliefs, improve bioavailability through 
application of simple techniques such as viscosity enhancement and increase of pre- 
gastric residence time and reduce the frequency of administration of dosage forms with 
the overarching accomplishment of enhancing patient healthcare through novel 
formulation excipients and developmental strategies.  
 
As discussed above, there is both a societal and a scientific requisite to further develop 
ODT formulations through the testing of existing new materials and novel formulation 
strategies. The proposed work in the thesis has been investigated to develop a 
necessary framework to illustrate the properties of material suitability in the formulation 
of freeze-dried ODTs. Together with studying and developing novel product 
development methodologies with the ultimate aim of engineering novel ODTs based on 
composition and the dosage form being accepted by a wide range of patient 
populations from diverse backgrounds. 
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The objectives of the work can be classified into three critical domains: 
 
1. Evaluation and understanding of formulation development and characterisation 
of widely studied gelatin-based ODT preparations, to extract the key 
parameters in formulation and process development. 
 
2. Investigation of the suitability of various materials including cellulose 
derivatives, and synthetic polymers such as polyethylene oxide and polyvinyl 
alcohol-polyethylene glycol co-polymer through a systematic and 
comprehensive evaluation of material properties. 
 
3. Development and optimisation of novel sustained release ODTs through 
extensive studies on integration of multiple formulation methods into a simple 
and scalable technology. 
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2.1 Introduction 
Orally disintegrating tablets (ODTs), which are also referred to as orodispersible and 
fast disintegrating tablets, are tablets which when placed in the mouth, 
disperse/disintegrate rapidly before being swallowed, due to the action of saliva 
(Council of Europe, 2002). The Food and Drug Administration recommends that ODTs 
be considered as solid oral preparations that disintegrate rapidly in the oral cavity, with 
an in vitro disintegration time of approximately 30 seconds or less, when based on the 
United States Pharmacopeia disintegration test method or alternative (Food and Drug 
Administration, 2008). This form of solid dosage form is therefore highly applicable for 
groups of the population who commonly have difficulty in swallowing conventional solid 
dosage forms (e.g. conventional tablets and capsules), such as pediatric and geriatric 
patients (Abdelbary et al. 2005). 
 
A number of technologies have been used to manufacture ODTs including freeze-
drying (lyophilization), molding and conventional compression methods (Fu et al. 
2004). More recently new technologies such as tablet loading (Holm and Slot, 2009), 
compression of pulverized components (Bauer and Rohrer, 2007) and sublimation 
(Lee et al. 2002) have also been reported. 
 
However, ODTs manufactured using freeze-drying have been the most successful 
commercially. Tablets manufactured using this technology, generally exhibit rapid 
disintegration and dissolution due to their highly porous nature, which allows 
penetration of saliva into the matrix of the tablets, resulting in disintegration. The 
freeze-drying process involves the transition of water from liquid to solid during 
freezing, and then solid to vapor during sublimation (Aulton, 2002). A particular 
advantage of freeze-drying is that the solution is frozen such that the final dry product 
is a network of solid occupying the same volume as the original solution, resulting in a 
light and porous product which is readily soluble (Aulton, 2002). 
 
Gelatin and mannitol are both excipients which are used in the formulation of freeze-
dried ODTs. These materials are responsible for forming the highly porous matrix 
structure of the dosage form. Gelatin, a protein, which acts as a glassy amorphous 
compound, provides structural strength, whilst mannitol (a sugar alcohol) provides 
crystallinity, hardness and elegance. Water is used as a manufacturing process media, 
which induces the porous structure upon sublimation during the freeze-drying stage. 
(Sastry et al. 2000). 
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Interestingly, studies investigating molecular variations in gelatin configuration have 
shown that various factors such as pH and salt concentration influence its packing and 
solubility. A pH-swelling curve for lime processed gelatin (type B) has been reported 
(Sheppard, 1942). The results showed that adjusting the pH away from the isoelectric 
point resulted in a significant swelling of the material. Subsequently, the swelling 
properties of gelatin could potentially be utilized to increase the porosity of the freeze-
dried tablet matrix, and could lead to a reduction in disintegration time. Another study 
investigating the solubility of gelatin has shown that it exhibits its lowest solubility at pH 
5 (isoelectric point), with improvements in solubility above the isoelectric point (Cortesi 
et al. 1999 and Benjakul et al. 2009). Other factors that have shown to influence gelatin 
swelling and solubility include the addition of neutral salts and variations in ionic 
strength of the formulation (Benjakul et al. 2009 and Xiao et al. 2004). Despite the 
availability of literature on gelatin behavior, there has been no work reported in 
exploiting gelatin properties under different conditions in the formulation of ODTs. 
 
Besides varying parameters such as pH and ionic strength that will potentially influence 
the physicochemical properties of gelatin, another factor which has received very little 
attention is particle size reduction. Ball milling is a widely used technique to reduce 
particle size (Zahrani and Fathi, 2009) and has been shown to influence the transition 
of materials from crystalline to amorphous form (Lefort et al. 2004 and Mallick et al. 
2008); to change the performance of a variety of dosage forms by improving their 
solubility (Huang et al. 2008), dissolution (Van Eerdenbrugh et al. 2007), and 
bioavailability (Liversidge and Cundy, 1995).  
 
The aim of the current study was to exploit the various process parameters such as 
adjustment of pH, ionic strength of the formulation and ball milling to study their 
influence on tablet properties with the aim of reducing disintegration time without 
compromising tablet hardness. The formulated tablets used in this study consisted of 
9% w/w gelatin and 30% w/w (of the dried tablet weight) mannitol, as excipients. The 
choice of formulation was influenced by the preliminary results which showed that the 
above combination exhibited high tablet hardness and long disintegration time (around 
two minutes). 
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2.2 Materials 
Gelatin (type B, 60 and 75 bloom) and mannitol were supplied by Sigma-Aldrich 
Chemicals (Poole, UK). HPLC grade methanol was supplied by Fisher Scientific 
(Loughborough, UK). Ibuprofen, sodium chloride and sodium hydroxide were supplied 
by Sigma-Aldrich Chemicals (Poole, UK). Hydrochloric acid was supplied by Fisher 
Scientific (Loughborough, UK). All chemicals were used without further purification. 
 
2.3 Methods 
 
2.3.1 Preparation of Freeze-Dried Tablets 
Gelatin was dissolved in double-distilled water at about 40°C, followed by the addition 
of mannitol to form a solution. 1.5 g of the resulting solution was dosed into a tablet 
mould, frozen at –70°C for a minimum of sixty minutes and freeze-dried 
(ADVANTAGE, Freeze-Dryer, VIRTIS) according to the following regime; primary 
drying for forty eight hours at a shelf temperature of –40°C, secondary drying for ten 
hours at a shelf temperature of 20°C and vacuum pressure of 6.67 Pa (50 mTorr). A 
minimum of ten tablets were prepared for each formulation. 
 
2.3.2 Ball Milling 
Mixtures of gelatin and mannitol were milled using a planetary micro mill (FRITSCH 
Pulverisette 7, Germany), with 45 mL agate grinding bowls and 10 mm diameter agate 
balls at room temperature. The milling process was performed under various 
conditions, as shown in Table 2.1, in order to investigate the effect of the milling 
parameters, i.e., milling time, rotation speed, and ball: powder weight ratio, on the; 
wettability, porosity of the milled samples and glass transition of the formulations in 
their frozen state prior to freeze-drying. Ultimately the effect of milling on the properties 
of the freeze-dried tablets, namely; disintegration time, porosity, hardness and 
fracturability were investigated. The weight of the gelatin-mannitol mixture was 3 g for 
all of the milling conditions. The milling parameters were determined using MODDE 
factorial-experimental design software. 
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Table 2.1 Ball milling conditions of the various formulations.  
Formulation Milling Time 
(minutes) 
Rotation Speed 
(rpm) 
Ball: Powder 
Weight Ratio 
N1 15 100 5 
N2 60 100 5 
N3 15 400 5 
N4 60 400 5 
N5 15 100 15 
N6 60 100 15 
N7 15 400 15 
N8 60 400 15 
N9 37.5 250 10 
N10 37.5 250 10 
N11 37.5 250 10 
 
2.3.3 Differential Scanning Calorimetry (DSC) 
DSC (Pyris Diamond DSC and Intercooler 2P: Perkin Elmer, Wellessey, USA) was 
used to determine the glass transition temperature (Tg) of the formulations in their 
frozen state (before freeze-drying). 10–15 mg of the liquid samples were loaded into 
aluminum pans, cooled to –65°C at a rate of 5°C/min with a nitrogen purge of 20 
mL/min, an empty aluminum pan was used as a reference for all measurements.  
 
The resulting thermograms were analyzed by Pyris manager software. Tg values were 
determined from the intersection of relative tangents to the baseline. Three 
samples/measurements were taken for each formulation, and the mean values ± 
standard error were reported. 
 
2.3.4 Wettability Analysis 
The wettability of the milled and non-milled (control formulation) samples were 
analyzed using the Wilhelmy method, to determine their contact angle. A Camtel© 
(Hertfordshire, UK) QCT-100 surface tensiometer was used to determine the contact 
angle and subsequent wettability of the samples.  
 
Glass slides measuring 24 × 24 mm in size were covered with 12 × 24 mm double-
sided adhesive tape. The glass slides were then placed in the various formulations, to 
coat them. Excess formulation was removed by gentle tapping to ensure a uniform 
coat. Glass slides were then securely attached to the microbalance of the apparatus, 
and during wettability analysis, a glass beaker containing the test liquid (80 mL of 
double distilled water) was raised and lowered at a rate of 0.200 mm/s, to immerse the 
glass slides. During this period, contact angles were determined automatically at 
regular intervals. 
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Each formulation was analyzed in triplicate for their greatest contact angle, and mean ± 
standard error is reported. The test liquid was replaced for analyzing each formulation. 
 
A linear relationship between wetting time (wettability) and disintegration time of rapidly 
disintegrating tablets has been reported (Sunada and Bi, 2002). Therefore, analysis of 
the wettability of excipients is a useful tool in understanding the performance 
(disintegration time) of fast disintegrating tablets. 
 
2.3.5 Powder Porosity Analysis 
The porosity of the milled and non-milled (control formulation) samples were measured 
using helium pycnometry (MULTIPYCNOMETER, Quantachrome Instruments, 
Hampshire, UK). 1 mL of sample was placed in a suitably sized sample cup and 
subjected to helium pycnometry, to determine the true density of the sample. The true 
density value was then used in the following equation (Equation 2.1) to determine the 
porosity of the sample: 
 
Porosity = (1 – bulk density/true density x 100%) (Equation 2.1) 
 
Bulk density was determined by considering, the mass and volume of the sample. 
Three porosity measurements were taken for each formulation, and the mean ± 
standard error is reported. The porosity of the samples was expressed as a 
percentage. 
 
2.3.6 Mechanical Properties of the Tablets 
The mechanical properties of the tablets (hardness and fracturability) were investigated 
with a texture analyzer (QTS 25: Brookfield, Essex, UK) equipped with a 245.17 N load 
cell. The instrument was calibrated by standard weights of 4.90 N and 49.03 N. The 
tablets were placed in a holder with a cylindrical hole. The hardness was taken as the 
peak force after 1mm penetration of a 5 mm diameter probe at a rate of 6 mm/min. 
Three measurements were taken for both hardness and fracturability, for each 
formulation, and the mean ± standard error is reported. 
 
2.3.7 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2°C, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 per minute. 
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Three tablets were evaluated from each formulation, and the mean values ± standard 
error is reported. 
 
2.3.8 Tablet Porosity 
The porosity of the tablets was measured using helium pycnometry 
(MULTIPYCNOMETER, Quantachrome Instruments, Hampshire, UK). Two freeze-
dried tablets were placed in a suitably sized sample cup and subjected to helium 
pycnometry, to determine the true density of the tablets. The true density value was 
then used in the equation, as reported above (Equation 2.1), to determine the porosity 
of the tablets.  
 
Bulk density was determined by considering tablet weight, diameter and thickness. The 
diameter and thickness of the tablets were determined using a screw gauge (LINEAR 
Farnell). Three porosity measurements were taken for each formulation, and the mean 
values ± standard error is reported. The porosity of the tablets is expressed as a 
percentage. 
 
2.3.9 Statistical Analysis and Factorial-Experimental Design 
The effect of milling on the performance and properties of freeze-dried tablets was 
compared to those of the control (non-milled formulation); using one-way analysis of 
variance (ANOVA) with the Dunnett multiple comparisons test. The significant effect of 
treatment/level of statistical significance was judged as being p < 0.05, with a 
confidence limit of 95%. This statistical analysis test was also used for the ionic 
strength study.  
 
In terms of factorial-experimental design, the milling factors consisted of; milling time 
(ranging from 15–60 minutes), rotation speed (ranging from 100–400 rpm) and 
ball:powder weight ratio (ranging from 5–15). Eleven formulations were proposed, 
which underwent different milling conditions, according to the three factors, as shown 
in Table 2.1. 
 
The responses measured included excipient properties; wettability, powder porosity 
and glass transition (of the formulations in their frozen state, prior to freeze-drying). 
The responses measured also included tablet properties; disintegration time, porosity, 
hardness and fracturability.  
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Statistical analysis of the dissolution of ibuprofen from tablets prepared from both non-
milled and milled excipients was performed using the unpaired t-test with Welch 
correction. This statistical analysis test was also used for the pH study. Ibuprofen was 
used as a model active pharmaceutical ingredient (API), as it is a readily available API. 
Also, the majority of API’s used in freeze-dried ODTs are insoluble or poorly soluble in 
water, and as ibuprofen is poorly soluble in water, it was deemed as a suitable model 
API to use in the dissolution study. 
 
2.3.10 Morphological Examination 
The inner structural morphology and pore size of the freeze-dried tablets were 
examined by scanning electron microscopy (SEM, STEREOSCAN 90, Cambridge 
Instrument). Thin horizontal and vertical samples of the tablets were prepared by 
cutting them with a surgical blade. The samples were placed onto double-sided 
adhesive strips on aluminum stubs and coated with a thin layer of gold using a sputter 
coater (Polaron SC500, Polaron Equipment, Watford, UK) at 20 mA for three minutes 
(this was performed twice for each set of samples) and then examined by the SEM. 
The acceleration voltage (kV) and the magnification can be seen on each micrograph. 
The pore size of the freeze-dried tablets was measured by using the scale which was 
visible on each micrograph. The average pore size was measured by measuring the 
pore diameter of around 10 randomly selected individual pores, from these values the 
average pore diameter was calculated. 
 
2.3.11 Dissolution Study and HPLC Conditions 
The dissolution rate of ibuprofen from the two formulations (milled and non-milled 
tablet excipients), was examined using a Caleva 8ST dissolution bath. The two 
formulations were analyzed in triplicate. The dissolution system employed was USP 
dissolution apparatus 2 (paddle at 50 rpm rotation speed), for a test time of 60 minutes. 
The dissolution medium consisted of 900 mL of pH 7.2 phosphate buffer at 37°C. 
Dissolution samples were filtered through a 0.45 µm Nylon syringe filter, to remove 
undissolved ibuprofen. 10 µL of the samples were analyzed by HPLC (Dionex), with 
UV detection performed at 230 nm, on a Thermo Scientific Hypersil Gold C18 250 × 
4.6 mm 5 micron column, with methanol:water (80:20) as the mobile phase and a flow 
rate of 1.00 mL/min.  
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2.4 Results and Discussion 
 
2.4.1 Influence of Changes in pH on Tablet Formation 
The first phase of the study investigated the influence of changes in pH of formulation 
solution comprising of gelatin and mannitol. Three pH values of 3, 5 and 8 were 
chosen to determine the effect of pH variation below, at and above the isoelectric point 
of gelatin. The results showed that tablets prepared from solutions with pH adjusted to 
3 resulted in severely denatured/degraded tablets when compared to formulations 
prepared at pH 5 and 8.  
 
The instability of the formulation at pH 3, which included the detection of no Tg, can be 
attributed to various reasons including acid hydrolysis of gelatin, maximum stability of 
gelatin at pH values between 5 and 8 and incompatibility of mannitol in strongly acidic 
solutions (Lund, 1994, Northrop, 1921 and Kramer and Inglott, 1971). The lack of 
intact tablet formation resulted in no further characterization of formulations prepared 
at pH 3. 
 
2.4.1.1 Glass Transition and Tablet Mechanical Properties 
DSC analysis of the formulation adjusted to pH 8, in its frozen state (prior to freeze-
drying), indicated that this formulation exhibited a mean onset Tg of –29.1 ± 0.4 °C, 
whilst the control formulation (pH 5) exhibited a mean onset Tg of –29.8 ± 0.5 °C. The 
results have shown that pH adjustment does not have any plasticization effect or 
reduced the physical stability of the formulations in their frozen state (prior to freeze-
drying). 
 
Measurement of hardness of the resultant tablets prepared upon pH adjustment to 8 
indicated a mean hardness of 60.0 ± 1.7 N, compared to 52.4 ± 8.8 N, the mean 
hardness of the tablets prepared at pH 5. Adjustment of the pH to 8 did not 
significantly vary the hardness when compared to pH 5 (p > 0.05). Similar results were 
obtained for fracturability studies. 
 
2.4.1.2 Tablet Porosity, SEM and Disintegration Time Analysis 
Porosity analysis of the formulation adjusted to pH 8, as shown in Figure 2.1, indicated 
that there were significant differences between tablet porosity upon adjustment of pH. 
The mean porosity value of formulations prepared at pH 8 was 93.7 ± 0.1%, whilst the 
formulations prepared at pH 5 exhibited a mean porosity value of 87.7 ± 0.2% (p < 
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0.0001). The differences in porosity upon pH adjustment of the formulation can 
possibly be due to differences in swelling properties of gelatin upon change in pH. 
Previous studies have shown that increasing the pH above isoelectric point of gelatin 
resulted in greater swelling of strands due to variations in molecular chains of gelatin 
molecules thereby resulting in larger pore sizes within the tablet matrix (Rowe et al. 
2009 and Lin et al. 2002). 
 
 
Figure 2.1 The effect of formulation pH on the porosity of the freeze-dried tablets 
(mean ± S.E., n = 3). 
 
To further study the differences in porosity, anatomical studies using scanning electron 
microscopy were carried out. SEM analysis of the formulation adjusted to pH 8, as 
shown in Figures 2.2a and 2.2b, further supports the swelling behavior of gelatin upon 
pH variations. The 2-dimensional porous structure of the freeze-dried tablets of the 
formulation adjusted to pH 8, appeared to exhibit greater average pore diameter (100–
140 µm) and thinner average pore wall thickness (20 µm) (Figures 2.2a and 2.2b), 
compared to the freeze-dried tablets of the control formulation (average pore diameter 
of 90 µm, and average pore wall thickness of 40 µm), as shown in Figures 2.3a and 
2.3b. This observation can be attributed to the swelling behavior of gelatin at pH 8 
(Sheppard et al. 1942) that results in the formation of larger pores with thinner walls. 
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(a)                                                                  (b) 
Figure 2.2 (a) SEM image of the tablet matrix of the formulation adjusted to pH 8. 
Horizontal Sample. Low Magnification, ×23; (b) SEM image of the tablet matrix of the 
formulation adjusted to pH 8. Horizontal Sample. High Magnification, ×205. 
 
    
(a)                                                                 (b) 
Figure 2.3 (a) SEM image of the tablet matrix of the control formulation. Horizontal 
Sample. Low Magnification, ×22; (b) SEM image of the tablet matrix of the control 
formulation. Horizontal Sample. High Magnification, ×176. 
 
Analysis of the disintegration time of the formulation adjusted to pH 8, as shown in 
Figure 2.4, indicated a mean disintegration time of 54 ± 1.7 s, whereas the formulation 
prepared at pH 5 exhibited a mean disintegration time of 132 ± 25.4 s. Adjustment of 
pH resulted in the reduction of disintegration time by over a half (p < 0.05), as shown 
in Figure 2.4 This observation can be attributed to two factors. Firstly, porosity and 
SEM studies revealed that the tablets prepared at pH 8 had higher porosity and 
thinner pore walls which could result in an increase in water uptake and subsequent 
better wetting/dispersibility (He et al. 2008). Secondly, previously published reports 
have shown that aqueous solubility of gelatin is influenced by variations in pH with 
values above the isoelectric point of the material exhibiting an increase in its solubility 
(Cortesi et al. 1999 and Benjakul et al. 2009). 
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Figure 2.4 The effect of formulation pH on the disintegration time of the freeze-dried 
tablets (mean ± S.E., n = 3). 
 
As reported previously, the Food and Drug Administration recommends that ODTs be 
considered as solid oral preparations that disintegrate rapidly in the oral cavity, with an 
in vitro disintegration time of approximately 30 seconds or less, when based on the 
United States Pharmacopeia disintegration test method or alternative (Food and Drug 
Administration, 2008). As Figure 2.4 shows, despite disintegration time decreasing 
from 132 ± 25.4 s to 54 ± 1.7 s, this value is greater than the 30 s value recommended 
by the Food and Drug Administration.  
 
2.4.2 Influence of Ionic Strength 
To investigate the influence of ionic strength, various ratios of sodium chloride were 
incorporated in the formulation with gelatin and mannitol. The results revealed that 
sodium chloride had a concentration dependant influence. Formulations comprising of 
a 1:40 molar ratio of gelatin:sodium chloride resulted in a collapse of the final product 
with no tablet formation. Lower molar ratios (1:5, 1:10, 1:20 and 1:30) produced intact 
tablets and were characterized further for mechanical as well as thermal properties. 
 
2.4.2.1 Glass Transition and Tablet Mechanical Properties Analysis 
DSC analyses of formulations with 1:5–1:30 molar ratios of gelatin:sodium chloride, as 
shown in Table 2.2, indicated mean onset Tg values comparable to the control 
formulation. The mean onset Tg values were –29.3 ± 0.1 °C, –30.5 ± 0.1 °C, –31.2 ± 
0.2 °C and –31.7 ± 0.2°C, for 1:5, 1:10, 1:20 and 1:30 ratios, respectively, whilst the 
control formulation exhibited a mean onset Tg value of  
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–29.8 ± 0.5 °C. Statistical analysis of the results indicated that the formulations 
consisting of gelatin:sodium chloride in molar ratios of 1:20 and 1:30, exhibited mean 
onset Tg values which were significantly different (p < 0.01) from the control 
formulation.  
 
Table 2.2 Glass transition data of the formulations consisting of various ratios of 
gelatin:sodium chloride. 
Formulation Mean Onset 
Tg (°C) 
Standard 
Error 
Control –29.8 0.5 
1:5 –29.3 0.1 
1:10 –30.5 0.1 
1:20 –31.2 0.2 
1:30 –31.7 0.2 
 
These results are in coherence with previous research investigating the effect of 
cations and anions of various electrolytes on the glass transition temperature of frozen 
solutions of excipients commonly used in freeze-drying, resulting in a decrease in 
glass transition temperature upon increasing ion concentration (Nesarikar and Nassar, 
2007). Formulations consisting of 1:20 and 1:30 gelatin:sodium chloride molar ratios, 
did exhibit significantly different mean onset Tg values relative to the control 
formulation (p < 0.01). However, as the difference was only around 2°C, the structural 
collapse/shrinkage seen with the tablets of the formulation consisting of a 
gelatin:sodium chloride molar ratio of 1:40 was considered a physical rather than a 
thermal stability issue.  
 
The inclusion of sodium chloride in the formulations with gelatin:sodium chloride molar 
ratios of 1:5–1:30 did not result in a significant increase in tablet hardness when 
compared to the control (p > 0.05), as shown in Table 2.3. Formulations with 
gelatin:sodium chloride molar ratios of 1:5, 1:10, 1:20 and 1:30, exhibited hardness 
values of 63.6 ± 5.6 N, 63.2 ± 8.0 N, 70.1 ± 2.1 N and 67.8 ± 8.3 N, respectively, whilst 
the control formulation had a mean value of 52.4 ± 8.8 N.  
 
Table 2.3 Tablet hardness data of the formulations consisting of various ratios of 
gelatin:sodium chloride. 
Formulation Mean Tablet Hardness 
(N) 
Standard Error 
Control 52.4 8.8 
1:5 63.6 5.6 
1:10 63.2 8.0 
1:20 70.1 2.1 
1:30 67.8 8.3 
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Analysis of the fracturability of the tablets of formulations with gelatin:sodium chloride 
molar ratios of 1:5–1:30 indicated that there was no statistical difference in the 
fracturability values of the various ratios of sodium chloride when compared to the 
control.  
 
2.4.2.2 Tablet Porosity, SEM and Disintegration Time Analysis 
The inclusion of sodium chloride in the formulations resulted in differences in porosity 
of the tablets. Statistical analysis of the results indicated that the formulations 
consisting of gelatin:sodium chloride molar ratios of 1:5, 1:20 and 1:30, showed tablet 
porosities which were statistically significant (p < 0.01), when compared to the tablet 
porosity of the control formulation. There appeared to be a general trend that 
increasing the molar ratio of gelatin:sodium chloride from 1:5 to 1:20, produced a 
general increase in tablet porosity (1:5, 1:10 and 1:20, exhibited tablet porosity values 
of 88.70 ± 0.08%, 87.70 ± 0.08% and 89.50 ± 0.10%, respectively). The differences in 
porosity upon inclusion of sodium chloride can potentially be attributed to the 
differences in swelling behavior of gelatin in the presence of monovalent ions. 
Previous research has highlighted that the presence of sodium chloride had a bearing 
on the cross-linking of gelatin strands (Collett and Moreton, 2002). It is possible that 
inclusion of sodium chloride reduced the cross-linking during gelation which 
subsequently influenced tablet porosity.  
 
These results were further confirmed by SEM. SEM micrographs showed that the 
inclusion of sodium chloride in the formulations produced porous structures which 
generally exhibited the formation of larger pores and thinner pore walls (Figures 2.5a 
and 2.5b), compared to the porous structure of the control formulation (Figures 2.3a 
and 2.3b). 
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(a)                                                                  (b) 
Figure 2.5 (a) SEM image of the tablet matrix of the 1:30 gelatin:soluble salt molar 
ratio formulation. Vertical Sample. Low Magnification, ×25; (b) SEM image of the 
tablet matrix of the 1:30 gelatin:soluble salt molar ratio formulation. Vertical Sample. 
High Magnification, ×205. 
 
Horizontal sections of the tablets with gelatin:sodium chloride molar ratios of 1:10, 
1:20 and 1:30, revealed average pore diameters of 100, 210 and 120 µm, 
respectively. Interestingly, tablets with a 1:20 gelatin:sodium chloride molar ratio, 
exhibited the greatest tablet porosity and shortest disintegration time of the four 
gelatin-soluble salt formulations. SEM analysis of the tablets revealed that increasing 
gelatin:soluble salt molar ratio appeared to increase disruption/damage to the porous 
matrix structures. The formulation with gelatin:sodium chloride molar ratio of 1:30, in 
particular, exhibited structural instability (as it appeared that pores had collapsed, 
forming cavities in the matrix) as shown in Figures 2.5a and 2.5b. This was likely due 
to the higher gelatin:soluble salt molar ratio, which appeared to weaken the structure, 
which led to the collapse of pores. 
 
Analysis of the tablet disintegration times of formulations with gelatin:sodium chloride 
molar ratios of 1:5–1:30, showed that the inclusion of sodium chloride in the 
formulations with gelatin:sodium chloride molar ratios of 1:10 (126.7 ± 4.0 s) and 1:20 
(102.3 ± 10.1 s), did not produce a significant reduction in disintegration time 
compared to the control formulation (132.0 ± 25.6 s mean disintegration time) (p > 
0.05). The formulation with a gelatin:sodium chloride molar ratio of 1:5 produced a 
disintegration time (134.7 ± 12.0 s) comparable to the control formulation.  
 
2.4.3 Milling Study 
Ball milling has several pharmaceutical applications, which rely on a number of milling 
factors/parameters, such as; milling time, number of milling balls and milling jar 
volume, to fulfil their applications. These milling factors/parameters have a large range 
of operation, e.g. milling time can range from a few minutes to several hours, thus 
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making the possible number of milled sample formulations very large. Hence, factorial-
experimental design software was used in order to propose a more 
suitable/manageable number of formulations (as shown in Table 2.1), which 
underwent various milling conditions based on three parameters; milling time, rotation 
speed and ball:powder weight ratio. 
 
2.4.3.1 Wettability Analysis 
The wettability analysis results are shown in Figure 2.6. Formulations N7 (milling 
conditions; milling time of 15 minutes, at a rotation speed of 400 rpm, with a 
ball:powder weight ratio of 15) and N11 (milling conditions; milling time of 37.5 
minutes, at a rotation speed of 250 rpm, with a ball:powder weight ratio of 10) showed 
the lowest contact angles, 94.0 ± 0.3° and 94.1 ± 1.0° respectively, and thus the 
greatest wettability (p < 0.05), whilst the control formulation exhibited a contact angle 
of 120.7 ± 11.0°. Milling is regularly used for the reduction of particle size (Mallick et al. 
2008), the observed improvement in wettability as a result of ball milling, can be 
attributed to a reduction in particle size and subsequent increase in surface area of the 
formulations (Kim et al. 2010). 
 
 
Figure 2.6 Analysis of the wettability of the milled formulations, expressed through 
their determined contact angle (mean ± S.E., n = 3).  
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2.4.3.2 Powder Porosity Analysis 
A significant variation in powder porosity between the formulations was recorded, as 
some of the mixtures exhibited greater porosity than the control (non-milled, 62.1 ± 
0.3%), whilst others showed lower porosity. Formulation N8 showed the greatest 
porosity of 69.55 ± 0.1%, whilst formulation N6 produced the lowest value of 49.19 ± 
0.2%. The porosity of the studied formulations is associated with their bulk density 
(Staniforth, 2002). Therefore, as porosity varies between the formulations, so do their 
bulk density, which is related to the way in which the particles of the formulations are 
packed, during sample porosity analysis (Staniforth, 2002). As milling is associated 
with particle size reduction, the various milling conditions are expected to produce a 
range of differing particle sizes. It is therefore expected that the way these particles 
pack during porosity analysis varies greatly, which results in differences in inter-
particulate void spaces and subsequent variation in porosity between the formulations. 
All eleven of the formulations exhibited statistical significance, which indicates that ball 
milling has a significant effect on the porosity of the powders. Formulation N10 had a p 
value of < 0.05, whilst all the other formulations had a p value of < 0.01. 
 
2.4.3.3 Glass Transition and Tablet Mechanical Properties Analysis 
DSC analysis of freeze-dried products is essential in order to fully appreciate and 
understand critical formulation properties such as the collapse temperature of the 
formulation (Tang and Pikal, 2004). The macroscopic collapse temperature of a 
formulation is defined as the temperature above which the freeze-dried product loses 
macroscopic structure and collapses during freeze-drying (Mackenzie, 1966). The 
macroscopic collapse temperature is closely related to the glass transition temperature 
of the formulation in its frozen state (Pikal and Shah, 1990). Therefore, in order to 
produce an acceptable freeze-dried product, it is always required to freeze dry a 
formulation at a temperature lower than the macroscopic collapse temperature (Pikal, 
1990a and Pikal, 1990b). 
 
Six of the eleven formulations exhibited glass transition temperatures which were 
considered not statistically significant (p > 0.05), when compared to the mean glass 
transition temperature of the control (non-milled) formulation. It can therefore be 
concluded that ball milling does not adversely affect the physical stability of the 
formulations in their frozen state or induce a plasticization effect, as comparable glass 
transition temperatures were observed.  
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All eleven of the formulations produced tablet hardness values which were not 
statistically significant (p > 0.05), when compared to the value of the control (non-
milled) formulation (62.2 ± 3.8 N). Formulation N5 had the tablet hardness value of 
55.0 ± 5.0 N, whilst formulation N10 produced the tablets which had hardness of 65.3 
± 1.0 N. 
 
Similar results were obtained for fracturability analysis as no significant differences 
were observed when compared to the non-milled control formulation. 
 
2.4.3.4 Tablet Porosity, SEM and Disintegration Time Analysis 
Tablet porosity is a critical property of ODTs, as highly porous tablets allow the rapid 
penetration of saliva into the tablet, which results in rapid oral disintegration. Tablet 
porosity significantly impacts the initial wetting and dispersion of active pharmaceutical 
ingredients (He et al. 2008). It is therefore advisable to make tablets as porous as 
possible in order to achieve rapid disintegration. However, it is important to note that 
the physical/mechanical properties of the tablets such as hardness, should be 
maintained (He et al. 2008). In general it is considered that increasing tablet porosity 
leads to an increase in water uptake and subsequent better wetting/dispersibility of 
active pharmaceutical ingredients (He et al. 2008), and consequently tablets exhibit 
shorter disintegration times. 
 
The control formulation had porosity of 93.4 ± 0.4%. Formulation N6 produced tablets 
with the highest porosity of 94.4 ± 0.3%, whilst formulation N5 resulted in tablets with 
the lowest porosity of 92.9 ± 0.1%.  
 
All studied formulations exhibited tablet porosities which were not statistically 
significant (p > 0.05), when compared to the tablet porosity of the control formulation.  
 
These data were further confirmed with the SEM analysis as no microscopic 
differences were observed between milled and non-milled formulations. 
 
The disintegration time was slightly different between the formulations. The control 
(non-milled) had a mean disintegration time of 23 ± 1 s. Tablets from formulation N5 
exhibited the greatest disintegration time of 28 ± 2 s, whilst formulations N2, N10 and 
N11 all had the shortest disintegration time of 21 s.  
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2.4.3.5 Dissolution Study Analysis 
Figure 2.7 illustrates the mean dissolution results for ibuprofen tablets, prepared from 
non-milled and milled tablet excipients. Although the time required for 80% ibuprofen 
dissolution from the tablets prepared from non-milled and milled materials, were 20 
and 10 minutes, respectively, statistical analysis of the results indicated that there was 
no significant difference (p > 0.05) in the dissolution behavior of ibuprofen from the two 
tablet formulations. The results have therefore shown that milling the excipients did not 
influence ibuprofen dissolution from the lyophilized ODTs.        
 
 
Figure 2.7 Dissolution profile of ibuprofen from lyophilized ODTs, prepared from non-
milled and milled tablet excipients (mean ± S.E., n = 3).  
 
Tablet porosity and disintegration time are both critical properties in determining active 
pharmaceutical ingredient dissolution, as tablet porosity in particular, significantly 
impacts the initial wetting and dispersion of active pharmaceutical ingredients (He et 
al. 2008). Initial results from this milling study, indicated that ball milling did not 
significantly affect tablet porosity and tablet disintegration time, when compared with 
tablets prepared from non-milled excipients. Therefore, comparable dissolution profiles 
of ibuprofen from tablets prepared from non-milled and milled materials was expected. 
 
2.5 Conclusions 
The study has shown that process parameters such as pH adjustment can have a 
significant influence on the disintegration time of gelatin based orally disintegrating 
tablets. The reduction in disintegration time did not compromise tablet hardness, which 
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is a key parameter to measure ODT performance. The reduction in disintegration time 
can be attributed to an increase in tablet porosity, which allows the more rapid 
penetration of saliva or disintegrating medium into the tablet matrix, and an increase in 
gelatin solubility. The inclusion of sodium chloride in the formulations, to modify the 
ionic strength of the formulations, had an effect on tablet porosity and the glass 
transition of the formulations. However, inclusion of sodium ions is concentration 
dependent, with tablets comprising of higher salt concentration resulting in structural 
collapse/shrinkage. The study has also shown that ball milling influences formulation 
characteristics, such as powder porosity, and improves powder wettability. 
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3.1 Introduction 
Methocel™ cellulose ethers are cellulose-derived water-soluble polymers (DOW 
Chemical Company, 2002). The majority of Methocel™ products are based on 
hydroxypropyl methylcellulose (HPMC), whilst the remaining products are based on 
methylcellulose (DOW Chemical Company, 2002). 
 
HPMC, which is also referred to as hypromellose, is defined as a partly O-methylated 
and O-(2-hydroxypropylated) cellulose (British Pharmacopoeia Commission, 2011), for 
which the structural formula is shown in Figure 3.1. In terms of its appearance, it is a 
white or creamy-white fibrous or granular powder that is odourless and tasteless 
(Rogers, 2009).   
 
Figure 3.1 Structural formula of HPMC, where R is H, CH3, or CH3CH(OH)CH2. Figure 
obtained from Rogers (2009). 
 
HPMC is practically insoluble in hot water, acetone, anhydrous ethanol and toluene, 
whilst it is soluble in cold water, in which it forms a colloidal solution (British 
Pharmacopoeia Commission, 2011). 
 
In order to form an aqueous solution of HPMC, a method called the “hot/cold” 
technique is used, which utilises the insolubility of HPMC in hot water (DOW Chemical 
Company, 2002). The technique involves firstly dispersing the HPMC powder in 1/5 to 
1/3 of the total volume of water, that has been heated to above 90ºC (DOW Chemical 
Company, 2002). To ensure complete solubilisation of the HPMC powder, the 
remaining volume of water is then added as cold water to reduce the temperature of 
the dispersion (DOW Chemical Company, 2002). Once the dispersion reaches critical 
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temperature, HPMC becomes water soluble which results in hydration of the powder 
and an increase in solution viscosity (DOW Chemical Company, 2002). 
 
HPMC has a broad spectrum of applications in pharmaceutical formulations, in which it 
is used widely in oral, nasal, topical and ophthalmic formulations (Rogers, 2009). In 
terms of oral products, it is principally used as a tablet binder (Chowhan, 1980), in film-
coating (Rowe, 1980) and as a matrix-former in sustained-release tablet formulations 
(Dahl et al. 1990). Another application of HPMC in oral formulations is its use in liquid 
formulations as a suspending and/or thickening agent (Food and Drug Administration, 
2011), whilst it has the same application/use in topical and ophthalmic formulations 
(Rogers, 2009). 
 
The broad application spectrum of HPMC in pharmaceutical formulations is credited to 
its versatility as a molecule. HPMC is adaptable in terms of molecular weight, which 
has a bearing on solution viscosity, and is versatile in terms of degree of substitution, 
which influences its water solubility.  
 
As already mentioned, some Methocel™ products are based on methylcellulose (DOW 
Chemical Company, 2002), which is defined as a partly O-methylated cellulose (British 
Pharmacopoeia Commission, 2012), for which the structural formula is shown in Figure 
3.2. 
 
Figure 3.2 Structural formula of methylcellulose, where the structure shown is with 
complete substitution of the available hydroxyl units with methoxyl units. Figure 
obtained from Allen Jr (2012). 
 
Methylcellulose has a similar appearance to HPMC; white, fibrous powder or granules, 
which is practically odourless and tasteless (Allen Jr, 2012). As with HPMC, 
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methylcellulose is practically insoluble in hot water, and also in acetone, anhydrous 
ethanol and toluene, whilst it is soluble in cold water, in which it forms a colloidal 
dispersion (British Pharmacopoeia Commission, 2012), which is prepared by the 
already discussed “hot/cold” technique (DOW Chemical Company, 2002).  
 
Similar to HPMC, methylcellulose has a wide range of applications in pharmaceutical 
formulations, in which it is widely used in oral, topical and ophthalmic preparations 
(Allen Jr, 2012). Methylcellulose is used as a binding agent (Wan and Prasad, 1989 
and Itiola and Pilpel, 1991), disintegrant (Esezobo, 1989) and as a matrix-
forming/sustained-releasing agent (Sanghavi et al. 1990) in tablet formulations. It also 
has applications as a suspending or thickening agent in oral liquid preparations (Dalal 
and Narurkar, 1991). 
 
In terms of topical products, methylcellulose is used as a thickening agent (Allen Jr, 
2012), whilst for ophthalmic preparations, it is used as a vehicle for eye-drops 
(Gerbino, 2005). 
 
HPMC and methylcellulose have both been investigated in the formulation of 
lyophilised ODTs. Corveleyn and Remon (1998 and 2000) reported the use of HPMC 
and methylcellulose as binding and emulsifier-tablet binding agents. Corveleyn and 
Remon (1998) reported in a study, in which HPMC was evaluated as an emulsifier-
tablet binding agent, in the preparation of dry emulsion tablets and that HPMC 
concentration had a significant influence on tablet strength and disintegration time. In 
the study reported by Corveleyn and Remon (1998), two HPMC grades were 
evaluated; Methocel™ E15LV and K100LV. 
 
The difference between Methocel™ E15LV and K100LV grades, is that the E15LV 
grade has a methoxyl degree of substitution of 1.9 and a hydroxypropyl molar 
substitution of 0.23, whilst the K100LV grade has a methoxyl degree of substitution of 
1.4 and a hydroxypropyl molar substitution of 0.21 (DOW Chemical Company, 2002). 
The E15LV grade has a viscosity of 15 mPa s, whilst the K100LV grade has a viscosity 
of 100 mPa s (typical viscosity values for 2% (w/v) aqueous solutions, measured at 
20ºC) (DOW Chemical Company, 2002). The “LV” suffix found in the names of both 
grades, refers to “low viscosity” grades (DOW Chemical Company, 2002). 
 
Ahmed et al. (2011) reported a study which evaluated the use of maltodextrin as a 
sugar-matrix former along with several cellulosic binders in the preparation of 
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nimesulide freeze-dried ODTs.  The study investigated the different grades including 
Methocel™ E5LV, E15LV and A15LV. The grades differ in that both E5LV and E15LV 
are HPMC grades, whilst the A15LV is a grade of methylcellulose. In terms of the two 
HPMC grades, both have a methoxyl degree of substitution of 1.9 and a hydroxypropyl 
molar substitution of 0.23 (DOW Chemical Company, 2002). The E5LV grade has a 
nominal viscosity of 5 mPa s, whilst the E15LV grade has a nominal viscosity of 15 
mPa s (DOW Chemical Company, 2002).  
 
Tablet characteristics, in vitro/in vivo disintegration time and in vitro dissolution of 
nimesulide were investigated using full factorial design (Ahmed et al. 2011). The 
optimized ODT formulation consisted of 5% w/v maltodextrin DE 29, 2% w/v Methocel™ 
E15LV and 5% w/v nimesulide, which exhibited a disintegration time of less than 10s, 
and 70% dissolution of nimesulide within 2 minutes, in comparison to 1.52% of the 
drug alone and 7.25% of an immediate release commercial tablet (Ahmed et al. 2011). 
The study suggested that the optimized ODT formulation maybe an alternative to 
conventional nimesulide formulations such as formulations administered via 
intramuscular or rectal routes, which are inconvenient to patients (Ahmed et al. 2011). 
 
The studies carried out by Ahmed et al. (2011) and Corveleyn and Remon (1998) 
evaluated two grades of HPMC as binders in freeze-dried ODTs. Ahmed et al. (2011) 
studied Methocel™ E5LV and E15LV, whilst Corveleyn and Remon (1998) investigated 
Methocel™ E15LV and K100LV. The three different grades of HPMC which were 
evaluated (both Ahmed et al. (2011) and Corveleyn and Remon (1998) evaluated 
Methocel™ E15LV), are all low viscosity grades of HPMC. 
 
Due to the considerable versatility of Methocel™, the aim of this chapter was to carry 
out a more extensive, systematic and comprehensive evaluation of its application as a 
binder in lyophilised ODTs, in terms of evaluating both low and high viscosity grades, 
as well as investigating grades which possess different methoxyl and hydroxypropyl 
degrees of substitution. 
 
Table 3.1 shows the grades of Methocel™ which were investigated in this study, for 
their application as binders in freeze-dried ODTs. Several formulations were prepared 
based on each of the seven grades of Methocel™ evaluated in this study. Each 
formulation prepared was assessed for its ability to form intact tablets, which were 
subsequently characterised for hardness and disintegration time. The viscosity and 
thermal properties (determined by DSC) of the formulations were also assessed. 
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Table 3.1 Information detailing the different grades of Methocel™ evaluated in this study. 
Methocel 
 Grade 
Substitution Type (First two digits refer to the 
approximate percentage content of the methoxy group 
(OCH3). Second two digits refer to the approximate 
percentage content of the hydroxypropoxy group 
(OCH2CH(OH)CH3)). 
Nominal 
Viscosi-
ty 
 at 20°C 
(mPa s) 
Methoxyl 
Degree 
 of 
Substitution 
Methox-
yl 
 % 
Hydroxypro-
pyl 
 Molar 
Substitution 
Hydroxyp-
ropyl 
 % 
A15LV N/A 15 1.8 30 N/A N/A 
A4M N/A 4,000 1.8 30 N/A N/A 
E3LV 2910 3 1.9 29 0.23 8.5 
K3LV 2208 3 1.4 22 0.21 8.1 
K100LV 2208 100 1.4 22 0.21 8.1 
K4M 2208 4,000 1.4 22 0.21 8.1 
K100M 2208 100,000 1.4 22 0.21 8.1 
Note: The initial letter “A” of the Methocel™ grade refers to methylcellulose products, whilst the initial letters “E” and “K” refer to HPMC products. 
The number that follows the initial letter refers to the viscosity of the products. Relating to the viscosity of the products, the letter “M” refers to 
1,000. The suffix “LV” refers to low viscosity products. Information included in this table was obtained from Rogers (2009) and DOW Chemical 
Company (2002). 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three: Methocel™ (Hydrophilic Cellulose Ethers) 
 
74 
 
3.2 Materials 
Methylcellulose (Methocel™ A15LV (Lot No. DT292864) and A4M (Lot No. DT241464)), 
HPMC (Methocel™ E3LV (Lot No. DT220342), K3LV (Lot No. DT232237), K100LV (Lot 
No. DT199337), K4M (Lot No. DT243235) and K100M (Lot No. DT259593)) were 
supplied by Colorcon Ltd. (Dartford, UK). Mannitol was supplied by Sigma-Aldrich 
Chemicals (Poole, UK). All the chemicals were used without further purification. 
 
3.3 Methods 
 
3.3.1 Preparation of Freeze-Dried Tablets 
For Methocel™ A and K based formulations, respectively, the required amount of 
polymer was mixed with half of the desired volume of water at 70°C and 80-90ºC, 
respectively. The remaining half of the desired volume of water at ambient temperature 
was then added to the hot polymer suspension, in order to form a clear aqueous 
solution. This was followed by the addition of mannitol, to form the final solution.  
 
1.5 g of the resulting solutions were dosed into a tablet mould, frozen at -70°C for a 
minimum of sixty minutes and freeze-dried (ADVANTAGE, Freeze-Dryer, VIRTIS), 
according to the following regime; primary drying for forty eight hours at a shelf 
temperature of -40°C, secondary drying for ten hours at a shelf temperature of 20°C, 
and vacuum pressure of 6.67 Pa (50 mTorr). A minimum of ten tablets were prepared 
for each formulation. 
 
3.3.2 Formulation Viscosity Analysis 
For all formulations, the viscosities of 100 mL samples were measured using a DV-I+ 
Brookfield digital viscometer (Harlow, UK). The viscosities of the formulations were 
measured at 37 ± 2°C, in order to replicate the viscosity of the formulations in the oral 
cavity, at physiological temperature. The viscometer spindles were selected based on 
the viscosity of the individual formulations, as each spindle is suitable for analysing a 
certain viscosity range. The rotational speed of the spindle was set at 100 rpm. Each 
formulation was analysed in triplicate, and the mean values ± standard deviation is 
reported. 
 
3.3.3 Concentration Profiling and Macroscopic Evaluation of the Formulations 
During the preparation of the formulations, several visual assessments were carried 
out in order to evaluate the polymers as binders. The solubility of the material was 
assessed by observing the ease at which the polymer went into solution. The ease of 
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dosing of the formulations was also assessed, in terms of the viscosity of the prepared 
formulations. 
 
In terms of the macroscopic evaluation of the tablets, several assessments were 
carried out in order to evaluate the ability of the polymers to form robust tablets with 
satisfactory mechanical strength. The first assessment involved the evaluation of the 
ability of the formulations to form intact tablet shaped dosage forms following freeze-
drying. The physical appearance of the tablets was assessed, classifying them as 
either soft or hard, and having either elastic or a more robust/solid consistency. The 
ability of the tablets to be removed from the moulds was also assessed. Finally, the 
performance of the tablets when handled was assessed, to observe if they deformed 
permanently or retained their shape. 
 
The first phase of the investigation was focussed on concentration profiling of the low 
viscosity grades of Methocel™ (A15LV, E3LV, K3LV and K100LV) to determine the 
optimum binder concentrations and understand their function as binders. Tables 3.2-
3.5 represent the various formulations that were prepared with the four low viscosity 
grades of Methocel™.  
 
Table 3.2 Formulation details of Methocel™ A15LV formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 30 
1 70 
2 30 
2 70 
3 30 
3 70 
5 30 
5 70 
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Table 3.3 Formulation details of Methocel™ E3LV formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
5 0 
5 30 
10 0 
10 30 
11 0 
11 30 
 
Table 3.4 Formulation details of Methocel™ K3LV formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
5 0 
5 30 
10 0 
10 30 
 
Table 3.5 Formulation details of Methocel™ K100LV formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 30 
1 70 
3 30 
3 70 
 
The second phase of the investigation was focussed on concentration profiling of the 
high viscosity grades of Methocel™ (A4M, K4M and K100M) to determine the optimum 
binder concentrations and understand their role as binders. Tables 3.6-3.8 represent 
the various formulations that were prepared with the three high viscosity grades of 
Methocel™.  
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Table 3.6 Formulation details of Methocel™ A4M formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation.  
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 30 
1 70 
2 30 
2 70 
 
Table 3.7 Formulation details of Methocel™ K4M formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 30 
1 70 
2 30 
2 70 
 
Table 3.8 Formulation details of Methocel™ K100M formulations, detailing the 
concentrations of Methocel™ and mannitol used in each formulation. 
Methocel™ 
Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 30 
1 70 
2 30 
2 70 
 
 
3.3.4 Differential Scanning Calorimetry (DSC) 
DSC (Pyris Diamond DSC and Intercooler 2P: Perkin Elmer, Wellessey, USA) was 
used to determine the glass transition temperature (Tg) and thermal properties of the 
formulations in their frozen state (before freeze-drying). 10-15 mg of liquid samples of 
the formulations were loaded into aluminium pans, cooled from 25ºC to -65ºC at a rate 
of 5ºC/min, and then heated to 20ºC at a rate of 5ºC/min, with a nitrogen purge of 20 
mL/min. An empty aluminium pan was used as a reference for all measurements.  
 
The resulting thermograms were analysed by Pyris manager software. Tg values were 
determined from the intersection of relative tangents to the baseline, and other thermal 
properties of the formulations were also assessed. Three measurements were taken 
for each formulation, and the mean values ± standard deviation were reported. 
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3.3.5 Tablet Hardness and Fracturability 
The hardness and fracturability of the tablets was investigated using a texture analyzer 
(QTS 25: Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was 
calibrated by standard weights of 500 g and 5 kg. The tablets were placed in a holder 
with a cylindrical hole. The hardness was taken as the peak force after 1 mm 
penetration of a 5 mm diameter probe at a rate of 6 mm/min. The fracturability was 
taken as the peak force after 3 mm penetration of a 1 mm diameter probe at a rate of 6 
mm/min. Three measurements were taken for each formulation and the mean ± 
standard deviation is reported. 
 
3.3.6 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2ºC, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 rpm. Three 
tablets were evaluated from each formulation, and the mean values ± standard 
deviation is reported. 
 
3.3.7 Investigation of Tablet Porosity 
The porosity of the tablets was measured using helium pycnometry 
(MULTIPYCNOMETER, Quantachrome Instruments, Hampshire, UK). Two freeze-
dried tablets were placed in a suitably sized sample cup and subjected to helium 
pycnometry, to determine the true density of the tablets. The true density value was 
then inserted into the equation, as shown below, to determine the porosity of the 
tablets. 
 
                                Porosity =  1 –  bulk density    x 100% 
       true density 
 
(Equation 3.1) 
                                                                           
Bulk density was determined by considering; the mass of the tablets, the diameter of 
the tablets, and the height/depth of the tablets. The diameter and height/depth of the 
tablets were determined using a screw gauge (LINEAR Farnell). Three porosity 
measurements were taken for each formulation, and the mean values ± standard 
deviation is reported. The porosity of the tablets is expressed as a percentage. 
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3.3.8 Statistical Analysis 
Statistical analyses of the formulation and tablet characterisation results were 
performed using GraphPad Prism 5 statistical analysis software. One-way analysis of 
variance (ANOVA) was the statistical analysis test performed, using the Tukey post 
test. A significance level of p < 0.05 (95% confidence interval) was judged as being 
statistically significant.    
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3.4 Results and Discussion 
 
3.4.1 Low Viscosity Grades of Methocel™ 
 
3.4.1.1 Concentration Profiling and Macroscopic Evaluation of the Formulations 
of Low Viscosity Grades of Methocel™ 
Tables 3.9-3.12 represent the macroscopic evaluation of the tablets prepared from the 
various formulations that were prepared with the four low viscosity grades of 
Methocel™. 
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Table 3.9 Concentration profiling and macroscopic evaluation of the various Methocel™ A15LV formulations prepared. 
 
 
 
 
 
 
Formulation Comments 
1% w/w Methocel A15LV with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were soft with a “spongy/foamy” consistency. The tablets were 
easy to remove from the moulds, and showed a very elastic nature following handling (returned to their 
original shape following compression). 
1% w/w Methocel A15LV with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were very soft/fragile, and broke/disintegrated when handled. The 
tablets could not be removed from the moulds. 
2% w/w Methocel A15LV with 
30% w/w (of dried tablet 
weight) mannitol 
Not all the tablets dried satisfactorily and formed intact compacts. Those that did dry satisfactorily were 
relatively solid in nature, with a “spongy/foamy” consistency. The tablets were easy to remove from the 
bijou tubes, and were difficult to deform following handling (as tablets returned to their original shape 
following compression). 
2% w/w Methocel A15LV with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. However the tablets were soft/fragile, and broke/disintegrated when handled. 
The tablets could not be removed from the moulds. 
3% w/w Methocel A15LV with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets not formed.  
3% w/w Methocel A15LV with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. However the tablets were fragile and disintegrated when handled. The tablets 
were easily removed from the moulds. 
5% w/w Methocel A15LV with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets not formed. 
5% w/w Methocel A15LV with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were very hard/solid, and did not deform/break when handled. The 
tablets were easily removed from the moulds. 
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Table 3.10 Concentration profiling and macroscopic evaluation of the various Methocel™ E3LV formulations prepared. 
Formulation Comments 
1% w/w Methocel E3LV Intact tablets formed. Tablets were soft with a “spongy/foamy” consistency. Tablets did not deform 
when handled, they retained their shape. Tablets easily removed from moulds. 1% w/w Methocel E3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
5% w/w Methocel E3LV Intact tablets formed. Tablets were hard and robust. Tablets did not deform when handled, they 
retained their shape. Tablets easily removed from moulds. The 5% w/w Methocel E3LV tablets 
(mannitol-free), had a noticeable “spongy/foamy” consistency. 
5% w/w Methocel E3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
10% w/w Methocel E3LV Intact tablets formed. Tablets were very hard and robust. Tablets did not deform when handled, they 
retained their shape. Tablets easily removed from moulds. 10% w/w Methocel E3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
11% w/w Methocel E3LV 
11% w/w Methocel E3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
 
Table 3.11 Concentration profiling and macroscopic evaluation of the various Methocel™ K3LV formulations prepared. 
Formulation Comments 
1% w/w Methocel K3LV Intact tablets formed. Tablets were soft with a “spongy/foamy” consistency. Tablets did not deform 
when handled, they retained their shape. Tablets easily removed from the moulds. 1% w/w Methocel K3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
5% w/w Methocel K3LV Intact tablets formed. Tablets were hard and robust. Tablets did not deform when handled, they 
retained their shape. Tablets easily removed from moulds. 5% w/w Methocel K3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
10% w/w Methocel K3LV Intact tablets formed. Tablets were very hard and robust. Tablets did not deform when handled, they 
retained their shape. Tablets easily removed from moulds. 10% w/w Methocel K3LV with 30% 
w/w  
(of dried tablet weight) Mannitol 
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Table 3.12 Concentration profiling and macroscopic evaluation of the various Methocel™ K100LV formulations prepared. 
Formulation Comments 
1% w/w Methocel K100LV 
with 30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were soft with a “spongy/foamy” consistency. Tablets retained shape when 
handled, and did not deform permanently. 
1% w/w Methocel K100LV 
with 70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. However, very soft/fragile, and the tablets broke/disintegrated easily when handled. 
Tablets could not be removed from the moulds intact. 
3% w/w Methocel K100LV 
with 30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were hard with a noticeable “spongy” consistency. Tablets retained shape 
when handled, and did not deform permanently. 
3% w/w Methocel K100LV 
with 70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were hard and physically stable, and did not deform when handled. The 
tablets were relatively easily removed from the moulds. 
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Observations made during the formulation of Methocel™ A15LV, revealed that this 
grade could be used in concentrations up to 5% w/w with higher concentrations 
proving difficult to dose due to their high viscosities. The viscosity results (Figure 3.3) 
revealed that the workable viscosity range for this grade of Methocel™, in order to 
prepare tablets was 0.77 ± 0.15 to 16.40 ± 9.76 mPa s.  Macroscopic evaluation of the 
tablets of formulations made from this grade of Methocel™ indicated that this grade of 
the polymer did produce intact tablets from most of the formulations. However, it was 
not possible to make tablets from formulations containing 3 and 5% w/w Methocel™ 
with 30% w/w (of dried tablet weight) mannitol, as intact tablets were not formed 
following freeze-drying. Interestingly, the corresponding formulations consisting of 70% 
w/w (of dried tablet weight) mannitol, did form intact tablets suggesting that the ability 
of mannitol to function as a matrix supporting agent with this particular grade of 
Methocel™ is concentration dependent, as mannitol concentration of 30% w/w (of dried 
tablet weight) was not sufficient to provide the necessary matrix support to form intact 
tablets.  
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Figure 3.3 Viscosity analysis results of Methocel™ low viscosity grade formulation A15LV. Viscosity analyses of the formulations were carried 
out in triplicate and the mean values ± standard deviation are reported. 
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Formulations of Methocel™ A15LV at 1 and 2% w/w, resulted in intact “elastic” tablets 
which were easily removable from the moulds. Tablets containing 70% w/w (of dried 
tablet weight) mannitol, were softer and fragile compared to tablets made of 30% w/w 
mannitol. A possible explanation of this phenomenon could be based on matrix 
disruption of binder network upon inclusion of higher concentration of supporting 
agents. This can be related to the way that plasticisers disrupt and weaken the 
intermolecular interactions between polymer chains used in tablet coatings which 
subsequently alters the mechanical properties of the polymer (Wen and Park, 2010). 
The formulation containing 5% w/w Methocel™ and 70% w/w (of dried tablet weight) of 
mannitol produced the most satisfactory intact tablets that were hard/solid in nature 
and did not deform or break when handled. Those tablets were also easily removed 
from the moulds.  
 
Studies investigating the optimisation of the concentration of matrix supporting agents 
in the formulation of freeze-dried ODTs have been previously reported. Chandrasekhar 
et al. (2009) investigated the influence of mannitol, sorbitol and sucrose concentrations 
on the hardness and disintegration times of the tablets. AlHusban et al. (2010c) 
additionally reported a study investigating the optimisation of the concentration of 
matrix supporting agents. AlHusban et al. (2010c) investigated the influence of amino 
acid (proline and serine used in combination) concentrations on the properties of the 
formulations and tablets. 
 
Concentration profiling and macroscopic evaluation of Methocel™ E3LV formulations 
tablets, are shown in Table 3.7 Methocel™ E3LV polymer could be formulated up to 
concentration of 11% w/w and further increase in concentration was limited by poor 
solubility of the binder. Macroscopic evaluation of the tablets of Methocel™ E3LV 
formulations revealed that this low viscosity grade polymer did produce intact tablets. 
At a polymer concentration of 1% w/w, the tablets were soft with a noticeable 
“spongy/foamy” consistency. They did not deform when handled and retained their 
original shape. The tablets were also easily removed from their moulds. 
 
Increasing polymer concentration to 5, 10 and 11% w/w, resulted in tablets which were 
hard and robust. The tablets of these formulations were also easily removed from their 
moulds. 
 
Evaluation of Methocel™ K3LV formulations and tablets are shown in Table 3.8 In 
terms of the observations made for Methocel™ K3LV formulations, it was possible to 
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use Methocel™ K3LV up to 10% w/w in the formulations. Higher concentrations of the 
polymer solution could not be prepared due to limitations in solubility. Macroscopic 
evaluation of the tablets of formulations made from Methocel™ K3LV indicated that this 
low viscosity grade polymer did produce intact tablets. With a polymer concentration of 
1% w/w, the formed tablets were very soft and “spongy/foamy” in consistency. Whilst 
with polymer concentrations of 5 and 10% w/w, the formed tablets were hard and 
robust. The tablets also would withstand manual handling, and retain their shape upon 
removal from their moulds. Macroscopic evaluation of the tablets of formulations made 
from Methocel™ K3LV indicated that this low viscosity grade polymer can be used as a 
binder in freeze-dried ODTs, due to the formation of hard and robust tablets. 
 
Analysis for Methocel™ K100LV based formulations are shown in Table 3.12. During 
manufacture of Methocel™ K100LV based formulations, a number of observations were 
made. Concentrations of polymer above 3% w/w could not be formulated due to 
difficulties in dosing the solution into tablet moulds. Analysis of viscosity results (Figure 
3.4D) provide the evidence for the workable range of 1.79 ± 0.06 to 32.97 ± 1.27 mPa 
s. 
 
Macroscopic evaluation of the tablets of formulations made from the K100LV grade 
indicated that this grade of polymer produced intact tablets. The formulation which 
consisted of 1% w/w Methocel™ K100LV and 30% w/w (of dried tablet weight) 
mannitol, produced soft tablets which had a “spongy/foamy” consistency. The tablets 
retained their shape when handled, and did not deform permanently. Increasing 
mannitol concentration to 70% w/w (of dried tablet weight), resulted in tablets which 
were fragile and broke/disintegrated easily when handled. Increasing Methocel™ 
K100LV concentration to 3% w/w with both 30 and 70% w/w (of dried tablet weight) 
mannitol, resulted in tablets which were hard and did not deform when handled. 
Increasing mannitol concentration from 30 to 70% w/w (of dried tablet weight) 
appeared to produce tablets which were harder and more robust. 
 
Concentration profiling and macroscopic evaluation of the Methocel™ low viscosity 
grades formulations and tablets indicated that formulation viscosity is a critical 
parameter, which influences ease of dosing and the successful formation of intact and 
robust tablets. E.g. Methocel™ E3LV and K3LV which were the two lowest viscosity 
grades (as shown in Table 3.1), could be formulated up to 10 and 11% w/w, 
respectively. Whilst Methocel™ K100LV, which had the highest viscosity grade out of 
the four grades that were investigated could only be formulated up to 3% w/w. 
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It was also observed that although Methocel™ E3LV and K3LV exhibit the same 
viscosity (as shown in Table 3.1), the E3LV grade could be formulated up to a higher 
concentration. This is proposed to be attributed to the greater percentage content of 
methoxyl and hydroxypropyl groups within E3LV grade relative to the K3LV, as shown 
in Table 3.1, which increases the hydrophilic nature of HPMC. In relation to this 
observation, Ahmed et al. (2011) reported that Methocel™ E grades are more 
hydrophilic than Methocel™ A grades, due to the presence of more polar (hydroxyl) 
groups. This study indicates that chemical structure is also a critical parameter which 
determines the suitability of a material to function as a binder with freeze-dried ODTs, 
as it governs at which concentrations the material can be used. 
 
3.4.1.2 Evaluation of the Thermal Properties of the Formulations of Low 
Viscosity Grades of Methocel™ 
Freeze-dried products and formulations possess a number of significant formulation 
properties which are related to the freeze-drying method used, such as the collapse 
temperature of the formulation, API stability and excipient properties (Tang and Pikal, 
2004). The collapse temperature of the formulation is defined as the temperature 
above which the freeze-dried product loses its structure and collapses during freeze-
drying (Mackenzie, 1966), which is generally around 2ºC greater than the glass 
transition temperature of the formulation in its frozen state (Pikal and Shah, 1990). To 
produce a freeze-dried product or formulation of high quality, it is essential therefore to 
freeze-dry the formulation at a lower temperature than the collapse temperature (Pikal, 
1990a and Pikal, 1990b). 
 
DSC is a useful tool which can provide useful information on the important formulation 
properties of freeze-dried products/formulations, as discussed above. This information 
can subsequently be used to design suitable freeze-drying methods which will produce 
formulations of high quality.  
 
DSC analysis of Methocel™ A15LV formulations indicated that formulations containing 
1 and 2% w/w methylcellulose and 30% w/w (of dried tablet weight) mannitol, produced 
no clear/detectable thermal transitions, which were attributable to Methocel™ or 
mannitol (Figure 3.4 A). Formulations consisting of 3% w/w Methocel™ and 30% w/w 
(of dried tablet weight) mannitol produced thermograms which exhibited several 
thermal transitions which were attributed to mannitol. Glass transitions were observed 
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at around -26 and -22ºC, respectively, whilst exothermic crystallisation peaks were 
observed at around -16ºC.  
 
 
 
 
 
 
  
Figure 3.4 DSC analysis thermogram of ; (A) 1% w/w Methocel™ A15LV with 30% w/w 
mannitol, (B) 1% w/w Methocel™ A15LV with 70% w/w mannitol, (C) 1% w/w 
Methocel™ E3LV with 30% w/w mannitol, (D) 5% w/w Methocel™ E3LV with 30% w/w 
mannitol, (E) 1% w/w Methocel™ K3LV with 30% w/w mannitol, all during the heating 
phase of the DSC method. The concentration of mannitol is expressed as % w/w of 
dried tablet weight.   
 
 
 
 
A 
B C 
D E 
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Figure 3.4 DSC analysis thermogram of ; (F) 5% w/w Methocel™ K3LV with 30% w/w 
mannitol, (G) 10% w/w Methocel™ K3LV with 30% w/w mannitol, (H) 1% w/w 
Methocel™ K100LV with 30% mannitol and (I) 1% w/w Methocel™ K100LV with 70% 
w/w mannitol formulations samples, all during the heating phase of the DSC method. 
The concentration of mannitol is expressed as % w/w of dried tablet weight.   
 
The glass transition observed at around -26ºC was attributed to the mannitol phase 
plasticised by unfrozen water (Cavatur et al. 2002). The transition at around -22ºC was 
attributed to the amorphous freeze-concentrate of mannitol, whilst the crystallisation 
peaks observed at around -16ºC correspond to mannitol hydrate and the unfrozen 
water associated with the amorphous phase of mannitol (Cavatur et al. 2002). 
 
Interestingly, the 5% w/w Methocel™ A15LV formulation with 30% w/w (of dried tablet 
weight) mannitol exhibited glass transitions at around -28ºC, which was attributed to 
the amorphous freeze-concentrate of mannitol (Cavatur et al. 2002). It is assumed that 
the reason for a single thermal transition with this formulation, in comparison to the 
three events observed with the 3% w/w Methocel™ formulation, is possibly to do with 
the increase in Methocel™ concentration which alters the composition of the 
formulation. Thermal events for water soluble components vary depending on the type 
and concentration of the added excipients.  
 
All of the Methocel™ A15LV formulations which consisted of 70% w/w (of dried tablet 
weight) mannitol, produced several thermal transitions, as shown in Figure 3.4B. The 
DSC thermograms of the formulations indicated a glass transition at around -27 to -
F G 
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30°C, followed by an endothermic melt at ~ -23°C, which has been postulated to being 
a glass transition (Cavatur et al. 2002). These two thermal transitions were followed by 
an exothermic crystallisation transition at ~ -18°C, which was attributable to the 
crystallisation of both mannitol hydrate and unfrozen water associated with the 
amorphous phase (Cavatur et al. 2002). 
 
It therefore appears that mannitol concentration is a critical factor in promoting thermal 
transitions such as crystallisation and glass transition, as thermal transitions were more 
clearly evident with formulations consisting of 70% w/w (of dried tablet weight) 
mannitol. 
 
The influence of mannitol concentration on the observed thermal transitions has been 
reported by AlHusban et al. (2010d). AlHusban et al. (2010d) investigated mannitol 
concentrations of 10, 30, 50 and 70% (of total solid material), and observed that 
mannitol maintained an amorphous state at 10 and 30% (of total solid material), whilst 
at 50 and 70% (of total solid material) mannitol underwent crystallisation. AlHusban et 
al. (2010d) reported that increasing the concentration of mannitol promotes its 
crystallisation.  
 
Evaluation of the thermal properties of Methocel™ E3LV and K3LV formulations, 
respectively, revealed that the DSC thermograms of the mannitol-free formulations 
exhibited no thermal transitions which were attributable to Methocel™ or mannitol. The 
same was observed with the formulations which included 1% w/w Methocel™ and 30% 
w/w (of dried tablet weight) mannitol, as shown in Figures 3.4C and 3.4E, respectively.  
 
The 5% w/w Methocel™ E3LV formulation with 30% w/w (of dried tablet weight) 
mannitol, produced thermograms which exhibited a single thermal transition, as shown 
in Figure 3.4D. Exothermic crystallisation peaks were observed at around -17ºC which 
were attributable to the crystallisation of mannitol hydrate and unfrozen water (Cavatur 
et al. 2002). Despite the presence of the crystallisation peak, it was interesting to note 
that the glass transition of the amorphous freeze-concentrate of mannitol was not 
observed. It has been previously reported that the crystallisation of mannitol hydrate 
and unfrozen water occurs immediately after the glass transition of the freeze-
concentrate of mannitol (Cavatur et al. 2002), therefore this glass transition was 
expected to be observed.  
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5 and 10% w/w Methocel™ K3LV formulations with 30% w/w (of dried tablet weight) 
mannitol displayed thermograms which revealed a single thermal transition which 
corresponds to mannitol, as shown in Figures 3.4F and 3.4G. Glass transitions were 
observed at around -27ºC, which were postulated to be attributable to the glass 
transition of the amorphous freeze-concentrate of mannitol (Cavatur et al. 2002).  
 
On the other hand, the 10 and 11% w/w Methocel™ E3LV formulations with 30% w/w 
(of dried tablet weight) mannitol, produced thermograms which displayed several 
thermal transitions which correspond to the thermal profile of mannitol (Figures not 
shown). Glass transitions were observed at around -30 and -24ºC, respectively, and 
crystallisation peaks were observed at around -19ºC. The glass transitions observed at 
around -30ºC were attributable to the mannitol phase plasticised by unfrozen water, 
whilst the glass transitions observed at around -24ºC correspond to the amorphous 
freeze-concentrate of mannitol (Cavatur et al. 2002). The crystallisation peaks 
observed at around -19ºC, were attributable to both mannitol hydrate and unfrozen 
water (Cavatur et al. 2002). 
 
The thermal transitions recorded with the 10 and 11% w/w Methocel™ E3LV with 30% 
w/w (of dried tablet weight) mannitol formulations, were also observed with the 
Methocel™ K100LV formulations, which included 70% w/w (of dried tablet weight) 
mannitol, as shown in Figure 3.4I. Interestingly, no thermal transitions were observed 
with the Methocel™ K100LV formulations which included 30% w/w (of dried tablet 
weight) mannitol as shown in Figure 3.4H.  
 
Results from the above investigations also provide conclusive evidence on the freeze 
drying regime followed in the formulation of various concentrations of the different 
binders. All the studies were carried out at -40ºC which was below the transition 
temperatures recorded for the different compositions investigated. The study also 
provides further evidence of concentration dependence for thermal transitions with 
smaller concentration of the total solid material providing multiple thermal events when 
compared to formulations comprising of higher water soluble content.  
 
3.4.1.3 Viscosity and Mechanical Properties Analyses of Methocel™ Low 
Viscosity Grades Formulations and Tablets 
Concentration profiling and macroscopic evaluation of Methocel™ low viscosity grades 
formulations revealed that the preparation of Methocel™ A15LV and K100LV 
formulations were limited due to the high viscosity of the formulations at low Methocel™ 
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concentrations. With the A15LV and K100LV grades, formulations could only be 
prepared up to a concentration of 5 and 3% w/w, respectively.  
 
Due to formulation viscosity being the limiting factor in preventing formulations being 
prepared at higher concentrations, viscosity analysis of the preparations were carried 
out to identify the “workable” viscosity range for the different grades of Methocel™. 
Additionally, analyses of the mechanical properties of the prepared tablets were carried 
out in parallel to formulation viscosity analysis to investigate the relationship between 
formulation viscosities (which is related to Methocel™ concentration) and the formation 
of intact tablets.  
 
The viscosity analysis results for Methocel™ A15LV formulations are shown in Figure 
3.3. For the formulations containing 30 and 70% w/w (of dried tablet weight) mannitol, 
an increase in methylcellulose concentration did not show any significant change in 
formulation viscosity (p > 0.05). Comparing the viscosities of the formulations 
consisting of 30% w/w (of dried tablet weight) mannitol, with their corresponding 
formulations which consisted of 70% w/w (of dried tablet weight) mannitol, revealed no 
significant difference in formulation viscosity (p > 0.05).  
 
Viscosity analysis results of Methocel™ E3LV and K3LV formulations, shown in Figures 
3.5A and 3.5B respectively, revealed comparable results. The results indicated that 
increasing Methocel™ concentration resulted in an increase in formulation viscosity (p 
<0.05). This can be attributed to an increase in the density of the polymer network and 
an increase in the interaction between polymer chains. This particular trend was 
observed with both the mannitol-free formulations and the formulations which included 
mannitol. 
 
Comparing the viscosities of the mannitol-free formulations with the formulations 
containing mannitol, the results showed that there was no significant difference 
observed with the 1% and 5% w/w formulations, for both E3LV and K3LV formulations 
(p > 0.05). 
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Figure 3.5 Viscosity analysis results of Methocel™ low viscosity grade formulations; (A) E3LV and (B) 
K3LV formulations. Viscosity analyses of the formulations were carried out in triplicate and the mean 
values ± standard deviation are reported. 
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Figure 3.5 Viscosity analysis results of Methocel™ low viscosity grade formulation (C) K100LV formulations. Viscosity analyses of the 
formulations were carried out in triplicate and the mean values ± standard deviation are reported. 
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5 and 10% w/w Methocel™ K3LV formulations together with the 10 and 11% w/w 
Methocel™ E3LV formulations, revealed that the viscosities of the formulations 
containing mannitol exhibited greater viscosities than their mannitol-free formulation 
counterparts (p < 0.05). This could be due to the increased amount of solute in the 
formulations, and therefore increased intermolecular interactions in the formulations 
(Miyawaki et al. 2003), which resulted in these formulations exhibiting greater 
viscosities. 
 
In terms of Methocel™ K100LV formulations shown in Figure 3.5C, the results revealed 
that increasing Methocel™ concentration resulted in an increase in formulation viscosity 
(p < 0.05). This trend of results was observed with both formulations which consisted of 
30 and 70% w/w (of dried tablet weight) mannitol. Comparing the viscosities of the 
formulations consisting of 30% w/w (of dried tablet weight) mannitol with the viscosities 
of the formulations consisting of 70% w/w (of dried tablet weight) mannitol, revealed 
that comparable results were observed with the 1% w/w Methocel™ formulations (p > 
0.05). However, with the 3% w/w Methocel™ formulations, increasing mannitol 
concentration from 30 to 70% w/w (of dried tablet weight) resulted in an increase in 
formulation viscosity (p < 0.05). The working viscosity range for Methocel™ K100LV 
formulations varied from 1.79 ± 0.06 to 32.97 ± 1.27 mPa s. 
 
Following the analyses of the viscosities of the formulations, the mechanical properties 
of the prepared tablets were evaluated. Tablet hardness and fracturability analysis of 
the formulations were carried out in order to provide an assessment of the mechanical 
properties of the tablets. Tablet hardness and fracturability testing differ in that 
hardness testing involves an assessment of the compressibility of the tablet with a 5 
mm diameter probe, whilst fracturability testing involves the penetration of a 1 mm 
diameter probe into the tablet binder matrix of the tablet. Tablet hardness testing 
therefore assesses the mechanical properties of the tablet as a whole, whilst 
fracturability testing focuses on the mechanical properties of the internal tablet binder 
matrix structure of the tablets. 
 
Tablet hardness analysis of Methocel™ A15LV formulations showed that only two tablet 
formulations were suitable for testing; formulations which consisted of 3 and 5% w/w 
Methocel™ A15LV with 70% w/w (of dried tablet weight) mannitol. The other tablet 
formulations were not suitable for testing as some of the tablets were simply too soft to 
provide a result while some of the tablets could not be removed from the moulds due to 
their fragility.  
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Tablet fracturability measurements of Methocel™ A15LV formulations did not take 
place, as a number of formulations from this grade of Methocel™ did not produce 
tablets suitable for characterisation/analysis. As a result, extracting trends from the 
results would not have been possible. 
 
Looking at the viscosity analysis in parallel with the mechanical properties analysis 
data, the results indicated that the high viscosity (low workable range) of some of the 
Methocel™ grades was responsible for weak mechanical properties of the resultant 
tablets. Even then, from the 8 formulations prepared in total, only two polymer grades 
were suitable for hardness testing. The high viscosity of these formulations prevented 
greater concentrations of Methocel™ being used to prepare more robust tablets, which 
would have been suitable for tablet hardness testing.  
 
Tablet formulations not being suitable for testing was also an issue for the 1% w/w 
Methocel™ K3LV and E3LV formulations, respectively, together with the 1% w/w 
Methocel™ K100LV formulation consisting of 70% w/w (of dried tablet weight) 
mannitol.  
 
Of the Methocel™ A15LV formulations which did provide results, the 3% w/w 
Methocel™ formulation with 70% w/w (of dried tablet weight) mannitol produced tablets 
which exhibited a hardness of 7.26 ± 2.07 N, whilst the corresponding 5% w/w 
Methocel™ formulation tablets displayed a hardness of 13.23 ± 7.02 N. There was no 
significant difference in tablet hardness between these two formulations (p > 0.05).  
 
Tablet hardness results of Methocel™ E3LV formulations, shown in Figure 3.6, 
indicated that for the tablets produced from mannitol-free formulations, increasing 
Methocel™ concentration from 5 to 10 and 11% w/w, resulted in an increase in tablet 
hardness (p < 0.05). This trend of increasing polymer concentration resulting in an 
increase in tablet hardness can be attributed to the formation of a more extensive and 
robust tablet binder matrix being formed as polymer concentration was increased. This 
particular trend was also observed with the tablets of formulations which included 
mannitol (p <0.05). 
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Figure 3.6 Tablet hardness analysis results for Methocel™ E3LV formulations tablets. 
Tablet hardness analyses of the formulations were performed in triplicate and the 
mean values ± standard deviation are reported. 
 
Ahmed et al. (2011) reported in a study which evaluated the use of maltodextrin as a 
matrix former along with several cellulosic binders in the preparation of freeze-dried 
ODTs, that the concentration of cellulosic binders (Methocel™ E5LV, E15LV and 
A15LV) had a significant effect on the friability of the tablets. The authors attributed this 
to the higher binding capacity of the binders at higher concentrations. This can be 
related to the tablet hardness results, where it was observed that increasing Methocel™ 
E3LV concentration resulted in an increase in tablet hardness.  
 
Comparing the tablet hardness of the mannitol-free formulations, with the tablets 
produced from formulations which included mannitol, indicated no significant difference 
in the results (p > 0.05). This was similarly observed with the 10% w/w Methocel™ 
K3LV formulations, of which the results are shown in Table 3.13. However, in the case 
of the 5% w/w formulations, the inclusion of mannitol in the formulation resulted in a 
reduction in tablet hardness.  
 
Table 3.13 Tablet hardness analysis results for Methocel™ K3LV formulations tablets. 
Tablet hardness analyses of the formulations were performed in triplicate and the 
mean values ± standard deviation are reported. 
Formulation Tablet Hardness (N) ± S.D. 
5% w/w Methocel K3LV 5.510 ± 0.57 
5% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
3.077 ± 0.99 
10% w/w Methocel K3LV 14.616 ± 5.68 
10% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
13.913 ± 5.32 
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The results for Methocel™ K3LV formulations also revealed that increasing Methocel™ 
concentration from 5 to 10% w/w, did not result in an increase in tablet hardness (p > 
0.05). This trend of results was observed with both the mannitol-free and containing 
formulations. 
 
Tablet fracturability analysis results of Methocel™ E3LV and K3LV formulations, shown 
in Tables 3.14 and 3.15, displayed comparable results. With the mannitol-free 
formulations, increasing Methocel™ concentration from 5 to 10% w/w, resulted in an 
increase in the robustness of the tablet binder matrices, as greater force was required 
to penetrate the tablets. This observation can be attributed to the formation of a more 
extensive tablet binder matrix as Methocel™ concentration is increased, as a 
consequence the tablets are harder and more robust. 
 
Table 3.14 Tablet fracturability analysis results for Methocel™ E3LV formulations 
tablets. Tablet fracturability analyses of the formulations were performed in triplicate, 
and the mean values ± standard deviation are reported. 
Formulation Tablet Fracturability (N) ± S.D. 
5% w/w Methocel E3LV 1.956 ± 1.00 
5% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
2.197 ± 0.19 
10% w/w Methocel E3LV 8.577 ± 1.07 
10% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
2.848 ± 0.30 
11% w/w Methocel E3LV 4.491 ± 0.65 
11% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
2.289 ± 0.68 
 
Table 3.15 Tablet fracturability analysis results for Methocel™ K3LV formulations 
tablets. Tablet fracturability analyses of the formulations were performed in triplicate, 
and the mean values ± standard deviation are reported. 
Formulation Tablet Fracturability (N) ± S.D. 
5% w/w Methocel K3LV 2.930 ± 0.34 
5% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
2.573 ± 0.85 
10% w/w Methocel K3LV 4.300 ± 0.64 
10% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
2.760 ± 0.34 
 
With the Methocel™ E3LV formulations, an unexpected/anomalous result was observed 
in which the mannitol-free formulation of the 11% w/w Methocel™ formulation exhibited 
a lower tablet fracturability value than the 10% w/w formulation. It was expected that 
the 11% w/w formulation would display a greater value due to the formation of more 
robust tablets at a higher concentration of Methocel™. 
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The results for the mannitol-included formulations revealed that increasing Methocel™ 
concentration did not affect tablet fracturability, as comparable results were observed 
(p > 0.05). This of course was not the case with the mannitol-free formulations, which 
suggests that the inclusion of mannitol in the formulations, influences tablet 
fracturability. To investigate this further, the tablet fracturability of the mannitol-free 
formulations were compared with the tablet fracturability of the mannitol-included 
formulations. 
 
Comparing the tablet fracturability of the mannitol-free formulations with that of the 
mannitol-included formulations, the results revealed that in the case of the 5% w/w 
Methocel™ formulations, comparable results were observed (p > 0.05). However, with 
the 10% w/w Methocel™ formulations and the 11% w/w Methocel™ E3LV formulations, 
interesting results were observed in which the mannitol-included formulations 
displayed lower tablet fracturability values than the mannitol-free formulations.  
 
These results suggested that the inclusion of mannitol in the formulations had a 
detrimental effect on tablet fracturability. It appeared that mannitol disrupted and 
subsequently weakened the tablet binder matrix, as a result the robustness of the 
tablets deteriorated. It therefore can be concluded that mannitol had a plasticisation 
effect, which subsequently modified the tablet binder matrix structure.    
 
These results could possibly be related to the DSC results reported earlier. E.g. the 10 
and 11% w/w Methocel™ E3LV formulations with 30% w/w (of dried tablet weight) 
mannitol, exhibited the crystallisation of mannitol. It may be possible that the 
crystallisation of mannitol disrupted the tablet binder matrix of Methocel™, which 
resulted in the deterioration of the robustness of the tablets.  
 
Tablet hardness results of Methocel™ K100LV formulations, shown in Table 3.16, 
revealed that increasing Methocel™ concentration from 1 to 3% w/w resulted in an 
increase in tablet hardness (p < 0.05). There was no significant difference in tablet 
hardness between the two 3% w/w Methocel™ formulations (p > 0.05). 
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Table 3.16 Tablet hardness analysis results for Methocel™ K100LV formulations 
tablets. Tablet hardness analyses of the formulations were carried out in triplicate and 
the mean values ± standard deviation are reported. 
Formulation Tablet Hardness (N) ± S.D. 
1% w/w Methocel K100LV with 30% w/w  
(of dried tablet weight) Mannitol 
0.111 ± 0.09 
3% w/w Methocel K100LV with 30% w/w  
(of dried tablet weight) Mannitol 
4.179 ± 1.40 
3% w/w Methocel K100LV with 70% w/w  
(of dried tablet weight) Mannitol 
4.829 ± 3.25 
 
Tablet fracturability measurements of Methocel™ K100LV formulations did not take 
place, as a number of formulations from this grade of Methocel™ did not produce 
tablets suitable for characterisation/analysis.  
 
3.4.1.4 Tablet Disintegration Time Analysis and Porosity Measurements of 
Methocel™ Low Viscosity Grades Formulations 
Freeze-Dried ODTs are extremely porous in nature, as a result of undergoing 
sublimation during the freeze-drying process. It has been identified that the highly 
porous structure of the tablets is responsible for this type of dosage form 
demonstrating instantaneous disintegration in the mouth following administration 
(Seager, 1998). In order to investigate the relationship between tablet porosity and 
disintegration time further, the effect of Methocel™ concentration and the inclusion of 
mannitol in the formulation on tablet porosity and subsequently disintegration time was 
assessed. 
 
Tablet disintegration time analysis results of Methocel™ A15LV formulations, showed 
that only two tablet formulations were suitable for testing; formulations which consisted 
of 3 and 5% w/w Methocel™ A15LV with 70% w/w (of dried tablet weight) mannitol, as 
discussed with the tablet hardness results.  
 
Both of these formulations exhibited disintegration times of greater than 180 s. This 
was also observed with the 10 and 11% w/w mannitol-free formulations of Methocel™ 
E3LV, along with the mannitol-free formulation of 10% w/w Methocel™ K3LV. These 
high tablet disintegration times can be attributed to the formation of highly extensive 
and robust tablet binder matrices which require a significant amount of time to 
disintegrate. 
 
Porosity measurement of Methocel™ A15LV formulations did not take place, as a 
number of formulations from this grade of Methocel™ did not produce tablets suitable 
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for characterisation/analysis. As a result, extracting trends from the results would not 
have been possible. 
 
The tablet disintegration time results of Methocel™ K3LV and E3LV formulations, as 
shown in Figures 3.7A and 3.7B, showed comparable results. 
 
 
 
Figure 3.7 Tablet disintegration time analysis results for Methocel™; (A) E3LV and (B) 
K3LV formulations. Tablet disintegration time analyses of the formulations were carried 
out in triplicate, and the mean values ± standard deviation are reported. 
   
The results indicated that polymer concentration had a significant effect on tablet 
disintegration time, as increasing polymer concentration resulted in an increase in 
tablet disintegration time (p <0.05). This trend of results can be attributed to the 
formation of a more extensive tablet binder matrix as polymer concentration is 
0
20
40
60
80
100
120
140
160
180
200
5%
Methocel
5%
Methocel
with 30%
Mannitol
10%
Methocel
10%
Methocel
with 30%
Mannitol
11%
Methocel
11%
Methocel
with 30%
Mannitol
D
is
in
te
gr
at
io
n
 T
im
e
 (
s)
 
Formulation 
0
20
40
60
80
100
120
140
160
180
200
5% Methocel 5% Methocel with
30% Mannitol
10% Methocel 10% Methocel
with 30%
Mannitol
D
is
in
te
gr
at
io
n
 T
im
e
 (
s)
  
Formulation 
A 
B 
Chapter Three: Methocel™ (Hydrophilic Cellulose Ethers) 
 
103 
 
increased (Abdelbary et al. 2004). This tendency was observed with the mannitol-free 
and included formulations.  
 
Ahmed et al. (2011) similarly reported that increasing Methocel™ concentration resulted 
in an increase in in vitro and in vivo disintegration time of freeze-dried ODTs. The 
authors attributed this to the higher binding capacity of Methocel™ at higher 
concentrations. 
 
These results correlated with the tablet porosity results, shown in Tables 3.17 and 
3.18, which showed that increasing Methocel™ concentration from 5-10% w/w, resulted 
in a reduction in tablet porosity (p < 0.05). This observation was found with the 
mannitol-free and containing formulations, respectively, which can be attributed to the 
formation of a more extensive binder matrix, as a result of increasing Methocel™ 
concentration. Consequently, the porosity of the binder matrix is reduced. This relates 
to the disintegration time results as it is hypothesised that a reduction in tablet porosity 
results in an increase in tablet disintegration time, as the ability of disintegrating 
medium to ingress the porous structure of freeze-dried ODTs is restricted.  
 
Table 3.17 Tablet porosity analysis results for Methocel™ E3LV formulations tablets. 
Tablet porosity analyses of the formulations were carried out in triplicate, and the mean 
values ± standard deviation are reported. 
Formulation Tablet Porosity (%) ± S.D. 
5% w/w Methocel E3LV 100.21 ± 0.18* 
5% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
98.36 ± 0.16 
10% w/w Methocel E3LV 96.18 ± 0.33 
10% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
93.11 ± 0.14 
11% w/w Methocel E3LV 95.39 ± 0.33 
11% w/w Methocel E3LV with 30% w/w  
(of dried tablet weight) Mannitol 
92.58 ± 0.62 
*Tablet porosity values of 100 % have been reported. The results suggest that this 
method has reached the limit of its operation, possibly due to the high porosity of the 
samples. An alternative method of measuring tablet porosity might be more suitable for 
these samples. 
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Table 3.18 Tablet porosity analysis results for Methocel™ K3LV formulations tablets. 
Tablet porosity analyses of the formulations were carried out in triplicate, and the mean 
values ± standard deviation are reported. 
Formulation Tablet Porosity (%) ± S.D. 
5% w/w Methocel K3LV 100.25 ± 0.23* 
5% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
98.66 ± 0.25 
10% w/w Methocel K3LV 94.40 ± 0.57 
10% w/w Methocel K3LV with 30% w/w  
(of dried tablet weight) Mannitol 
93.57 ± 0.27 
*Tablet porosity values of 100 % have been reported. The results suggest that this 
method has reached the limit of its operation, possibly due to the high porosity of the 
samples. An alternative method of measuring tablet porosity might be more suitable for 
these samples. 
 
Comparing the tablet disintegration times of tablets from mannitol-free formulations, 
with the tablets from formulations which included mannitol has shown that the inclusion 
of mannitol in the formulations had a significant effect (Figure 3.7 A and B). Tablets 
which included mannitol in their formulation exhibited significantly shorter disintegration 
times, than tablets produced from mannitol-free formulations (p <0.05). The inclusion of 
mannitol in the formulations, has therefore shown to play a significant role is assisting 
tablet disintegration, and has shown to significantly shorten tablet disintegration time, 
in comparison to tablets produced from mannitol-free formulations. 
 
Porosity measurement of 10 and 11% w/w Methocel™ E3LV mannitol-included 
formulations revealed that these formulations exhibited comparable results (p > 0.05), 
however, the mannitol-free formulations revealed that the 11% w/w Methocel™ 
formulation displayed a lower porosity than the corresponding 10% w/w Methocel™ 
formulation (Table 3.17). This result indicated that the presence of mannitol in the 
formulation influences tablet porosity. For this reason, the porosity of mannitol-free 
formulations were compared to their mannitol-included formulations counterparts, to 
investigate the influence of mannitol further.   
 
Comparing the tablet porosities of the mannitol-free formulations with the formulations 
which included mannitol, the results revealed a clear trend. The inclusion of mannitol in 
the formulations resulted in a reduction in tablet porosity (Table 3.17) (p < 0.05). A 
possible explanation for this observation is that the presence of mannitol in the tablets 
reduces the porous space in the tablet binder matrix due to an increase in total solid 
content which therefore has a detrimental impact on the total porosity of the resultant 
tablet. This observation was similarly reported by Corveleyn and Remon (1997 and 
1998), in which increasing maltodextrin (a matrix forming agent) concentration resulted 
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in a decrease in tablet porosity. The authors reported that the ability of ice crystals to 
grow is reduced when a higher solute concentration is used (Corveleyn and Remon, 
1997 and 1998), and as the pores in freeze-dried products are formed from the ice 
crystals after sublimation (Dawson and Hockley, 1991), a reduction in pore size and 
subsequently porosity is observed. 
 
The tablet porosity results (Table 3.17) contradicted the tablet disintegration time 
results (Figure 3.7 A). The porosity results revealed a decrease in tablet porosity 
following the inclusion of mannitol in the formulations, whilst the tablet disintegration 
time results revealed a reduction in disintegration time following the addition of 
mannitol to the formulations. Theoretically speaking, a reduction in tablet porosity 
would be expected to have resulted in an increase in tablet disintegration time, as 
hypothesised and discussed above. 
 
These results suggested that with mannitol-included formulations, disintegration of the 
tablets is driven by the presence of mannitol in the formulations and not by tablet 
porosity, which subsequently reaffirms the role of mannitol as a disintegration 
enhancing agent (AlHusban et al. 2010b). The role of mannitol functioning as a 
disintegration enhancing agent is proposed to be attributed to its highly soluble nature. 
As when a tablet is introduced into disintegration medium, mannitol dissolves instantly 
which exposes the tablet binder matrix to the disintegrating medium to a greater extent 
than would be expected with a mannitol-free formulation tablet.   
 
Disintegration time analysis results of Methocel™ K100LV formulations tablets are 
shown in Table 3.19. The results revealed that increasing Methocel™ concentration 
resulted in an increase in tablet disintegration time (p < 0.05), which as discussed 
above can be attributed to the formation of a more extensive tablet binder matrix. 
There was no significant difference in tablet disintegration time, between the two 3% 
w/w formulations (p > 0.05), which showed that increasing mannitol concentration from 
30 to 70% w/w (of dried tablet weight), did not have an influence. 
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Table 3.19 Tablet disintegration time analysis results for Methocel™ K100LV 
formulations tablets. Tablet disintegration time analyses of the formulations were 
carried out in triplicate and the mean values ± standard deviation are reported. 
Formulation Tablet Disintegration Time (s) ± 
S.D. 
1% w/w Methocel K100LV with 30% w/w  
(of dried tablet weight) Mannitol 
24.00 ± 11.36 
3% w/w Methocel K100LV with 30% w/w  
(of dried tablet weight) Mannitol 
89.00 ± 13.05 
3% w/w Methocel K100LV with 70% w/w  
(of dried tablet weight) Mannitol 
70.00 ± 13.89 
 
Porosity measurement of Methocel™ K100LV formulations did not take place, as a 
number of formulations from this grade of Methocel™ did not produce tablets suitable 
for characterisation/analysis. As a result, extracting trends from the results would not 
have been possible. 
 
3.4.2 High Viscosity Grades of Methocel™ 
 
3.4.2.1 Concentration Profiling and Macroscopic Evaluation of the Formulations 
of High Viscosity Grades of Methocel™ 
Tables 3.20-3.22 represent the macroscopic evaluation of the tablets prepared from 
the various formulations of the high viscosity grades of Methocel™ respectively. 
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Table 3.20 Concentration profiling and macroscopic evaluation of the various Methocel™ A4M formulations prepared. 
 
Table 3.21 Concentration profiling and macroscopic evaluation of the various Methocel™ K4M formulations prepared. 
 
 
Formulation Comments 
1% w/w Methocel A4M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were soft with a “spongy/foamy” consistency. The tablets were 
easy to remove from the bijou tubes, and were difficult to deform during handling (i.e. when compressed, 
the tablets return to their original shape).  
1% w/w Methocel A4M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. However the tablets were very soft/fragile, and broke/disintegrated when handled. 
The tablets could not be removed from the moulds. 
2% w/w Methocel A4M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were tough, with a “spongy/foamy” consistency. The tablets were 
easy to remove from the bijou tubes, and were difficult to deform during handling (i.e. when compressed, 
the tablets return to their original shape). 
2% w/w Methocel A4M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets were formed. The tablets were hard/solid, with a noticeable elastic consistency. The tablets 
did not break when handled. The tablets were easily removed from the moulds. 
Formulation Comments 
1% w/w Methocel K4M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were soft, with a “spongy/foamy” consistency. Tablets retained shape when 
handled, and did not deform permanently. 
1% w/w Methocel K4M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. However the tablets were very soft/fragile, and the tablets broke/disintegrated easily 
when handled. The tablets could not be removed from the moulds intact. 
2% w/w Methocel K4M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were soft, although harder than the lower concentration formulations. The 
tablets had a “spongy/foamy” consistency. The tablets retained shape when handled, and did not deform 
permanently. 
2% w/w Methocel K4M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. The tablets were hard and physically stable. The tablets were relatively easily 
removed from the moulds. 
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Table 3.22 Concentration profiling and macroscopic evaluation of the various Methocel™ K100M formulations prepared.  
 
 
 
 
 
 
 
Formulation Comments 
1% w/w Methocel K100M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were very soft, with a “spongy/foamy” consistency. Tablets retained shape 
when handled, and did not deform permanently. 
1% w/w Methocel K100M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed, however the tablets were very soft/fragile, and the tablets broke/disintegrated easily 
when handled. The tablets could not be removed from the moulds intact. 
2% w/w Methocel K100M with 
30% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed. Tablets were soft, and noticeably harder than the lower concentration formulation. 
The tablets had a “spongy” consistency, and retained shape when handled. The tablets did not deform 
permanently when handled. 
2% w/w Methocel K100M with 
70% w/w (of dried tablet 
weight) mannitol 
Intact tablets formed, however the tablets were soft/fragile, and the tablets broke/disintegrated relatively 
easy when handled. The tablets could not be removed from the moulds intact. 
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Observations made during the preparation of the formulations of Methocel™ A4M, K4M 
and K100M, revealed that these grades of Methocel™ could be used up to 2% w/w and 
above this concentration the formulations proved too difficult to dose, due to their high 
viscosities. The viscosity results (Figures 3.8A and 3.8B) revealed that the workable 
viscosity ranges for these grades of Methocel™, in order to prepare tablets were; 0.46 ± 
0.36 to 1.60 ± 0.89, 19.63 ± 3.23 to 137.00 ± 4.82 and 78.63 ± 6.04 to 81.83 ± 5.11 
mPa s, respectively.  
 
 
 
Figure 3.8 Viscosity analysis results for Methocel™; (A) A4M and (B) K4M 
formulations. Viscosity analyses of the formulations were performed in triplicate and 
the mean values ± standard deviation are reported.   
 
Macroscopic evaluation of the tablets made from Methocel™ A4M formulations, 
revealed that intact tablets were produced from all of the formulations. The formulation 
containing 1% w/w methylcellulose and 70% w/w (of dried tablet weight) mannitol, 
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produced tablets which were very soft/fragile and broke/disintegrated easily when 
handled. These tablets could not be removed from the moulds. This is in contrast to 
the formulation consisting of 1% w/w Methocel™ A4M and 30% w/w (of dried tablet 
weight) mannitol, that produced soft tablets with a “spongy/foamy” consistency, i.e. 
when compressed, returned to their original shape. 
 
The formulation containing 2% w/w Methocel™ A4M and 30% w/w (of dried tablet 
weight) mannitol, produced tough tablets with “spongy/foamy” consistency. When they 
were handled and compressed, the tablets returned to their original state. Increasing 
mannitol concentration from 30 to 70% w/w (of dried tablet weight) resulted in harder 
tablets with a noticeable elastic consistency. The tablets did not break/disintegrate 
when handled, which is an indication of satisfactory physical stability. The improvement 
in the physical appearance of the tablets as a result of adjusting mannitol concentration 
can possibly be related to two factors. Firstly, an increase in total solid content of the 
formulation produced tablets with an increase in density. Secondly, crystallisation 
behaviour of mannitol possibly played a part, as a result of increased concentration of 
the excipient. Kim et al. (1998) reported that the physical state of mannitol after freeze-
drying is concentration dependent, and therefore this could be a factor in explaining 
why the physical appearance of the tablets improved following the adjustment of 
mannitol concentration. 
 
Tablet formulations made from the K4M grade produced intact tablets. In terms of the 
1% w/w formulations, increasing mannitol concentration from 30 to 70% w/w (of dried 
tablet weight), resulted in tablets which were very soft and fragile, which 
broke/disintegrated easily when handled. Increasing Methocel™ concentration to 2% 
w/w resulted in an improvement in the mechanical properties of the tablets. Increasing 
mannitol concentration also appeared to produce tablets which were harder and more 
physically stable.  
 
Macroscopic evaluation of the tablets prepared from Methocel™ K100M formulations, 
revealed that in terms of the 1% w/w formulations, it was observed that increasing 
mannitol concentration from 30 to 70% w/w (of dried tablet weight), resulted in the 
deterioration in the mechanical properties of the tablets as the tablets appeared softer 
and more fragile, which broke/disintegrated easily when handled. Increasing 
Methocel™ concentration to 2% w/w, resulted in an improvement in the mechanical 
properties of the tablets. In line with the 1% w/w Methocel™ formulations, increasing 
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mannitol concentration from 30 to 70% w/w (of dried tablet weight), resulted in the 
deterioration of the mechanical properties of the tablets. 
 
3.4.2.2 Evaluation of the Thermal Properties of the Formulations of High 
Viscosity Grades of Methocel™ 
The evaluation of the thermal properties of Methocel™ A4M, K4M and K100M 
formulations yielded comparable results. No thermal transitions attributable to 
Methocel™ or mannitol were observed with the 1 and 2% w/w Methocel™ with 30% w/w 
(of dried tablet weight) mannitol formulations, as shown in Figures 3.9A, 3.9C and 
3.9E. 
 
 
 
 
 
Figure 3.9 DSC analysis thermogram of; (A) 1% w/w Methocel™ A4M with 30% w/w 
mannitol and (B) 1% w/w Methocel™ A4M with 70% w/w mannitol, all during the 
heating phase of the DSC method. The concentration of mannitol is expressed as % 
w/w of dried tablet weight.   
 
A 
B 
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Figure 3.9 DSC analysis thermogram of; (C) 1% w/w Methocel™ K4M with 30% w/w 
mannitol, (D) 1% w/w Methocel™ K4M with 70% w/w mannitol, (E) 1% w/w Methocel™ 
K100M with 30% w/w mannitol and (F) 1% w/w Methocel™ K100M with 70% w/w 
mannitol, all during the heating phase of the DSC method. The concentration of 
mannitol is expressed as % w/w of dried tablet weight.   
 
Thermal evaluation of the formulations consisting of 70% w/w (of dried tablet weight) 
mannitol revealed several thermal transitions, which were attributed to mannitol, as 
shown in Figures 3.9B, 3.9D and 3.9F. Glass transitions were observed at around -30 
and -23ºC, respectively, whilst exothermic crystallisation peaks were observed at 
around -18ºC. 
 
The glass transitions observed at around -30ºC were attributed to the glass transition 
of the mannitol phase plasticised by unfrozen water (Cavatur et al. 2002). Similarly, the 
glass transitions observed at around -23ºC were associated with the amorphous 
freeze-concentrate of mannitol (Cavatur et al. 2002). Exothermic crystallisation peaks 
observed at around -18ºC could be due to the crystallisation of both mannitol hydrate 
and the unfrozen water, associated with the amorphous phase of mannitol (Cavatur et 
al. 2002). 
 
3.4.2.3 Viscosity, Tablet Hardness and Disintegration Time Analysis of 
Methocel™ High Viscosity Grades Formulations and Tablets 
Similar to the low viscosity grade formulations, concentration profiling and macroscopic 
evaluation of Methocel™ high viscosity grades formulations, indicated that the 
C D 
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preparation of Methocel™ A4M, K4M and K100M formulations were restricted due to 
the high viscosity of the formulations. With all three high viscosity grades of Methocel™, 
formulations could only be prepared up to concentrations of 2% w/w. 
 
As these grades of Methocel™ could only be used up to a concentration of 2% w/w, 
and their use being limited in this regard, viscosity analysis of the formulations were 
performed in order to establish the “workable” viscosity range for these grades of 
Methocel™. Additionally, the impact of this on the formation of intact and robust tablets 
was investigated, by undertaking tablet hardness analysis. These tablets were also 
examined for their disintegration times.      
 
The viscosity analysis results for Methocel™ A4M formulations, are shown in Figure 
3.8A. The results revealed that increasing methylcellulose concentration from 1 to 2% 
w/w did not result in any significant change in formulation viscosity (p > 0.05). 
Increasing mannitol concentration from 30 to 70% w/w (of dried tablet weight) also 
showed not to influence formulation viscosity (p > 0.05). This was observed with both 
the 1 and 2% w/w Methocel™ formulations. The “workable” viscosity range for this 
grade of Methocel™ that allowed satisfactory dosing was 0.46 ± 0.36 to 1.60 ± 0.89 
mPa s. 
   
Methocel™ K100M formulations also displayed comparable results. The 1% w/w 
Methocel™ formulation with 30% w/w (of dried tablet weight) mannitol, exhibited a 
viscosity of 81.83 ± 5.11 mPa s, whilst the formulation consisting of 70% w/w (of dried 
tablet weight) mannitol displayed a viscosity of 78.63 ± 6.04 mPa s (p > 0.05). The 2% 
w/w Methocel™ formulations, proved too viscous to analyse, as a result the “workable” 
viscosity range for this grade of Methocel™ was found as being 78.63 ± 6.04 to 81.83 ± 
5.11 mPa s.   
 
Analysis of the viscosities of Methocel™ K4M formulations, shown in Figure 3.8B, 
revealed that increasing Methocel™ concentration resulted in an increase in formulation 
viscosity (p < 0.05). This can be attributed to an increase in the density of the polymer 
network which ultimately results in the increase in the interaction between polymer 
chains.  
 
Increasing mannitol concentration from 30 to 70% w/w, revealed comparable results 
with the 1% w/w Methocel™ formulations (p > 0.05). However, with the 2% w/w 
Methocel™ formulations, increasing mannitol concentration resulted in a decrease in 
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formulation viscosity (p < 0.05). The formulation consisting of 30% w/w mannitol 
displayed a viscosity of 137.00 ± 4.82 mPa s, whilst the formulation comprising of 70% 
w/w mannitol exhibited a viscosity 98.07 ± 12.45 mPa s (p < 0.05). This could possibly 
be attributed to mannitol acting as a plasticiser, at higher concentrations. Increasing 
mannitol concentration from 30 to 70% w/w appeared to weaken and decrease the 
molecular chain interactions of Methocel™ K4M polymer chains, and therefore resulted 
in a reduction in viscosity. A similar observation was reported in a study which 
investigated the effect of polyols on plasticising corn starch (Qiao et al. 2011). 
 
Qiao et al. (2011) studied the effect of using mixtures of conventional plasticiser; 
glycerol, and higher molecular weight polyols, e.g. xylitol, on the plasticisation of corn 
starch. Qiao et al. (2011) reported that high molecular weight polyols reduced the 
strong molecular chain interactions (hydrogen-bonds) in starch. Moreover, the 
molecular chain mobility of starch increases following the addition of small plasticiser 
molecules, which results in decreasing melt viscosity (Qiao et al. 2011). 
 
The “workable” viscosity range for Methocel™ K4M formulations was found as being 
19.63 ± 3.23 to 137.00 ± 4.82 mPa s. 
 
Due to the high viscosity of the formulations at low Methocel™ concentrations, and the 
fact that the Methocel™ grades could only be used up to concentrations of 2% w/w, 
tablet hardness analysis of the formulations, revealed that the majority of the 
formulations did not provide results when tested, which suggested that the tablets were 
too soft/fragile. It is apparent that greater concentrations of Methocel™ are required in 
order to form robust tablets, suitable for hardness testing. The formulation viscosity of 
these high viscosity grades of Methocel™ has shown to be the limiting factor, for the 
successful formation of intact and robust tablets, which exhibit satisfactory mechanical 
properties. 
 
In terms of formulations that were too soft/fragile to provide results, both the 1% w/w 
Methocel™ A4M formulations were not suitable. This was similarly observed with the 
Methocel™ K4M and K100M formulations. Additionally, the 2% w/w Methocel™ K4M 
and K100M formulations with 70% w/w (of dried tablet weight) mannitol, were not 
suitable for testing. 
 
Focussing on the formulations which did provide results, the 2% w/w Methocel™ A4M 
formulation with 30% w/w (of dried tablet weight) mannitol displayed a tablet hardness 
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of 2.61 ± 0.04 N. Increasing mannitol concentration to 70% w/w, yielded comparable 
tablet hardness as a value of 5.05 ± 1.38 N was observed (p > 0.05). The results 
therefore suggested that increasing mannitol concentration did not result in improving 
the mechanical properties of the tablets. 
 
This observation could possibly be attributed to the molecular weight of Methocel™ 
A4M relative to that of mannitol. Due to the vast difference in molecular weight 
between these two excipients, it may be possible that increasing mannitol 
concentration did not exert a significant effect on supporting the tablet binder matrix of 
Methocel™ A4M, consequently its influence was minimal.  
 
The K4M and K100M formulations (2% w/w Methocel™ with 30% w/w (of dried tablet 
weight) mannitol) yielded similar tablet hardness results. The K4M formulation 
displayed a value of 2.62 ± 0.10 N, whilst the K100M formulation exhibited a tablet 
hardness of 2.66 ± 0.15 N (p > 0.05). 
 
In terms of the tablet disintegration time analysis of Methocel™ A4M formulations, 
increasing mannitol concentration from 30 to 70% w/w (with the 2% w/w Methocel™ 
formulations), resulted in an increase in tablet disintegration time (p < 0.05). The 
formulation consisting of 30% w/w (of dried tablet weight) mannitol displayed a 
disintegration time of 59.00 ± 6.51 s, whilst the formulation comprising of 70% w/w (of 
dried tablet weight) mannitol exhibited a disintegration time of 99.00 ± 12.12 s (p < 
0.05).  
 
Tablet disintegration time analysis of Methocel™ high viscosity grades formulations, 
therefore revealed that there was similarity in trend as with tablet hardness analysis 
results as the majority of the formulations were not suitable for testing. The 
formulations which were suitable for analysis were the same as for tablet hardness 
analysis.   
 
Corveleyn and Remon (1997 and 1998) reported that increasing maltodextrin (matrix 
forming agent) concentration resulted in an increase in tablet disintegration time, due 
to a reduction in tablet porosity. It is therefore possible that increasing mannitol 
concentration in the Methocel™ A4M formulations, reduced tablet porosity and as a 
result the ability of water to penetrate the tablet binder matrix and disintegrate the 
tablet was restricted, which resulted in an increase in tablet disintegration time. 
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The Methocel™ K4M and K100M formulations (both 2% w/w Methocel™ with 30% w/w 
(of dried tablet weight) mannitol) produced tablets which displayed comparable 
disintegration times (p > 0.05). The Methocel™ K4M formulation exhibited a 
disintegration time of 93.00 ± 20.03 s, whilst the K100M formulation demonstrated a 
disintegration time of 116.00 ± 16.56 s (p > 0.05).  
 
 
3.5 Conclusions 
Evaluating the several grades of Methocel™, which comprised of both low and high 
viscosity grades, revealed that the low viscosity grades, in particular; Methocel™ E3LV 
and K3LV, were suitable as binders in freeze-dried ODTs. 
 
With the higher viscosity grades, due to the highly viscous nature of these polymers, 
only low concentration formulations were prepared, as with higher concentrations 
dosing was not possible. As only low concentration formulations were prepared, the 
resulting tablets did not exhibit satisfactory mechanical properties, as extensive tablet 
binder matrices were not formed. 
 
Using the lower viscosity grades of Methocel™ produced more robust tablets, as 
formulations consisting of greater concentrations of polymer were produced, and as a 
result tablets exhibited more extensive binder matrices. 
 
Methocel™ E3LV appeared the most suitable grade for an application as a binder in 
freeze-dried ODTs. This grade of Methocel™ showed to produce tablets exhibiting a 
hardness of 11.74 ± 3.97 N and a disintegration time of 34.00 ± 7.94 s. This grade of 
Methocel™ was taken forward to future studies, in order to prepare HPMC-based 
formulations. 
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4.1 Introduction 
As discussed previously in Chapter One, one of the advantages/benefits of ODTs is 
that they can enhance the clinical effects of APIs through pre-gastric absorption, which 
can lead to an increase in bioavailability and reduction in adverse drug reactions 
(Seager, 1998). 
 
It has been reported that following the administration of freeze-dried ODTs, the 
contents of the formulations disperse over the buccal mucosa and are retained for a 
considerable length of time, following the rapid disintegration of the dosage form in the 
oral cavity (Wilson et al. 1987). Additionally, Seager (1998) reported that particles from 
Zydis® (freeze-dried fast-dissolving dosage form) formulations coat the buccal, 
pharyngeal and gastric mucosa, following administration of the dosage form. 
 
It can be concluded that as freeze-dried ODTs disperse in the oral cavity and are 
retained for a considerable length of time in the pre-gastric regions, absorption of 
suitable APIs takes place resulting in rapid onset of action. 
 
In relation to the work carried out by Wilson et al. (1987) and Seager (1998), 
Chandrasekhar et al. (2009) carried out a study which investigated the role of 
formulation excipients in the development of lyophilised fast-disintegrating tablets. In 
this study the authors investigated the addition of viscosity-modifying polymers 
(Carbopol and Pluronic) to improve and aid pre-gastric retention by increasing 
formulation viscosity with the ultimate objective of promoting pre gastric absorption and 
rapid bioavailability.  
 
Polyethylene oxide (PEO), which is also referred to as Polyox™, is a non-ionic 
homopolymer of ethylene oxide and is represented by the formula: 
 
(OCH2CH2)n 
 
in which n represents the average number of oxyethylene groups (United States 
Pharmacopeial Convention, 2003). 
 
PEO appears as a white to off-white, free-flowing powder, which has a slight 
ammonical odour (Maximilien, 2011). It is soluble in water and a range of organic 
solvents such as chloroform, acetonitrile and methylene chloride, whilst it is insoluble in 
most alcohols, ethylene glycol and aliphatic hydrocarbons (Bailey and Kolesky, 1976). 
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PEO is available in a wide range of molecular weight grades, from 100,000 – 
8,000,000 and is widely applicable in pharmaceutical formulations including; tablet 
binding, controlled release solid dose matrix systems, mucosal bioadhesives and 
transdermal drug delivery systems (DOW Chemical Company, 2002). PEO also has an 
application as a viscosity-increasing agent (Maximilien, 2011). In terms of its tablet 
binding capability, PEO can be used at concentrations of 5-85% (Maximilien, 2011). 
 
PEO has been reported to be very effective as a mucoadhesive polymer (Bottenberg et 
al. 1991). Its application as a mucoadhesive polymer is attributed to its water solubility, 
hydrophilicity, high molecular weight, hydrogen bonding functionality and its 
biocompatibility (DOW Chemical Company, 2002). Additionally, as PEO exists as a 
long linear chain structure, this allows strong interpenetrating networks to form with 
mucus (DOW Chemical Company, 2002). It is therefore evident that PEO has a 
number of properties/attributes which makes it extremely applicable and effective as a 
mucoadhesive polymer. 
 
As a continuation of the study by Chandrasekhar et al. (2009), Polyox™, which as 
discussed has applications as a; viscosity-increasing agent, mucoadhesive agent and 
tablet binding agent, is proposed to be investigated for its applications in freeze-dried 
ODTs. It is hypothesised that the viscosity-increasing, mucoadhesive and binding 
properties of Polyox™, could potentially be utilised to increase the retention of active 
ingredients in the pre-gastric regions, such as the buccal and pharyngeal mucosa, and 
subsequently encourage pre-gastric absorption. 
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4.2 Materials 
Polyethylene oxide (Polyox™; N10 (Lot No. DT353617), 1105 (Lot No. DT314288), N-
60K (Lot No. DT305827) and Coagulant (Lot No. DT307830) were supplied by 
Colorcon Ltd. (Dartford, UK). Mannitol was supplied by Sigma-Aldrich Chemicals 
(Poole, UK). 
 
4.3 Methods 
 
4.3.1 Preparation of Freeze-Dried Tablets 
For the preparation of polyethylene oxide-based tablets, the required amount of 
polymer was added to double-distilled water at ambient temperature, followed by the 
addition of mannitol to form a solution. 1.5 g of the resulting solutions were dosed into 
a tablet mould, frozen at -70°C for a minimum of sixty minutes and freeze-dried 
(ADVANTAGE, Freeze-Dryer, VIRTIS), according to the following regime; primary 
drying for forty eight hours at a shelf temperature of -40°C, secondary drying for ten 
hours at a shelf temperature of 20°C, and vacuum pressure of 6.67 Pa (50 mTorr). A 
minimum of ten tablets were prepared for each formulation. 
 
4.3.2 Formulation Viscosity Analysis 
For all formulations, the viscosities of 100 mL samples were measured using a DV-I+ 
Brookfield digital viscometer (Harlow, UK). The viscosities of the formulations were 
measured at 37 ± 2°C, in order to replicate the viscosity of the formulations in the oral 
cavity, at physiological temperature. The viscometer spindles were selected based on 
the viscosity of the individual formulations, as each spindle is suitable for analysing a 
certain viscosity range. The rotational speed of the spindle was set at 100 rpm. Each 
formulation was analysed in triplicate, and the mean values ± standard deviation is 
reported. 
 
4.3.3 Concentration Profiling and Macroscopic Evaluation of the Formulations  
Table 4.1 shows the grades of Polyox™ which were evaluated in this study, and as can 
be seen the grades differ greatly in terms of approximate molecular weight and 
subsequently viscosity, which allowed a broad evaluation of Polyox™ as an excipient.  
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Table 4.1 Information detailing the different grades of Polyox™ evaluated in this study, 
which highlights the differences between the grades. 
Polyox™ Grade Approximate 
Number of 
Repeating Units 
Approximate 
Molecular Weight 
Viscosity at 25°C 
(mPa s) 
N10 2,275 100,000 30-50 
(5% solution) 
1105 20,000 900,000 8,800 – 17,600 
(5% solution) 
N-60K 45,000 2,000,000 2,000 – 4,000 
(2% solution) 
Coagulant 114,000 5,000,000 5,500 – 7,500 
(1% solution) 
 
During the preparation of the formulations, several visual assessments were carried 
out in order to evaluate the polymers as binders. The solubility of the material was 
assessed by observing the ease at which the polymer went into solution. The ease of 
dosing of the formulations was also assessed, in terms of the viscosity of the prepared 
solution/suspension and also the consistency of the formulation, i.e. if it had a cohesive 
or non-cohesive appearance. 
 
In terms of the visual and physical assessment of the tablets, several assessments 
were carried out in order to evaluate the ability of the polymers to form robust tablets 
with satisfactory mechanical strength. The first assessment involved the evaluation of 
the ability of the formulations to form intact tablet shaped dosage forms, following 
freeze-drying. The physical appearance of the tablets was assessed, classifying them 
as either soft or hard, and having either elastic or a more robust/solid consistency. The 
ability of the tablets to be removed from the moulds was also assessed. Finally, the 
performance of the tablets when handled was assessed, to observe if they deformed 
permanently or retained their shape. 
 
4.3.4 Differential Scanning Calorimetry (DSC) 
DSC (Pyris Diamond DSC and Intercooler 2P: Perkin Elmer, Wellessey, USA) was 
used to determine the glass transition temperature (Tg) and other thermal properties of 
the formulations in their frozen state (before freeze-drying). 10-15 mg of liquid samples 
of the formulations were loaded into aluminium pans, cooled from 25ºC to -65ºC at a 
rate of 5ºC/min, and then heated to 20ºC at a rate of 5ºC/min, with a nitrogen purge of 
20 mL/min. An empty aluminium pan was used as a reference for all measurements.  
 
The resulting thermograms were analysed by Pyris manager software. Tg values were 
determined from the intersection of relative tangents to the baseline, and other thermal 
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properties of the formulations were also assessed. Three measurements were taken 
for each formulation, and the mean values ± standard deviation were reported. 
 
4.3.5 Tablet Hardness and Fracturability 
The hardness and fracturability of the tablets was investigated using a texture analyzer 
(QTS 25: Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was 
calibrated by standard weights of 500 g and 5 kg. The tablets were placed in a holder 
with a cylindrical hole. The hardness was taken as the peak force after 1 mm 
penetration of a 5 mm diameter probe at a rate of 6 mm/min. The fracturability was 
taken as the peak force after 3 mm penetration of a 1 mm diameter probe at a rate of 6 
mm/min. Three measurements were taken for each formulation, and the mean ± 
standard deviation is reported. 
 
4.3.6 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2ºC, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 rpm. Three 
tablets were evaluated from each formulation, and the mean values ± standard 
deviation is reported. 
 
4.3.7 Investigation of Tablet Porosity 
The porosity of the tablets was measured using helium pycnometry 
(MULTIPYCNOMETER, Quantachrome Instruments, Hampshire, UK). Two freeze-
dried tablets were placed in a suitably sized sample cup and subjected to helium 
pycnometry, to determine the true density of the tablets. The true density value was 
then inserted into the equation, as shown below, to determine the porosity of the 
tablets. 
 
Porosity =  1 –  bulk density      x 100% 
         true density 
 
(Equation 4.1) 
                                                                           
Bulk density was determined by considering; the mass of the tablets, the diameter of 
the tablets, and the height/depth of the tablets. The diameter and height/depth of the 
tablets were determined using a screw gauge (LINEAR Farnell). Three porosity 
measurements were taken for each formulation, and the mean values ± standard 
deviation is reported. The porosity of the tablets is expressed as a percentage. 
 
Chapter Four: Polyox™ (Synthetic Polyethylene Oxide) 
 
123 
 
4.3.8 Statistical Analysis 
Statistical analyses of the formulation and tablet characterisation results were 
performed using GraphPad Prism 5 statistical analysis software. One-way analysis of 
variance (ANOVA) was the statistical analysis test performed, using the Tukey post 
test. A significance level of p < 0.05 (95% confidence interval) was judged as being 
statistically significant.    
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4.4 Results and Discussion 
 
4.4.1 Concentration Profiling and Macroscopic Evaluation of the Formulations 
Due to the versatility of Polyox™, the aim of this chapter was to carry out an evaluation 
of its applications in lyophilised ODTs, in terms of both low and high viscosity grades.  
Several formulations were prepared based on each of the four grades of Polyox™ 
evaluated in this study. Each formulation prepared was assessed for its ability to form 
intact tablets, which were subsequently characterised for hardness and disintegration 
time. The viscosity and thermal properties (determined by DSC) of the formulations 
were also assessed. 
 
The first phase of the investigation was focussed on concentration profiling of the four 
grades of Polyox™, in order to understand its function as an excipient in freeze-dried 
ODTs.  Tables 4.2-4.5 represent the various formulations that were prepared with the 
four grades of Polyox™. Tables 4.6-4.9 represent the macroscopic evaluation of the 
resultant tablets respectively. Both mannitol inclusive and free formulations were tested 
to determine the effect of inclusion of matrix supporting agents in the formulation and 
to identify the specific role of Polyox™ within the tablets.  
 
Table 4.2 Formulation details of Polyox™ N10 formulations, detailing the 
concentrations of Polyox™ and mannitol used in each formulation. 
Polyox™ Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
5 0 
5 30 
10 0 
10 30 
 
 
Table 4.3 Formulation details of Polyox™ 1105 formulations, detailing the 
concentrations of Polyox™ and mannitol used in each formulation. 
Polyox™ Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
1 70 
3 0 
3 30 
3 70 
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Table 4.4 Formulation details of Polyox™ N-60K formulations, detailing the 
concentrations of Polyox™ and mannitol used in each formulation. 
Polyox™ Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
1 70 
2 0 
2 30 
2 70 
 
 
Table 4.5 Formulation details of Polyox™ Coagulant formulations, detailing the 
concentrations of Polyox™ and mannitol used in each formulation. 
Polyox™ Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet 
weight) 
1 0 
1 30 
1 70 
2 0 
2 30 
2 70 
 
Tables 4.6-4.9 detail the macroscopic evaluation of the prepared tablets, from the 
various grades and subsequent formulations.  
Chapter Four: Polyox™ (Synthetic Polyethylene Oxide) 
 
126 
 
Table 4.6 Concentration profiling and macroscopic evaluation of the various 
formulations prepared with the Polyox™ N10 grade. 
Formulation Comments 
1% w/w Polyox™ N10 Intact tablets formed. Tablets were very soft and deformed 
permanently (plastic deformation) when handled. Tablets 
did not have elastic properties, i.e. did not retain shape 
when handled. Low viscosity grade Polyox™ N10 was not 
suitable as a binder in ODTs, at a concentration of 1% 
w/w. 
1% w/w Polyox™ N10 
with 30% w/w  
(of dried tablet weight) 
Mannitol 
Intact tablets formed. Tablets were very soft and deformed 
permanently (plastic deformation) when handled. Tablets 
did not have elastic properties, i.e. did not retain shape 
when handled. Low viscosity grade Polyox™ N10 at a 
concentration of 1% w/w with 30% w/w (of dried tablet 
weight) mannitol, was not suitable as a formulation for 
ODTs. 
5% w/w Polyox™ N10 Intact tablets formed. Tablets were harder than the 1% 
w/w tablets but still deformed permanently (plastic 
deformation) when handled. Tablets did not retain shape 
when handled. Low viscosity grade Polyox™ N10 was not 
suitable as a binder in ODTs, at a concentration of 5% 
w/w. 
5% w/w Polyox™ N10 
with 30% w/w  
(of dried tablet weight) 
Mannitol 
Intact tablets formed. Tablets were soft and deformed 
permanently when handled. Tablets did not retain shape 
when handled. Polyox™ N10 at a concentration of 5% w/w 
with 30% w/w (of dried tablet weight) mannitol, was not 
suitable as a formulation for ODTs.  
10% w/w Polyox™ N10 Intact tablets formed. Tablets were very hard and robust, 
and retained shape when handled. However, the tablets 
did deform permanently when excessive force was 
applied, when handled. Tablets were relatively difficult to 
remove from the moulds. Low viscosity grade Polyox™ N10 
at a concentration of 10% w/w, was suitable as a binder in 
ODTs. 
10% w/w Polyox™ N10 
with 30% w/w  
(of dried tablet weight) 
Mannitol 
Intact tablets formed. Tablets were hard and robust, and 
retained shape when handled. However, tablets did 
deform when excessive force was applied, when handled. 
Tablets were relatively difficult to remove from the moulds. 
Low viscosity grade Polyox™ N10 at a concentration of 
10% w/w with 30% w/w (of dried tablet weight) mannitol, 
was a suitable formulation for ODTs.  
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Table 4.7 Concentration profiling and macroscopic evaluation of the various 
formulations prepared with the Polyox™ 1105 grade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation Comments 
1% w/w Polyox™ 1105 
 
Intact tablets were formed. The tablets were very soft, 
with a “spongy/foamy” consistency. The tablets were 
relatively easy to remove from the bijou tubes. The 
tablets deformed-permanently (i.e. lost shape) very 
easily when handled. 
1% w/w Polyox™ 1105 with 
30% w/w 
(of dried tablet weight) 
mannitol 
 
1% w/w Polyox™ 1105 with 
70% w/w 
(of dried tablet weight) 
mannitol 
3% w/w Polyox™ 1105 
 
Intact tablets were formed. The tablets were soft, but 
harder than the lower polymer concentration tablets. 
The tablets had a “spongy/foamy” consistency. The 
tablets were difficult to remove from the bijou tubes. 
The tablets deformed-permanently (i.e. lost shape) 
very easily when handled. 
3% w/w Polyox™ 1105 with 
30% w/w 
(of dried tablet weight) 
mannitol 
 
3% w/w Polyox™ 1105 with 
70% w/w 
(of dried tablet weight) 
mannitol 
 
Intact tablets were formed. The tablets were very 
tough, with a noticeable “spongy/foamy” consistency. 
The tablets were very difficult to remove from the bijou 
tubes. The tablets deformed-permanently (i.e. lost 
shape) when handled. 
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Table 4.8 Concentration profiling and macroscopic evaluation of the various 
formulations prepared with the Polyox™ N-60K grade. 
 
Table 4.9 Concentration profiling and macroscopic evaluation of the various 
formulations prepared with the Polyox™ Coagulant grade. 
 
 
Formulation Comments 
1% w/w Polyox™ N-60K 
 
Intact tablets were formed. The tablets were soft with 
an “elastic” consistency. The tablets were relatively 
easy to remove from the bijou tubes. The tablets 
deformed-permanently (i.e. lost shape) easily when 
handled. 
1% w/w Polyox™ N-60K 
with 30% w/w 
(of dried tablet weight) 
mannitol 
 
1% w/w Polyox™ N-60K 
with 70% w/w 
(of dried tablet weight) 
mannitol 
2% w/w Polyox™ N-60K 
 
Intact tablets were formed. The tablets were soft but 
harder than the lower polymer concentration tablets. 
The tablets had an “elastic” consistency. The tablets 
were difficult to remove from the bijou tubes, and 
deformed-permanently (i.e. lost shape) easily when 
handled. 
2% w/w Polyox™ N-60K 
with 30% w/w 
(of dried tablet weight) 
mannitol 
 
2% w/w Polyox™ N-60K 
with 70% w/w 
(of dried tablet weight) 
mannitol 
 
Intact tablets were formed. The tablets were tough, 
with an “elastic” consistency. The tablets were difficult 
to remove from the bijou tubes, and deformed-
permanently (i.e. lost shape) easily when handled. 
Formulation Comments 
1% w/w Polyox™ 
Coagulant 
Intact tablets were formed. The tablets were soft with 
an “elastic” consistency. The tablets were relatively 
easy to remove from the bijou tubes, and deformed-
permanently (i.e. lost shape) easily when handled. 
1% w/w Polyox™ 
Coagulant with 30% w/w 
 (of dried tablet weight) 
mannitol 
1% w/w Polyox™ 
Coagulant with 70% w/w 
 (of dried tablet weight) 
mannitol 
2% w/w Polyox™ 
Coagulant 
Intact tablets were formed. The tablets were soft with 
an “elastic” consistency. The tablets were difficult to 
remove from the bijou tubes, and deformed-
permanently (i.e. lost shape) easily when handled. 
2% w/w Polyox™ 
Coagulant with 30% w/w 
 (of dried tablet weight) 
mannitol 
2% w/w Polyox™ 
Coagulant with 70% w/w 
 (of dried tablet weight) 
mannitol 
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The macroscopic evaluation of Polyox™ N10 formulations and tablets are shown in 
Table 4.6. Formulations comprising of 1, 5 and 10% w/w Polyox™ N10 were prepared 
in order to observe and evaluate the effects of Polyox™ N10 concentration on the 
properties of the formulations and tablets, over a broad concentration range.  This low 
viscosity grade Polyox™ polymer has shown to produce intact tablets. With a polymer 
concentration of 1% w/w, the tablets were very soft and deformed permanently (i.e. lost 
their shape) when handled. Therefore, Polyox™ N10 at a concentration of 1% w/w was 
not suitable as a binder in ODTs. The inclusion of mannitol in the formulation did not 
appear to have a significant effect on the physical appearance of the tablets. Similar to 
the mannitol-free formulation, the tablets were very soft and lost their shape when 
handled. This composition which includes mannitol, was not therefore suitable as a 
formulation for ODTs. 
 
Increasing Polyox™ N10 concentration to 5% w/w, produced tablets which were harder 
than the 1% w/w tablets, however the 5% w/w formulation tablets still lost their shape 
when handled. Polyox™ N10 at a concentration of 5% w/w was not suitable as a binder 
in ODTs. Including mannitol at a concentration of 30% w/w (of dried tablet weight), in 
the formulation, did not appear to significantly improve or deteriorate the physical 
appearance of the tablets. The tablets were soft, although noticeably harder than the 
1% w/w Polyox™ N10 tablets, and lost their shape when handled. As a result, this 
concentration was not suitable as a formulation for ODTs, as this formulation did not 
form hard and robust tablets which can withstand manual handling. 
 
The formulation which consisted of 10% w/w Polyox™ N10 produced tablets which 
were hard and robust, which also retained their shape when handled. However, when 
excessive force was applied during handling the tablets, they did deform. The tablets 
were also more difficult to remove from the moulds, than the tablets which consisted of 
1 and 5% w/w Polyox™ N10, respectively. The inclusion of mannitol in the formulation 
did not significantly improve or deteriorate the physical appearance of the tablets. The 
tablets were hard and robust, which could retain their shape when handled. This 
particular composition is a suitable formulation for ODTs. 
 
A possible reason why tablets which consisted of 1 and 5% w/w Polyox™ N10 
underwent permanent deformation (i.e. lost their shape/could not retain their shape), 
could be due to the fact that Polyox™ is a linear chain polymer and is thermoplastic in 
nature (DOW, 2002). Polyox™ is based on the polyethylene structure which is 
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considered as a plastic material, which exhibits limited elasticity (i.e. the tablets do not 
retain their shape when handled/the tablets do not return to their original shape when 
compressed), and is formable (i.e. can undergo plastic deformation) (Houwink and De 
Decker, 1971). 
 
Tablets which consisted of 10% w/w Polyox™ N10 were harder and more robust than 
the lower concentration Polyox™ N10 based formulation tablets, and were more 
resistant to deformation possibly because of the formation of a denser and extensive 
polymer binder network which produces harder and more robust tablets. 
 
Tablets which were produced from formulations which consisted of 1 and 5% w/w 
Polyox™ N10, respectively, were considered not suitable for tablet characterisation 
analysis. These tablets deformed permanently when handled (i.e. lost their shape). It 
was therefore decided not to analyse these tablets for; mechanical properties, porosity 
and disintegration time, as it would appear that the tablets would have provided 
inaccurate results and inaccurate representation of the tablets. 
 
The macroscopic evaluation of Polyox™ 1105 formulations and tablets are shown in 
Table 4.7. In terms of the observations made for Polyox™ 1105 formulations, it was 
possible to use this polymer up to 3% w/w in the formulations. Above this 
concentration, the formulations were too viscous to dose. The viscosity analysis results 
(Figure 4.1B) revealed that the workable viscosity range for this grade of Polyox™, was 
2.98 ± 0.11 to 71.33 ± 1.21 mPa s.  
 
Macroscopic evaluation of Polyox™ N-60K formulations and tablets are shown in Table 
4.8. In terms of the observations made for Polyox™ N-60K formulations, it was possible 
to use this polymer up to 2% w/w in the formulations. Above this concentration, the 
formulations were too viscous to dose. The viscosity analysis results (Figure 4.1C) 
revealed that the workable viscosity range for this grade of Polyox™, was 8.56 ± 0.93 to 
33.17 ± 2.45 mPa s. 
 
The macroscopic evaluation of Polyox™ Coagulant formulations and tablets are shown 
in Table 4.9. In terms of the observations made for Polyox™ Coagulant formulations, it 
was possible to use this polymer up to 2% w/w in the formulations. Above this 
concentration, the formulations were too viscous to dose. The viscosity analysis results 
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(Figure 4.1D) revealed that the workable viscosity range for this grade of Polyox™, was 
7.02 ± 0.91 to 58.67 ± 7.53 mPa s. 
 
The formulations prepared form Polyox™ grades; 1105, N-60K and Coagulant, were 
also very cohesive in nature, which made dosing very difficult in terms of accurate 
uniform dosing of the formulations. This is another reason why these grades could only 
be used at low concentrations. 
 
The tablets prepared from Polyox™; 1105, N-60K and Coagulant formulations 
underwent permanent deformation when handled, i.e. the tablets would not return to 
their original shape following manual compression and when handled.   
 
These three grades of Polyox™ have shown not to be suitable as binders in freeze-
dried ODTs, as the prepared tablets deformed permanently when handled, and 
therefore the prepared tablets were deemed not suitable for characterisation. However, 
it is hypothesised that the highly viscous and cohesive nature of these grades of 
Polyox™ could potentially be utilised in lower concentrations (below 0.5%w/w) to 
increase the retention of the formulations in the pre-gastric regions and subsequently 
encourage pre-gastric absorption. 
   
4.4.2 Viscosity Analysis of Polyox™ Formulations 
Viscosity analysis of freeze-dried ODT formulations is particularly important, as it can 
provide an indication of the ease of dosing of formulations, which can ultimately affect 
content uniformity of the resulting tablets. During concentration profiling of the 
formulations it was discovered that the Polyox™ 1105 grade could only be used up to 
3% w/w, whilst Polyox™ N-60K and Coagulant grades could only be used up to 2% 
w/w, respectively, due to the highly viscous and cohesive nature of the formulations. 
Viscosity analysis of the formulations will provide greater information regarding the 
“workable” viscosity range, which permits satisfactory dosing.  
 
Analysis of the viscosities of Polyox™ formulations, as shown in Figures 4.1A-D, 
showed that for the mannitol-free formulations, increasing Polyox™ concentration 
resulted in an increase in formulation viscosity (p < 0.05). This was also observed with 
the formulations which included mannitol (p < 0.05). 
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Figure 4.1 Viscosity analysis results for the prepared Polyox™; (A) N10 and (B) 1105 
formulations. Viscosity analyses of the formulations were performed in triplicate, and 
mean values ± standard deviation are reported. 
 
B 
A 
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Figure 4.1 Viscosity analysis results for the prepared Polyox™; (C) N-60K and (D) 
Coagulant formulations. Viscosity analyses of the formulations were performed in 
triplicate, and mean values ± standard deviation are reported. 
 
An increase in Polyox™ concentration resulted in an increase in formulation viscosity 
possibly due to an increase in the density of the polymer network which resulted in 
amplification in the interaction between polymer chains.   
 
With the Polyox™ N10 formulations, comparing the viscosities of the mannitol-free 
formulations with the formulations which included 30% w/w (of dried tablet weight) 
mannitol, indicated that the inclusion of mannitol resulted in an increase in formulation 
viscosity, in the case of the 1 and 10% w/w Polyox™ N10 formulations (p < 0.05).  
 
The inclusion of mannitol in the formulations resulting in an increase in viscosity could 
be attributed to the increased amount of solute in the formulations which results in 
D 
C 
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increased intermolecular interactions exhibiting greater viscosities (Miyawaki et al. 
2003). 
 
Both formulations based on 5% w/w Polyox™ N10, exhibited comparable viscosity (p > 
0.05). The mannitol-free formulation exhibited a viscosity of 2.16 ± 0.23 mPa s, whilst 
the formulation which included 30% w/w (of dried tablet weight) mannitol displayed a 
viscosity of 2.51 ± 0.06 mPa s. 
 
In terms of the 1% w/w formulations of the Polyox™ 1105 grade, the addition of 
mannitol at a concentration of 30% w/w (of dried tablet weight) showed not to affect 
formulation viscosity (p > 0.05). However, increasing mannitol concentration to 70% 
w/w (of dried tablet weight), resulted in an increase in formulation viscosity (p < 0.05).  
 
Interestingly, in the case of the 3% w/w Polyox™ 1105 formulations, the addition of 
mannitol at concentrations of 30 and 70% w/w (of dried tablet weight), respectively, 
resulted in a reduction in formulation viscosity (p < 0.05). This observation can possibly 
be attributed to mannitol acting as a plasticiser. The addition of mannitol appears to 
weaken and decrease the molecular chain interactions of Polyox™ 1105 polymer 
chains, and therefore results in a reduction in viscosity. A similar observation was 
reported in a study which investigated the effect of polyols on plasticising corn starch 
(Qiao et al. 2011). 
 
Qiao et al. (2011) investigated the plasticisation of corn starch by using mixtures of 
conventional plasticiser glycerol and higher molecular weight polyols, e.g. xylitol. Qiao 
et al. (2011) reported that the introduction of high molecular weight polyols significantly 
reduced the strong molecular chain interactions (hydrogen-bonds) in starch. 
Furthermore, the molecular chain mobility of starch increases following the addition of 
small plasticiser molecules, which results in decreasing melt viscosity (Qiao et al. 
2011). 
 
Comparing the viscosities of mannitol-free formulations of Polyox™ N-60K, with the 
formulations which included mannitol, revealed that in the case of the 1% w/w 
formulations, the addition of mannitol at a concentration of 30% w/w (of dried tablet 
weight) showed no effect on viscosity (p > 0.05). However, increasing mannitol 
concentration to 70% w/w (of dried tablet weight), resulted in an increase in viscosity (p 
< 0.05). This particular trend was also observed with the 2% w/w formulations. 
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In the case of the 1% w/w Polyox™ Coagulant formulations, the addition of mannitol at 
concentrations of 30 and 70% w/w (of dried tablet weight), respectively, resulted in a 
reduction in formulation viscosity (p < 0.05). No significant difference was observed in 
formulation viscosity, between the two mannitol-containing formulations (p > 0.05). 
Similar trends were observed for formulations containing 2%w/w  Polyox™ Coagulant. 
 
In terms of the workable viscosity ranges of Polyox™; 1105, N-60K and Coagulant 
formulations, Polyox™ 1105 formulations could be successfully dosed which composed 
of viscosities between 2.98 ± 0.11 and 71.33 ± 1.21 mPa s. On the other hand,  
Polyox™ N-60K and Coagulant formulations could be successfully dosed which 
comprised of viscosities between 8.56 ± 0.93 and 33.17 ± 2.45, and 7.02 ± 0.91 and 
58.67 ± 7.53 mPa s, respectively.   
 
4.4.3 Tablet Hardness, Fracturability and Thermal Analysis 
Tablet hardness and fracturability analysis of freeze-dried ODTs provides an 
assessment of the mechanical properties of the tablets. It is well acknowledged that 
freeze-dried ODTs generally exhibit poor mechanical properties than conventional 
tablets due to the porous framework of the formulation. Assessment of their 
mechanical properties is a vital parameter to determine the mechanical integrity of the 
formulation during handling, transportation and packaging. 
  
Tablet hardness analysis results for Polyox™ N10 formulations tablets, as shown in 
Table 4.10, indicate that both formulations produced tablets which exhibited 
comparable tablet hardness.  
 
 Table 4.10 Tablet hardness analysis results for the prepared Polyox™ N10 
formulations tablets. Tablet hardness analyses of the formulations were performed in 
triplicate, and the mean values ± standard deviation are reported. 
Formulation Tablet Hardness (N) ± S.D. 
10% w/w Polyox N10 2.364 ± 1.268 
10% w/w Polyox N10 with 30% w/w  
(of dried tablet weight) Mannitol 
4.192 ± 0.875 
 
The 10% w/w Polyox™ N10 mannitol-free formulation produced tablets which exhibited 
tablet hardness of 2.36 ± 1.27 N, whilst the formulation which included mannitol, 
produced tablets with  hardness of 4.19 ± 0.88 N (p > 0.05).  
 
The inclusion of mannitol in the formulation has therefore shown not to improve or 
deteriorate tablet hardness. 
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Table 4.11 shows the results from the analysis of tablet fracturability of Polyox™ N10 
formulations. The results indicated that both formulations produced tablets which 
displayed similar tablet fracturability.  
 
Table 4.11 Tablet fracturability analysis results for the prepared Polyox™ N10 
formulations tablets. Tablet fracturability analyses of the formulations were performed 
in triplicate, and the mean values ± standard deviation are reported. 
Formulation Tablet Fracturability (N) ± S.D. 
10% w/w Polyox N10 1.259 ± 0.461 
10% w/w Polyox N10 with 30% w/w  
(of dried tablet weight) Mannitol 
1.824 ± 0.789 
 
Tablets produced from the 10% w/w Polyox™ N10 mannitol-free formulation, displayed 
tablet fracturability of 1.26 ± 0.46 N, whilst the formulation which included mannitol 
exhibited tablet fracturability of 1.82 ± 0.79 N (p > 0.05).  
 
Including mannitol in the formulation has therefore shown not to affect the mechanical 
properties of the tablets. The resistance of the tablets to the penetrating fracturability 
probe is comparable for both the tablets formed from mannitol-free and mannitol 
included formulations. These results are in agreement with the tablet hardness results 
(Table 4.10), where it was also observed that the incorporation of mannitol in the 
formulation did not influence the mechanical properties of the tablets. 
 
It has been previously reported that mannitol provides crystallinity and subsequently 
hardness to freeze-dried ODTs (Seager, 1998). In order to investigate further the 
influence of mannitol on the mechanical properties of the tablets, the thermal 
properties of the formulations were evaluated using DSC.  
 
DSC analysis of mannitol-free formulations of Polyox™ N10, 1105, N-60K and 
Coagulant, produced thermograms which exhibited two endothermic melting peaks, as 
shown in Figures; 4.2A, 4.2C, 4.2E and 4.2G, respectively. The two melting peaks 
were observed at around -8ºC and at around 0ºC. The melting peaks observed at 
around -8°C, were attributed to the melting of strongly bound water (PEO-water 
hydrate) (Graham et al. 1990), in which water molecules bind strongly to polyethylene 
oxide molecules, resulting in strongly bound water referred to as non-freezeable water 
(Takei et al. 2002). This “strongly bound water” involves hydrogen bonding between 
the hydrogen of water molecules and the ether oxygen of polyethylene oxide 
molecules (Graham et al. 1990). The second melting peaks observed at around 0°C, 
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were attributed to the melting of free (bulk) water, which is also referred to as 
freezeable water (Takei et al. 2002). 
 
DSC analysis of mannitol-included formulations of Polyox™ N10, 1105, N-60K and 
Coagulant, produced thermograms which exhibited several thermal transitions, as 
shown in Figures; 4.2B, 4.2D and 4.2F, respectively. Glass transitions were observed 
with an onset of around -32ºC, which were attributed to the glass transition of the 
mannitol phase plasticised by unfrozen water (Cavatur et al. 2002). Second glass 
transitions were observed with an onset of around -25ºC, which were attributed to the 
glass transition of the amorphous freeze-concentrate of mannitol (Cavatur et al. 2002).  
 
Exotherms were also observed at around -22ºC, which were attributed to the 
crystallisation of both mannitol hydrate and the unfrozen water, which were associated 
with the amorphous phase of mannitol (Cavatur et al. 2002). The reason that 
crystallisation of both mannitol hydrate and the unfrozen water occurred so suddenly 
after the second glass transition, was due to the high molecular mobility of the 
amorphous freeze-concentrate above the glass transition temperatures. 
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Figure 4.2 DSC analysis thermogram of a; (A) 10% w/w Polyox™ N10 formulation 
sample, (B) 10% w/w Polyox™ N10 with 30% w/w (of dried tablet weight) mannitol 
formulation sample, (C) 1% w/w Polyox™ 1105 formulation sample, (D) 1% w/w 
Polyox™ 1105 with 30% w/w (of dried tablet weight) mannitol formulation sample, (E) 
2% w/w Polyox™ N-60K formulation sample, (F) 1% w/w Polyox™ N-60K with 70% w/w 
(of dried tablet weight) mannitol formulation sample and (G) 2% w/w Polyox™ 
Coagulant formulation sample, all during the heating phase of the DSC method. 
A B 
C D 
E F 
G 
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The thermograms of the mannitol-included formulations also revealed two endothermic 
melting peaks at around -8 and 0ºC, respectively. As discussed previously, the melting 
peaks observed at around -8ºC, were attributed to the melting of “strongly bound 
water”. The second melting peaks observed at around 0ºC, were attributed to the 
melting of free (bulk) water. 
 
Evaluation of the thermal properties of both the mannitol-free and mannitol-included 
formulations of 10% w/w Polyox™ N10, revealed that with the mannitol-included 
formulation, mannitol hydrate underwent crystallisation during the heating phase of the 
DSC method. Despite this thermal transition, the inclusion of mannitol in the 
formulation did not improve the mechanical properties of the tablets, as comparable 
tablet hardness and fracturability results were observed between the two formulations.  
 
Mannitol as a matrix supporting agent/structure former, has been reported to influence 
tablet hardness through a number of mechanisms. It has been reported that mannitol, 
due to its crystalline nature, imparts hardness to freeze-dried ODTs, when used in 
combination with a water-soluble polymer, which is generally amorphous in nature 
(Sastry et al. 2000, Kearney, 2003 and Seager, 1998). 
 
Another reported mechanism by which mannitol influences tablet hardness, is by 
functioning as a matrix supporting agent which acts by cementing the porous 
framework provided by the water soluble polymer (AlHusban et al. 2010b). Highlighting 
the influence of mannitol on the mechanical properties (tablet hardness and 
fracturability) of freeze-dried ODTs, Chandrasekhar et al. (2009) previously reported on 
the improvement/increase of the mechanical properties as a consequence of 
increasing mannitol concentration. 
  
DSC analysis of 2% w/w Polyox™ N-60K formulations with 30 and 70% w/w (of dried 
tablet weight) mannitol was not performed due to the highly viscous and cohesive 
nature of the formulations where sample preparation for DSC analysis could not be 
performed. This was also the case with 1 and 2% w/w Polyox™ Coagulant formulations 
consisting of 30 and 70% w/w (of dried tablet weight) mannitol. 
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4.4.4 Tablet Disintegration Time Analysis and Porosity Measurement of Polyox™ 
N10 Formulations   
The rapid disintegration time of freeze-dried ODTs, is the principal feature which 
distinguishes this type of dosage form from conventional tablets. Consequently, 
assessing tablet disintegration time is a prerequisite. The highly porous nature of 
freeze-dried ODTs, as a result of the formulations undergoing freeze-drying, is one 
factor which promotes the rapid disintegration of this type of dosage form. Assessing 
tablet porosity therefore provides useful information which allows further understanding 
of how the tablets disintegrate when exposed to the disintegrating medium.  
 
Analysis of the tablet disintegration time of Polyox™ N10 formulations, as shown in 
Table 4.12, has shown that the inclusion of mannitol in the formulation had a significant 
effect on tablet disintegration time. 
 
 Table 4.12 Tablet disintegration time analysis results for the prepared Polyox™ N10 
formulations tablets. Tablet disintegration time analyses of the formulations were 
performed in triplicate, and the mean values ± standard deviation are reported. 
Formulation Tablet Disintegration Time (s) ± 
S.D. 
10% w/w Polyox N10 69.67 ± 5.03 
10% w/w Polyox N10 with 30% w/w  
(of dried tablet weight) Mannitol 
32.00 ± 7.94 
 
The tablets produced from 10% w/w Polyox™ N10 mannitol-free formulation, exhibited 
a tablet disintegration time of 69.67 ± 5.03s, whilst the formulation which included 
mannitol displayed a tablet disintegration time of 32.00 ± 7.94s (p < 0.01). The 
inclusion of mannitol in the formulation has therefore shown to significantly reduce 
tablet disintegration time. 
 
A possible explanation of why the incorporation of mannitol in the formulations 
produced tablets which exhibited a reduced disintegration time, compared to tablets 
produced from mannitol-free formulations, could be due to the solubility of mannitol. As 
mannitol is soluble in water, when the tablet is exposed to the disintegration medium, 
mannitol instantly dissolves, which exposes the tablet binder matrix to the 
disintegration medium to a greater extent than would be expected with tablets 
produced from mannitol-free formulations. As a result, the tablets disintegrate in a 
shorter time.  
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The presence of mannitol in the formulation of freeze-dried ODTs has been reported to 
function not only as a matrix supporting agent/structure former, but also as a 
disintegration enhancing agent (AlHusban et al. 2010a). Mannitol therefore has dual 
functionality as an excipient, not only to influence the mechanical properties of the 
tablets by imparting hardness, but also to enhance the rapid disintegration of the 
tablets, due to its highly hydrophilic nature (AlHusban et al. 2010a).  
 
Analysis of the tablet porosity of Polyox™ N10 formulations, as shown in Table 4.13, 
has shown that the inclusion of mannitol in the formulation had a significant effect on 
tablet porosity. 
 
Table 4.13 Tablet porosity analysis results for the prepared Polyox™ N10 formulations 
tablets. Tablet porosity analyses of the formulations were performed in triplicate, and 
the mean values ± standard deviation are reported. 
Formulation Tablet Porosity (%) ± S.D. 
10% w/w Polyox N10 95.38 ± 0.54 
10% w/w Polyox N10 with 30% w/w  
(of dried tablet weight) Mannitol 
92.27 ± 0.24 
 
Tablets formulated from the 10% w/w Polyox™ N10 mannitol-free formulation exhibited 
a tablet porosity of 95.38 ± 0.54%, whilst tablets formulated from the formulation which 
included mannitol, displayed a tablet porosity of 92.27 ± 0.24% (p < 0.05). The 
inclusion of mannitol in the formulation has therefore shown to significantly reduce 
tablet porosity. 
 
A possible explanation of this observation is that the inclusion of mannitol in the 
formulation, resulted in an increase in the amount of solid material in the tablets, 
therefore the porous space in the tablets was reduced, which resulted in a reduction in 
tablet porosity. 
 
Evaluating the disintegration time and porosity results together, interestingly revealed 
that the reduction in tablet disintegration time as a result of the addition of mannitol in 
the formulation was not related to tablet porosity, as a reduction in tablet porosity was 
observed, which would usually suggest an increase in disintegration time. It can 
therefore be concluded that the reduction in tablet disintegration time can be attributed 
to mannitol functioning as a disintegration enhancing agent (AlHusban et al. 2010b).  
 
A number of formulation parameters have been identified which are reported to be 
responsible for the mechanism of disintegration of freeze-dried ODTs. Seager (1998) 
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and Kearney (2003) reported that the highly porous nature of freeze-dried ODTs, which 
allows the rapid ingress of saliva into the tablet matrix structure, is responsible for the 
instantaneous disintegration of these tablets in the mouth. Meanwhile, AlHusban et al. 
(2010a) identified the high hydrophilic/soluble nature of matrix supporting/disintegration 
enhancing agents, as being responsible. These materials dissolve upon hydration with 
saliva, which results in the disruption and ultimately disintegration of the tablets 
(AlHusban et al. 2010a).  
 
AlHusban and Mohammed (2011) and AlHusban et al. (2010b) identified that high 
tablet porosity and the high wettability of excipients, results in the swift disintegration of 
the tablets, as the short wetting time of excipients translates to quick disintegration of 
the tablets. AlHusban et al. (2010b) and Bi et al. (1996) reported linear positive 
correlations between the wetting time of excipients/tablets and tablet disintegration 
time.  
 
 
4.5 Conclusions 
Following the evaluation of the several grades of Polyox™ for potential applications with 
freeze-dried ODTs, the lowest viscosity grade (Polyox™ N10) produced robust tablets 
at a concentration of 10% w/w which were suitable for tablet hardness and 
disintegration testing. Tablets were produced which exhibited a hardness of 4.19 ± 
0.88 N and a disintegration time of 32.00 ± 7.94 s. This grade of Polyox™ therefore 
appeared most suitable as a binder in freeze-dried ODTs, from the four grades 
investigated.  
 
Formulations of Polyox™ 1105, N-60K and Coagulant were very viscous and cohesive 
at low concentrations. The viscosity analysis results highlighted the potential of these 
grades of Polyox™ to increase the retention of ODT formulations in the pre-gastric 
regions, and subsequently encourage pre-gastric absorption of APIs.  
 
With the higher viscosity grades of Polyox™ (1105, N-60K and Coagulant), due to the 
highly viscous and cohesive nature of the formulations, concentrations up to 2% w/w 
could only be used with the N-60K and Coagulant grades, whilst concentrations up to 
3% w/w could only be used with the 1105 grade, which could be successfully dosed. 
As a consequence, robust tablets which were suitable for tablet hardness and 
disintegration testing were not produced, as extensive binder matrices appeared not 
being formed at such low concentrations. 
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Additionally, the tablets produced with these three grades of Polyox™, underwent 
permanent deformation when handled, which could possibly be attributed to the linear 
chain nature of this polymer, which exhibits limited elasticity and can undergo plastic 
deformation.  
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5.1 Introduction 
Kollicoat® IR is a polyvinyl alcohol-polyethylene glycol graft co-polymer which has a 
principal application as an instant-release coating for tablets (BASF SE, 2010). The 
copolymer is composed of 75% polyvinyl alcohol units and 25% polyethylene glycol 
units, and is reported to be freely-soluble in water (BASF SE, 2010). In fact, due to the 
chemical structure of this co-polymer, it dissolves readily in acidic, neutral and alkaline 
aqueous media (BASF SE, 2010). It has been reported that Kollicoat® IR is effective as 
a coating material, as the polyvinyl alcohol component of the polymer provides good 
film-forming properties whilst the polyethylene glycol component functions as an 
internal plasticiser which provides flexibility to the material (Fouad et al. 2011). 
Kollicoat® IR is also favourable as a coating material as it displays lower viscosity than 
cellulose derivatives which allows it to be used at higher concentrations (Fouad et al. 
2011). 
 
Kollicoat® IR has also been shown to have binding properties in both mixer and fluid 
bed wet granulation methods which can be attributed to its film-forming ability (Fouad 
et al. 2011). Furthermore, a reported application of Kollicoat® IR is as a binder for 
rapidly dispersible/soluble granules or tablets (BASF SE, 2010).  In terms of the 
preparation of solid dispersions (using a hot stage extruder, spray drying or freeze-
drying), it has been reported that Kollicoat® IR can enhance the dissolution rate of bio-
pharmaceutics classification system class II drugs due to its high aqueous solubility 
and the resulting low viscosity of the aqueous medium. In addition, it also offers a wide 
range of advantages including its pH-independent solubility, surface activity and low 
viscosity (when it is dissolved in water) (Fouad et al. 2011). 
 
Kollicoat® IR has also been reported to be used in controlled/sustained-release tablet 
coatings owing to its pore forming ability (BASF SE, 2010). Siepmann et al. (2007) 
reported the effect of Kollicoat® IR in an ethylcellulose film. Siepmann et al. (2007) 
reported that the addition of Kollicoat® IR significantly increased the rate and extent of 
water uptake and the permeability of the films increased as Kollicoat® IR content 
increased. Adjusting the content of Kollicoat® IR in ethylcellulose-coated dosage forms 
can therefore control/modify drug release rates (Siepmann et al. 2007). The use of 
Kollicoat® IR in freeze-dried preparations (solid dispersions) has been reported 
previously (El-Badry et al. 2010). El-Badry et al. (2010) reported that freeze-dried solid 
dispersions of omeprazole-Kollicoat® IR mixtures exhibited dissolution at a rate seven 
times that of the physical mixture. 
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The current work aims to exploit the dual property (high aqueous solubility and its 
ability to function as a binder) offered by Kollicoat® IR in the formulation of freeze-dried 
orally disintegrating tablets (ODTs). This would have distinct advantages including low 
viscosity of the binder solution ensuring uniform dosing of samples into the moulds, 
faster disintegration rate of the tablets, solubility enhancement of BCS class II drugs 
and higher hardness of the resultant tablets.   
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5.2 Materials 
Kollicoat® IR was supplied by BASF SE (Ludwigshafen, Germany). Mannitol was 
supplied by Sigma-Aldrich Chemicals (Poole, UK). 
 
5.3 Methods 
 
5.3.1 Preparation of Freeze-Dried Tablets 
For the preparation of Kollicoat® IR formulations, the required amount of polymer was 
added to the desired amount of double-distilled water under stirring at ambient 
temperature, followed by the addition of mannitol (for formulations which included 
mannitol). The formulations were then stirred, until all formulation ingredients 
dissolved.1.5 g of the resulting solutions were dosed into a tablet mould, frozen at -
70°C for a minimum of sixty minutes and freeze-dried (ADVANTAGE, Freeze-Dryer, 
VIRTIS), according to the following regime; primary drying for forty eight hours at a 
shelf temperature of -40°C, secondary drying for ten hours at a shelf temperature of 
20°C, and vacuum pressure of 6.67 Pa (50 mTorr). A minimum of ten tablets were 
prepared for each formulation. 
 
5.3.2 Formulation Viscosity Analysis 
For all formulations, the viscosities of 100 mL samples were measured using a DV-I+ 
Brookfield digital viscometer (Harlow, UK). The viscosities of the formulations were 
measured at 37 ± 2°C, in order to replicate the viscosity of the formulations in the oral 
cavity at physiological temperature. The viscometer spindles were selected based on 
the viscosity of the individual formulations, as each spindle is suitable for analysing a 
certain viscosity range. The rotational speed of the spindle was set at 100 rpm. Each 
formulation was analysed in triplicate and the mean values ± standard deviation is 
reported. 
 
5.3.3 Concentration Profiling and Macroscopic Evaluation of the Formulations 
During the preparation of the formulations, several visual assessments were carried 
out in order to evaluate the polymers as binders. The solubility of the material was 
assessed by observing the ease at which the polymer went into solution. The ease of 
dosing of the formulations was also assessed, in terms of the viscosity of the prepared 
solution/suspension and also the consistency of the formulation, i.e. if it had a cohesive 
or non-cohesive appearance. 
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In terms of the visual and physical assessment of the tablets, several assessments 
were carried out in order to evaluate the ability of the polymers to form robust tablets 
with satisfactory mechanical strength. The first assessment involved the evaluation of 
the ability of the formulations to form intact tablet shaped dosage forms following 
freeze-drying. The physical appearance of the tablets was assessed, classifying them 
as either soft or hard, and having either elastic or a more robust/solid consistency. The 
ability of the tablets to be removed from the moulds was also assessed. Finally, the 
performance of the tablets when handled was assessed to observe if they deformed 
permanently or retained their shape. 
 
The first phase of the investigation was focussed on concentration profiling of 
Kollicoat® IR to determine the optimum binder concentration and understand its 
function as a binder or binder/disintegrant. Table 5.1 represents the various 
formulations that were prepared with Kollicoat® IR. Both mannitol inclusive and free 
formulations were tested to determine the effect of inclusion of matrix supporting 
agents in the formulation and to identify the specific role of Kollicoat® IR within the 
tablets.  
 
Table 5.1 Formulation details of Kollicoat® IR formulations detailing the concentrations 
of Kollicoat® IR and mannitol used in each formulation. 
 
 
5.3.4 Differential Scanning Calorimetry (DSC) 
DSC (Pyris Diamond DSC and Intercooler 2P: Perkin Elmer, Wellessey, USA) was 
used to determine the glass transition temperature (Tg) and thermal properties of the 
formulations in their frozen state (before freeze-drying). 10-15 mg of liquid samples of 
the formulations were loaded into aluminium pans, cooled from 25ºC to -65ºC at a rate 
Kollicoat® IR Concentration 
(% w/w) 
Mannitol Concentration 
(% w/w of dried tablet weight) 
1 0 
1 30 
5 0 
5 30 
10 0 
10 30 
10 50 
15 0 
15 30 
20 0 
20 30 
Chapter Five: Kollicoat® IR(Polyvinyl Alcohol-Polyethylene Glycol Co-Polymer) 
 
149 
 
of 5ºC/min and then heated to 20ºC at a rate of 5ºC/min with a nitrogen purge of 20 
mL/min. An empty aluminium pan was used as a reference for all measurements.  
 
The resulting thermograms were analysed by Pyris manager software. Tg values were 
determined from the intersection of relative tangents to the baseline, and other thermal 
properties of the formulations were also assessed. Three measurements were taken 
for each formulation and the mean values ± standard deviation were reported. 
 
5.3.5 Tablet Hardness Analysis 
The hardness of the tablets were investigated using a texture analyzer (QTS 25: 
Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated 
by standard weights of 500 g and 5 kg. The tablets were placed in a holder with a 
cylindrical hole. The hardness was taken as the peak force after 1 mm penetration of a 
5 mm diameter probe at a rate of 6 mm/min. Three measurements were taken for each 
formulation and the mean ± standard deviation is reported. 
 
5.3.6 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2ºC, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 rpm. Three 
tablets were evaluated from each formulation and the mean values ± standard 
deviation is reported. 
 
5.3.7 Investigation of Tablet Porosity 
The porosity of the tablets was measured using helium pycnometry 
(MULTIPYCNOMETER, Quantachrome Instruments, Hampshire, UK). Two freeze-
dried tablets were placed in a suitably sized sample cup and subjected to helium 
pycnometry, to determine the true density of the tablets. The true density value was 
then inserted into the equation as shown below to determine the porosity of the tablets. 
 
 
                                 Porosity =  1 -  bulk density   x 100% 
        true density 
 
(Equation 5.1) 
                                                                           
Bulk density was determined by considering the mass of the tablets, the diameter of 
the tablets, and the height/depth of the tablets. The diameter and height/depth of the 
tablets were determined using a screw gauge (LINEAR Farnell). Three porosity 
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measurements were taken for each formulation, and the mean values ± standard 
deviation is reported. The porosity of the tablets is expressed as a percentage. 
 
5.3.8 Statistical Analysis 
Statistical analyses of the formulation and tablet characterisation results were 
performed using GraphPad Prism 5 statistical analysis software. One-way analysis of 
variance (ANOVA) was the statistical analysis test performed, using the Tukey post 
test. A significance level of p < 0.05 (95% confidence interval) was judged as being 
statistically significant.    
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5.4 Results and Discussion 
 
5.4.1 Concentration Profiling and Macroscopic Evaluation of the Formulations 
The visual and physical assessment of Kollicoat® IR formulations and tablets are 
shown in Table 5.2. Kollicoat® IR formulations were formulated using concentrations of 
1, 5, 10, 15 and 20% w/w. These concentration values were selected in order to 
analyse the effects of Kollicoat® IR concentration on the properties of the formulations 
and tablets over a broad concentration range. 
 
Tablets which consisted of 1% w/w Kollicoat® IR appeared intact, however once any 
contact was made with the tablets, they disintegrated. These tablets were extremely 
soft, and did not withstand manual handling. Kollicoat® IR at a concentration of 1% w/w 
did not appear suitable as a binder for ODTs. Including mannitol in the formulation did 
not have an effect on the physical properties of the tablets. Similar to the mannitol-free 
formulation tablets, the tablets were soft and could not withstand manual handling. 
Once any contact was made with the tablets, they disintegrated.
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Table 5.2 Concentration profiling and macroscopic evaluation of the various Kollicoat® IR-based formulations prepared. 
Formulation Visual and Physical Assessment 
1% w/w Kollicoat® IR Intact tablets were formed, however once any contact was made with the tablets, they simply 
disintegrated. The tablets were extremely soft and did not have physical integrity, i.e. the tablets 
could not withstand manual handling. Kollicoat® IR at a concentration of 1% w/w does not appear 
suitable as a binder in ODTs. 
1% w/w Kollicoat® IR with 30% w/w  
(of dried tablet weight) Mannitol 
Intact tablets formed, however when any contact was made with the tablets they disintegrated. The 
tablets appeared extremely soft and did not retain their shape when handled. The tablets did not have 
any physical integrity and therefore could not withstand any physical contact. Kollicoat® IR at a 
concentration of 1% w/w with 30% w/w (of dried tablet weight) mannitol, does not appear suitable as 
a formulation for ODTs. 
5% w/w Kollicoat® IR Intact tablets formed. However, the tablets were very difficult to remove from the moulds. The tablets 
appeared very soft and did not have significant physical integrity. Once it was attempted to remove 
the tablets from the moulds, the tablets completely disintegrated. Kollicoat® IR at a concentration of 
5% w/w was not suitable as a binder in ODTs. 
5% w/w Kollicoat® IR with 30% w/w  
(of dried tablet weight) Mannitol 
Intact tablets formed, however when the tablets were handled or attempted to remove from the 
moulds, they disintegrated. The tablets were soft and did not retain their shape when handled. 
Kollicoat® IR at a concentration of 5% w/w with 30% w/w (of dried tablet weight) mannitol, does not 
result in a suitable formulation of ODT. 
10% w/w Kollicoat® IR With and 
Without 30 and 50% w/w (of dried 
tablet weight) Mannitol 
Intact tablets formed. The tablets were very hard and robust, with a noticeable slightly 
elastic/“spongy” nature. They retained their shape when handled, and were easily removed from the 
moulds. Kollicoat® IR at a concentration of 10% w/w is suitable as a binder in ODTs. 
15% w/w Kollicoat® IR With and 
Without 30% w/w (of dried tablet 
weight) Mannitol 
Intact tablets formed. The tablets were very hard and robust, which were noticeably harder than the 
10% w/w Kollicoat® IR formulations tablets. The tablets retained their shape when handled and were 
easily removed from the moulds. 
20% w/w Kollicoat® IR With and 
Without 30% w/w (of dried tablet 
weight) Mannitol  
Intact tablets formed. The tablets appeared very hard and robust, which were noticeably harder than 
the 15% w/w Kollicoat® IR formulations tablets. The tablets retained their shape when handled and 
were easily removed from the moulds. 
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Similar results as that for 1% w/w were obtained upon increasing the concentration of 
Kollicoat® IR to 5% w/w which resulted in fragile and easily deformable tablets. The 
tablets were soft and did not retain their shape when handled. Furthermore, addition of 
mannitol as a matrix supporting agent did not have any influence on the outcome for 
the formulation.  As a result, tablets produced from formulations which comprised of 
either 1 or 5% w/w Kollicoat® IR, were not suitable for characterisation analysis/studies. 
The tablets of these formulations could not be removed from their moulds intact; 
therefore these tablets could not undergo characterisation analysis/studies. A possible 
explanation for the weak tablet properties could be the inability of Kollicoat® IR to 
produce an extensive binder matrix which would provide a robust and strong network 
within the formulation upon sublimation of water. In addition, it is also possible that the 
extremely low viscosity of Kollicoat® IR formulations (refer to the Viscosity Analysis of 
Kollicoat® IR Formulations), results in limited/insufficient interaction between the 
polymer chains and hence when the formulations were freeze-dried, the resulting 
tablets were soft and could not withstand manual handling.  
 
Evaluation of 10% w/w Kollicoat® IR formulation produced tablets which were hard and 
robust, with a noticeable mild elastic nature. The tablets retained their shape when 
handled and were easily removed from their moulds. The inclusion of mannitol in the 
formulation produced tablets which displayed similar physical properties to the tablets 
formulated from the mannitol-free formulation. Similarly, tablets produced from the 
formulation which consisted of 10% w/w Kollicoat® IR with 50% w/w (of dried tablet 
weight) mannitol, were intact and appeared very hard and robust which retained their 
shape and were easily removed from the moulds.  
 
Increasing the concentration of Kollicoat® IR to 15 and 20%w/w resulted in intact 
tablets with considerable integrity upon handling. Similar macroscopic properties (as 
that of 10%w/w formulations) were recorded upon the inclusion of mannitol for the both 
the concentrations. Findings from these investigations demonstrated that a threshold 
concentration above 5% w/w of the polymer is needed for the formation of intact tablets 
and that extensive network formation within the tablet upon sublimation in the freeze 
drier occurs at higher concentrations.  
 
5.4.2 Evaluation of thermal properties  
Thermal characterisation of the formulation or its excipients provides vital information 
on optimisation of freeze drying protocol, excipient compatibility and stability 
considerations for the resultant formulation. Evaluation of excipient compatibility is 
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essential as previous research has shown that interaction between excipients could 
result in depression of crystallisation temperature or could detrimentally affect the 
quality of the final product after freeze-drying (Chandrasekhar et al., 2009). 
 
DSC analysis of mannitol-free formulations of Kollicoat® IR comprising of  1, 5, 10, 15 
and 20% w/w respectively produced thermograms which exhibited only a single 
thermal transition/event, as shown in Figure 5.1A. This thermal transition/event was 
attributed to the melting of ice/water at around 0ºC (Harris, 1992). No thermal 
transitions/events were observed which were attributed to Kollicoat® IR within the 
temperature range investigated.  
 
  
 
Figure 5.1 DSC analysis thermogram of a; (A) 10% w/w Kollicoat® IR formulation 
sample, (B) 5% w/w Kollicoat® IR with 30% w/w (of dried tablet weight) mannitol 
formulation sample and (C) 10% w/w Kollicoat® IR with 30% w/w (of dried tablet 
weight) mannitol formulation sample, all during the heating phase of the DSC method. 
 
DSC analysis of the formulations which included 30% w/w (of dried tablet weight) 
mannitol, revealed that 1, 5, 15 and 20% w/w Kollicoat® IR formulations exhibited 
different thermograms compared to the thermograms of the 10% w/w Kollicoat® IR 
formulations. Formulations with 1, 5, 15 and 20% w/w Kollicoat® IR formulations 
showed thermal signal which revealed no thermal transitions/events which were 
attributed to Kollicoat® IR or mannitol, as shown in Figure 5.1B. The only thermal 
transition/event which was present was the endothermic peak of the melting of 
ice/water at around 0ºC (Harris, 1992). 
A B 
C 
Chapter Five: Kollicoat® IR(Polyvinyl Alcohol-Polyethylene Glycol Co-Polymer) 
 
155 
 
 
DSC analysis of 10% w/w Kollicoat® IR with 30 and 50% w/w (of dried tablet weight) 
mannitol formulations produced thermograms which exhibited several thermal 
transitions/events as shown in Figure 5.1C. Two glass transitions were observed at -32 
and -25ºC, respectively, followed by immediate crystallisation at around -22ºC. The 
thermograms also exhibited two endothermic melting peaks at around -8 and 0ºC, 
respectively. The thermal transitions/events observed at -32, -25 and -22ºC, 
respectively, were attributed to mannitol. The transition at -32ºC was attributed to the 
glass transition of the mannitol phase plasticised by unfrozen water (Cavatur et al. 
2002). Similarly, the glass transitions observed at -25ºC were associated with the 
transition of amorphous freeze-concentrate of mannitol (Cavatur et al. 2002). 
Exothermic crystallisation peaks at around -22ºC could be due to the crystallisation of 
both mannitol hydrate and the unfrozen water associated with the amorphous phase of 
mannitol (Cavatur et al. 2002).  
 
In terms of the endothermic melting peaks observed at around -8 and 0ºC, 
respectively, the peak at around -8ºC were attributed to an association between water 
and Kollicoat® IR. Kollicoat® IR is a graft co-polymer of polyvinyl alcohol and 
polyethylene glycol (PEG) (BASF, 2010) and it has been reported that water binds 
strongly to PEG (Tirosh et al. 1998). It has also been reported in literature that DSC 
analysis of PEG solutions produces two endothermic melting peaks (Harris, 1992). The 
first at around -8ºC were attributed to the melting of a PEG-water hydrate in which 
water is strongly bound to Kollicoat® IR (Harris, 1992), which is also referred to as non-
freezable water (Takei et al. 2002). The second endothermic melting peak at around 
0ºC were attributed to the melting of ice, i.e. unbound “free” water (Harris, 1992). 
 
The thermal events which were attributed to mannitol and Kollicoat® IR with 10% w/w 
Kollicoat® IR and 30 and 50% w/w (of dried tablet weight) mannitol formulations, were 
concentration dependent as these events were not observed with 1, 5, 15 and 20% 
w/w Kollicoat® IR (with 30% w/w of dried tablet weight) and mannitol formulations. 
 
Interestingly, the endothermic melting peak at around -8ºC which was observed in 10% 
w/w Kollicoat® IR with 30 and 50% w/w (of dried tablet weight) mannitol formulations 
(Figure 5.1C), were not seen with the corresponding mannitol-free formulations, as 
shown in Figure 5.1A.  
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A likely explanation is that the inclusion of mannitol in the formulation increases the 
fraction of unfrozen/non-freezable water in the formulations (Ghosh and Coupland, 
2008 and McClements, 2004), resulting in the formation of PEG-water hydrate with 
melting temperature at around -8ºC. 
 
5.4.3 Viscosity Analysis of Kollicoat® IR Formulations 
Viscosity analysis was carried out for all the concentration ranges investigated 
irrespective of the inability of lower concentrations to form intact and robust tablets. 
The results showed that increase in concentration of the polymer resulted in the 
increase in viscosity (Figure 5.2) (p < 0.05). Similar trend of results was also observed 
with the formulations which included mannitol (p < 0.05). The increase in viscosity with 
increase in concentration can be attributed to an increase in the density of the polymer 
network which ultimately results in an increase in the interaction between polymer 
chains. 
 
Upon comparing formulation viscosities of the mannitol-free formulations with the 
formulations which included mannitol (for each concentration studied), the results 
revealed that the formulation viscosity increased with the inclusion of mannitol (p < 
0.05). A possible explanation of this observation could be the increased amount of 
solute in the formulations, which increases the intermolecular interactions within the 
liquid resulting in greater viscosity than the corresponding mannitol-free formulation 
(Miyawaki et al. 2003). However, the only exception to this trend was observed with 
10% w/w Kollicoat® IR and the corresponding formulation which included 30% w/w (of 
dried tablet weight) mannitol which were comparable (p > 0.05). 
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Figure 5.2 Viscosity analysis results for the Kollicoat® IR formulations prepared. Viscosity analyses of the formulations were performed in 
triplicate and the mean values ± standard deviation are reported. 
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5.4.4 Tablet Hardness Analysis of Kollicoat® IR Based Formulations 
One of the significant properties of freeze-dried ODTs that are assessed in addition to 
the disintegration time of the tablets is mechanical properties, including hardness. 
Hardness assessment in formulation development is key as it can have significant 
implication on the cost of the finished product due to the need for specialist packaging 
material. Freeze dried ODTs are made of a porous frame work which is strengthened 
by the inclusion of matrix supporting agents and as a consequence hardness 
measurement is vital for both packaging requirements as well as product performance. 
 
Tablet hardness analysis results for Kollicoat® IR formulations tablets are presented in 
Table 5.3. The results indicated that for the mannitol-free formulations, increasing 
Kollicoat® IR concentration from 10% through to 20% w/w resulted in an increase in 
tablet hardness (p < 0.05). Similar trend of results was also observed with the 
formulations which included mannitol (p < 0.05). 
 
Table 5.3 Tablet hardness analysis results for the prepared Kollicoat® IR formulations 
tablets. Tablet hardness analyses of the formulations were performed in triplicate, and 
the mean values ± standard deviation are reported.   
Formulation Tablet Hardness (N) ± S.D. 
10% w/w Kollicoat IR 5.944 ± 1.305  
10% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
11.274 ± 1.947 
10% w/w Kollicoat IR with 50% w/w  
(of dried tablet weight) Mannitol 
17.31 ± 0.83 
15% w/w Kollicoat IR 20.14 ± 2.10 
15% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
38.84 ± 2.57 
20% w/w Kollicoat IR 41.16 ± 3.92 
20% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
> 50 
 
The trend of increasing Kollicoat® IR concentration resulting in an increase in tablet 
hardness, can be attributed to an increase in the total solid content of the tablets and 
subsequent increase in the density of the tablet matrices which results in hard and 
robust tablets. The results can also possibly be related to the viscosity assessments in 
which it was observed that increasing Kollicoat® IR concentration resulted in an 
increase in viscosity due to an increase in the density of the polymer network and 
subsequently increase in polymer chain interaction.  
 
The incorporation of mannitol into the formulations resulted in a significant increase in 
tablet hardness when compared to their mannitol free counter parts (p < 0.05). This 
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increase in hardness can be attributed to a number of reasons. Firstly, the 
incorporation of mannitol in the formulations increases the total solid content of the 
tablets, and subsequently increases the density of the tablet matrices. Secondly, the 
results can be possibly related to the viscosity results where it was observed that the 
incorporation of mannitol increased the amount of solute in the formulations, therefore 
an increase in intermolecular interactions occurred which resulted in an increase in 
formulation viscosity. An increase in intermolecular interactions, as a result of the 
incorporation of mannitol in the formulations reaffirms the role of mannitol as a matrix 
supporting agent (Chandrasekhar et al. 2009) by strengthening the binder matrix of the 
tablets, which results in an increase in tablet hardness. A third explanation for the 
increase in hardness could be related to the DSC results. Mannitol has previously been 
reported to provide crystallinity and subsequently hardness to freeze-dried ODTs 
(Seager, 1998).  Results from DSC scans (Figure 5.1C) demonstrate that mannitol 
undergoes crystallisation which could explain the increase in tablet hardness relative to 
the mannitol-free formulations. 
 
5.4.5 Tablet Disintegration Time Analysis and Porosity Measurements   
Tablet disintegration time of Kollicoat® IR formulations, as shown in Table 5.4, revealed 
that increasing Kollicoat® IR concentration from 10 to 15% w/w resulted in an increase 
in tablet disintegration time (p < 0.05). Whilst increasing Kollicoat® IR concentration to 
20% w/w, produced tablets which exhibited disintegration times greater than three 
minutes. 
 
Table 5.4 Tablet disintegration time analysis results for the prepared Kollicoat® IR 
formulations tablets. Tablet disintegration time analyses of the formulations were 
performed in triplicate and mean values ± standard deviation are reported. 
Formulation Tablet Disintegration Time (s) ± 
S.D. 
10% w/w Kollicoat IR 37.00 ± 2.65 
10% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
29.00 ± 1.73  
10% w/w Kollicoat IR with 50% w/w  
(of dried tablet weight) Mannitol 
19.33 ± 2.08 
15% w/w Kollicoat IR 112.33 ± 29.37 
15% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
112.00 ± 11.36 
20% w/w Kollicoat IR > 180 
20% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
> 180 
  
In terms of the formulations which included mannitol, a similar trend was observed in 
which increasing Kollicoat® IR from 10 to 15% w/w resulted in an increase in tablet 
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disintegration time (p < 0.05). As with the mannitol-free formulation, increasing 
Kollicoat® IR concentration to 20% w/w produced tablets which exhibited disintegration 
times greater than three minutes. An increase in Kollicoat® IR concentration resulting in 
an increase in tablet disintegration time, can be attributed to a decrease in tablet 
porosity and an increase in total solid content of the tablets, which produces a more 
extensive tablet binder matrix, which requires greater time to disintegrate. 
 
To further evaluate the role of porosity on disintegration time of the tablets, helium 
pycnometry was used to assess total porosity of the finished dosage forms. Analysis of 
the tablet porosity results of Kollicoat® IR formulations, as shown in Table 5.5, revealed 
that increasing Kollicoat® IR concentration (for both mannitol included and mannitol 
free) resulted in a reduction in tablet porosity (p < 0.05). However, the 10% w/w 
Kollicoat® IR with 50% w/w (of dried tablet weight) mannitol formulation and 15% w/w 
Kollicoat® IR formulation exhibited comparable tablet porosities (p > 0.05), as did the 
15 and 20% w/w Kollicoat® IR formulations (p > 0.05). The trend of increasing 
Kollicoat® IR concentration resulting in a decrease in tablet porosity could possibly be 
attributed to the increase in tablet density upon increase of polymer concentration.  
 
Table 5.5 Tablet porosity analysis results for the prepared Kollicoat® IR formulations 
tablets. Tablet porosity analyses of the formulations were performed in triplicate and 
the mean values ± standard deviation are reported. 
Formulation Tablet Porosity (%) ± S.D. 
10% w/w Kollicoat IR 92.35 ± 0.22 
10% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
91.55 ± 0.48 
10% w/w Kollicoat IR with 50% w/w  
(of dried tablet weight) Mannitol 
86.33 ± 0.17 
15% w/w Kollicoat IR 88.47 ± 0.85 
15% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
85.34 ± 0.18 
20% w/w Kollicoat IR 84.14 ± 0.21 
20% w/w Kollicoat IR with 30% w/w  
(of dried tablet weight) Mannitol 
81.91 ± 2.74 
 
Upon comparing the disintegration time of mannitol-free formulations with the 
formulations which included mannitol, the results indicated that the 10% w/w 
formulations exhibited a shorter disintegration time than the mannitol-free formulation 
(p < 0.05). It was also observed that the formulation consisting of 50% w/w (of dried 
tablet weight) mannitol showed a shorter disintegration time than the formulation 
consisting of 30% w/w (of dried tablet weight) mannitol (p < 0.05). The results therefore 
suggest that mannitol plays a significant role in reducing disintegration time, and 
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subsequently confirms its function as a disintegration enhancing agent (AlHusban et al. 
2010b). 
 
 
5.5 Conclusions 
Evaluation of Kollicoat® IR as an excipient in freeze-dried ODTs has shown that the 
polymer functions as a binder and its functionality is concentration dependent. This 
study has shown that concentrations above 10% w/w result in intact, hard and robust 
tablets. E.g. a formulation consisting of 10% w/w Kollicoat® IR and 50% w/w (of dried 
tablet weight) mannitol, produced tablets which exhibited a hardness of 17.31 ± 0.83 N 
and a disintegration time of under twenty seconds (19.33 ± 2.08 s). Additionally, 
Kollicoat® IR possesses a number of advantages which makes it suitable as a binder in 
freeze-dried ODTs. Due to its low viscous nature, Kollicoat® IR can be used at high 
concentrations which allow the formation of very hard and robust tablets. Furthermore, 
as it’s freely-soluble in water, Kollicoat® IR formulations can be prepared at 
room/ambient temperature, which makes formulation preparation convenient. 
Moreover, Kollicoat® IR tablets exhibit a short disintegration time, especially when 
formulated in combination with mannitol.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Six: DOE Study 
 
162 
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Study Evaluating the Role of Excipients on the 
Properties of Freeze-Dried ODTs 
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6.1 Introduction 
Design of experiments (DOE) is defined as a structured, organised method for 
determining the relationship between factors affecting a process and the output of that 
process (Food and Drug Administration, 2009). In order to carry out a DOE 
investigation, factorial design is commonly used which involves the variation of two or 
more experimental variables or factors in a planned manner (in which the factors are 
being studied at two or more levels) (Armstrong and James, 1996). Factorial design 
establishes the relative order of importance of the factors and can indicate if factors 
interact (Armstrong and James, 1996). 
 
The principles of factorial design can be applied to pharmaceutical formulation 
development in which factors such as formulation excipients (concentration, function) 
can be investigated for their effect on the properties of pharmaceutical products. This 
ultimately allows formulations to be optimised in order for the finished products to 
exhibit the required properties/performance. 
 
The use of DOE and factorial design in the development and optimisation of freeze-
dried ODT formulations has been reported previously. Ahmed et al. (2011) reported the 
use of factorial design to investigate the use of maltodextrin as a sugar-matrix former 
along with cellulosic binders. The effects of formulation parameters on ODT properties 
were evaluated in order to identify an optimum formulation for the delivery of 
Nimesulide.  AlHusban et al. (2011) meanwhile employed the use of DOE and factorial 
design to optimise an ODT formulation suitable for delivering enteric coated 
multiparticulates of Omeprazole. The impacts of several formulation variables on the 
crucial properties of the formulations were evaluated. 
 
The aim of this chapter was to carry out a DOE study in order to evaluate the role of 
excipients on the properties of freeze-dried ODTs and subsequently optimise a 
formulation comprising of Methocel™ E3LV, Polyox™ N10 and mannitol, with the 
objective of investigating the performance of the tablets in terms of disintegration time, 
hardness and in vitro oral retention time. 
 
Methocel™ E3LV was selected as the binder in this DOE study based on the 
observations made in Chapter Three (Investigating the Application of Methocel™ 
(Hydrophilic Cellulose Ethers) as Binders in Freeze-Dried ODTs). Methocel™ E3LV 
was identified as the most suitable grade of Methocel™, from the several grades 
investigated, for an application as a binder in freeze-dried ODTs. Mannitol was chosen 
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to utilise its matrix supporting/structure forming and disintegration enhancing 
functionality. Polyox™ N10 was selected as an excipient to be investigated in this DOE 
study, based on the results from Chapter Four (Investigating the Application of Polyox™ 
(Synthetic Polyethylene Oxide) in Freeze-Dried ODTs) in order to exploit its  
mucoadhesive characteristics (Bottenberg et al. 1992) and its subsequent influence on 
in vitro oral retention of the formulations.  
 
As discussed above, one of the properties of the formulations investigated in this study 
was in vitro oral retention in order to give an assessment of the mucoadhesiveness of 
the formulations. Young and Smart (1998) reported a novel apparatus to measure the 
mucoadhesiveness of liquid or semi-solid formulations in the mouth and oesophagus. 
The Porcine Oesophageal Mucoadhesion Test System comprised of a test cell 
constructed from Perspex™ into which a previously isolated mucosa approximately 
150mm long was clamped to yield a test plane 120mm in length and 15mm wide, 
inclined at 30º to the horizontal. The apparatus was maintained at 37ºC and artificial 
saliva was applied at the top of the test plane to mimic salivary flow and prevent 
surface desiccation. Testing of formulations involved placing a sample at the top of the 
test plane and assessment of the resultant eluent fractions.  
 
The Porcine Oesophageal Mucoadhesion Test System has similarly been employed to 
study the elution behaviour of microparticles placed on a mucosal surface, in which the 
polymeric microspheres were investigated for drug delivery to the oral mucosa 
(Kockisch et al. 2003). A similar in vitro model was reported by Batchelor et al. (2002) 
in which the model assessed the adhesion of alginate solutions to porcine 
oesophageal tissue. The methodology involved a retention apparatus (which was 
relatively similar to The Porcine Oesophageal Mucoadhesion Test System apparatus) 
onto which porcine oesophageal tissue was mounted. Fluorescently labelled alginate 
solutions were dispersed onto the tissue and a washing solution was applied at a fixed 
rate to mimic saliva flow and the eluted material collected. Fluorimetric analysis 
allowed dose retention to be assessed as a function of time. 
 
Zhang (1998) employed the in vitro retention model, which was reported by Batchelor 
et al. (2002), to measure the oral retention of mucoadhesive buccal films with the 
exception that sabouraud agar was used as an alternative to porcine oesophageal 
tissue as the retention substrate. Agar was used as an alternative to porcine 
oesophageal tissue as it has been shown to have an in vitro-in vivo correlation when 
Chapter Six: DOE Study 
 
165 
 
comparing the adhesion of water soluble polymers to agar (in vitro) and nasal 
mucoadhesion (in vivo) (Nakamura et al. 1996). 
 
Bigucci et al. (2008) and Bertram and Bodmeier (2006) also used agar as the retention 
substrate in their methods which were adapted from Nakamura et al. (1996). Bigucci et 
al. (2008) used agar/mucin plates to measure the residence time of pectin-based 
microspheres used for the colon-specific delivery of vancomycin. Bertram and 
Bodmeier (2006) similarly used agar/mucin plates to measure the adhesion potential of 
nasal inserts. Agar gel has also been reported as a substitute for the oral mucosa, in 
order to test the adhesion of mucoadhesive films to the oral mucosa in vitro (Kuroya 
and Inoue, 1992). 
 
It was proposed to use the same apparatus/model which was reported by Batchelor et 
al. (2002) and Zhang (1998) in order to measure the in vitro oral retention time of ODT 
formulations from the DOE study. Agar was used as the retention substrate, which has 
been widely reported to be used in measuring mucoadhesion. The method involved 
placing a tablet on top of the test plane followed by addition of double-distilled water 
which mimicked saliva encountered in vivo and the time taken for the formulations to 
be completely removed from the test plane was recorded and referred to as retention 
time. 
         
Following the DOE study, a model API, nystatin was used in order to assess if the in 
vitro retention time of this API could be modified based on the composition of the 
formulations, using the in vitro oral retention apparatus. Nystatin is an antifungal agent 
used in the treatment of oropharyngeal candidiasis, which is usually available as an 
oral suspension (Peppas et al. 2009). When administering nystatin oral suspension, 
patients are advised that one-half of the dose should be placed in each side of the 
mouth and retained for as long as possible before being swallowed (Fougera and Co., 
2005). Formulating nystatin in the form of a freeze-dried ODT, is an innovative 
approach to delivering the antifungal agent to the mouth and subsequently treating 
oropharyngeal candidiasis. Modifying the retention of the API in the mouth by adjusting 
the composition of the formulation could potentially improve the treatment of 
oropharyngeal candidiasis.  
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6.2 Materials 
Polyethylene oxide (Polyox™ WSR N10, Lot No.: DT353617) and hydroxypropyl 
methylcellulose (Methocel™ E3LV, Lot No.: DT220342) were supplied by Colorcon Ltd. 
(Dartford, UK). Mannitol (Lot No.: BCBF4739V) was supplied by Sigma-Aldrich (Poole, 
UK). Agar Technical (Agar No. 3) was supplied by Oxoid Ltd. (Basingstoke, 
Hampshire, UK). Nystatin (≥ 4400 USP units/mg) was supplied by Scientific Laboratory 
Supplies (Nottingham, UK). 
 
6.3 Methods  
 
6.3.1 Preparation of Freeze-Dried Tablets 
For the preparation of the various formulations, firstly, the required amounts of 
mannitol and/or polyethylene oxide were added to half the required amounts of water 
(at ambient temperature) under stirring, until fully dissolved. These solutions were then 
heated to around 90ºC under stirring, followed by the addition of hydroxypropyl 
methylcellulose. Cold water was then added to solubilise the hydroxypropyl 
methylcellulose and form the final solutions. 
 
For formulations which did not contain both polyethylene oxide and mannitol, half the 
required amounts of water were heated to around 90ºC under stirring, followed by the 
addition of hydroxypropyl methylcellulose. Cold water was then added to solubilise the 
hydroxypropyl methylcellulose and form the final solutions. 
 
For the formulations which included nystatin, the required amounts of mannitol and/or 
polyethylene oxide were added to half the required amounts of water (at ambient 
temperature) under stirring, until fully dissolved. Nystatin was then added under 
stirring. These preparations were then heated to around 90ºC under stirring, followed 
by the addition of hydroxypropyl methylcellulose. Cold water was then added to 
solubilise the hydroxypropyl methylcellulose and form the final preparations.  
 
1.5g of the resulting preparations were dosed into a tablet mould, frozen at -70°C for a 
minimum of sixty minutes and freeze-dried (ADVANTAGE, Freeze-Dryer, VIRTIS), 
according to the following regime; primary drying for forty eight hours at a shelf 
temperature of -40°C, secondary drying for ten hours at a shelf temperature of 20°C, 
and vacuum pressure of 6.67 Pa (50 mTorr). A minimum of ten tablets were prepared 
for each formulation. 
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6.3.2 Formulation Viscosity Analysis 
For all formulations, the viscosities of 100 mL samples were measured using a DV-I+ 
Brookfield digital viscometer (Harlow, UK). The viscosities of the formulations were 
measured at 37 ± 2°C, in order to replicate the viscosity of the formulations in the oral 
cavity, at physiological temperature. The viscometer spindles were selected based on 
the viscosity of the individual formulations, as each spindle is suitable for analysing a 
certain viscosity range. The rotational speed of the spindle was set at 100 rpm. Each 
formulation was analysed in triplicate, and the mean values ± standard deviation is 
reported. 
 
6.3.3 Tablet Hardness 
The hardness of the tablets was investigated using a texture analyzer (QTS 25: 
Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated 
by standard weights of 500 g and 5 kg. The tablets were placed in a holder with a 
cylindrical hole. The hardness was taken as the peak force after 1 mm penetration of a 
5 mm diameter probe at a rate of 6 mm/min. Three measurements were taken for each 
formulation, and the mean ± standard deviation is reported. 
 
6.3.4 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2ºC, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 rpm. Three 
tablets were evaluated from each formulation, and the mean values ± standard 
deviation is reported. 
 
6.3.5 In Vitro Oral Retention Time 
In vitro oral retention time was measured (as a means of assessing in vitro oral 
mucoadhesion of the formulations) using an in vitro oral retention apparatus adapted 
from Zhang (2008) and Batchelor et al. (2002). The apparatus consisted of a Perspex® 
mounting block with dimensions; 100mm in length by 60mm in width and 15mm deep. 
A groove was cut into this block with dimensions; 100mm in length by 20mm in width 
and 5mm deep, into which liquid agar was dosed and allowed to set to mimic oral 
mucosal tissue. The mounting block was attached to a clamp (which was further 
attached to a stand) at an angle of 30º to the horizontal. The stand was placed within a 
temperature and humidity controlled environment (a Perspex® cabinet containing a 
water bath and a platform onto which the stand was placed).  
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Temperature and humidity were maintained at 37 ± 2ºC and > 90% RH, respectively, 
with these conditions monitored using a LogIT-Voyager temperature and humidity 
logging instrument (DCP Microdevelopments Ltd., Great Ellingham, Norfolk, UK). The 
cabinet had partially sealed glove access to enable procedures to be performed whilst 
carrying out measurements. Distilled water was used to mimic saliva and was 
delivered to the agar section of the Perspex® mounting block at a rate of 1 mL/min via 
a Gilson Minipuls 3 peristaltic pump (Gilson UK, Luton, Bedfordshire, UK). The flow 
was split into four channels to provide an even distribution of the distilled water over 
the agar section. 
 
In order to determine in vitro oral retention time of the formulations, a tablet was placed 
on the uppermost part of the agar section and the time taken for the tablet to be 
removed was recorded with the naked eye and recorded as the retention time. Three 
measurements were taken for each formulation and the mean values are reported.  
 
To determine the in vitro oral retention of nystatin, a tablet was placed on the 
uppermost part of the agar section and at 30s intervals, the material washed from the 
surface of the agar was collected into plastic vials. The vials were changed at 30s 
intervals in order to examine the in vitro oral retention of nystatin. Analysis of the 
amount of nystatin collected at 30s intervals was performed using HPLC analysis 
(method information detailed below), which allowed the in vitro oral retention of nystatin 
to be calculated, with reference to a previously performed calibration curve. Three 
measurements were taken for each formulation and the mean values are reported. 
 
6.3.6 HPLC (High Performance Liquid Chromatography) Analysis   
HPLC analysis of the collected nystatin samples were performed using reversed phase 
HPLC (Dionex AS50 autosampler, GP50 gradient pump and UVD170U detector: 
Dionex, Leeds, UK) at room temperature using a Phenomenex Gemini 5 μm C18 150 x 
4.60 mm column (Macclesfield, UK). The collected nystatin samples were filtered 
through a 0.45 μm nylon syringe filter (to remove undissolved API) and 30 μL of the 
samples were analysed, with UV detection performed at 305 nm, with methanol:water 
(70:30) as the mobile phase and a flow rate of 1.00 mL/min. 
 
6.3.7 Design of Experiments  
The design of experiments – factorial design used in this study was performed using 
MODDE software (version 8) (Umetrics AB, Umea, Sweden). The response surface 
modelling objective was selected, as it provides detailed modelling and optimisation of 
Chapter Six: DOE Study 
 
169 
 
the study. A central composite face quadratic model design was recommended by the 
software, which is composed of a full factorial design, which comprised 17 runs in total 
with 3 centre points.  
 
The factors (independent variables) investigated in this study were the concentrations 
of; Methocel™ E3LV, Polyox™ N10 and mannitol. Each factor was investigated at three 
different levels; low, medium and high, which were referred to as; -1, 0 and 1, as 
detailed in Table 6.1. The responses (dependent variables) measured in this study 
were; formulation viscosity, tablet hardness, tablet disintegration time and in vitro oral 
retention time of the formulations. Analysis of variance (ANOVA) was the statistical 
analysis of the data performed in this study.              
 
Table 6.1 Information detailing the concentration values of Methocel™ E3LV, Polyox™ 
N10 and mannitol relative to their levels, which were investigated in this study.  
 Concentration of Excipients (% w/w) 
Level of 
Concentration 
Methocel™ E3LV Polyox™ N10 Mannitol* 
-1 (Low Level) 5.0 0.0 0.0 
0 (Medium Level) 6.5 1.5 25.0 
1 (High Level) 8.0 3.0 50.0 
*Mannitol concentration expressed as % w/w (of dried tablet weight), relative to 6.5% 
w/w Methocel™ E3LV. 
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6.4 Results and Discussion 
As discussed earlier, the aim of this chapter was to evaluate the role of the excipients 
on the properties of freeze-dried ODTs and subsequently optimise a formulation 
comprising of Methocel™ E3LV, Polyox™ N10 and mannitol, with the objective of 
studying the performance of  tablets in terms of disintegration time, hardness and in 
vitro oral retention time. These three factors were investigated at three different 
levels/concentrations in order to evaluate their effect on the responses of the 
tablets/formulations. 
 
In this study, 17 formulations were prepared in total, which were subsequently 
characterised for viscosity, tablet hardness, tablet disintegration time and in vitro oral 
retention time. The results from the study are shown in Table 6.2, which revealed that 
formulation viscosity varied from 1.41 to 21.37 mPa s, between the 17 formulations 
prepared and analysed. Tablet hardness and disintegration time varied from 1.29 to 
20.82 N and 6.67 to 396.00 s, respectively. In terms of in vitro oral retention time of the 
formulations, the values varied from 25.67 to 164.67 s. 
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Table 6.2 Completed DOE study worksheet, which shows the compositions of the 17 formulations prepared and characterisation results for the 
formulations/tablets. Each characterisation/response result is a mean value (n=3). 
 Factors (Independent Variables) Responses (Dependent Variables) 
Exp. Name Run Order Methocel 
E3LV 
(% w/w) 
POLYOX 
N10 
(% w/w) 
Mannitol 
(% w/w) 
Formulation 
Viscosity 
(mPa s) 
Tablet 
Hardness 
(N) 
Disintegration 
Time (s) 
In Vitro Oral 
Retention 
Time (s) 
N1 4 5.0 0.0 0.0 1.41 1.29 59.33 55.67 
N2 5 8.0 0.0 0.0 3.26 6.89 363.67 66.67 
N3 14 5.0 3.0 0.0 4.65 1.45 290.00 164.67 
N4 10 8.0 3.0 0.0 13.33 7.02 176.67 82.67 
N5 12 5.0 0.0 50.0 2.10 8.04 6.67 25.67 
N6 9 8.0 0.0 50.0 4.98 14.83 16.67 50.00 
N7 3 5.0 3.0 50.0 8.59 11.48 27.00 32.67 
N8 17 8.0 3.0 50.0 21.37 20.82 55.33 38.33 
N9 8 5.0 1.5 25.0 3.70 5.42 79.67 45.33 
N10 1 8.0 1.5 25.0 8.61 13.89 75.00 34.33 
N11 15 6.5 0.0 25.0 2.54 6.91 39.33 31.67 
N12 6 6.5 3.0 25.0 10.33 9.70 56.67 32.00 
N13 7 6.5 1.5 0.0 4.84 3.38 396.00 40.33 
N14 2 6.5 1.5 50.0 5.81 11.50 40.33 31.00 
N15 16 6.5 1.5 25.0 4.34 8.63 64.00 29.67 
N16 13 6.5 1.5 25.0 5.21 7.09 57.67 32.67 
N17 11 6.5 1.5 25.0 5.49 7.19 127.67 34.33 
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The results showed wide variations in the four responses measured as a result of 
modifying the composition of the formulations in terms of the levels/concentrations of 
each factor. This suggested that the three factors investigated, exerted a significant 
effect on the four responses measured. 
 
The effect each factor had both individually and interactively on the four responses is 
shown in Table 6.3. In Table 6.3, the quantitative effect that each factor had on the 
responses is expressed as “Effect” and the level of significance of the quantitative 
effect is represented by a p value, where p < 0.05 is considered statistically significant. 
As can be seen in Table 6.3, in some cases factors exerted a positive effect on 
responses which resulted in an increase in response, whilst in other cases factors 
exhibited a negative effect on responses, which resulted in a decrease in response.   
 
Table 6.3 The quantitative effect each factor(s) has on the responses and associated 
level of significance, represented by p value, where p < 0.05 is considered statistically 
significant. 
 Formulation 
Viscosity 
Tablet 
Hardness 
Disintegration 
Time 
In Vitro Oral 
Retention Time 
Factor(s) Effect p 
Value 
Effect p 
Value 
Effect p 
Value 
Effect p 
Value 
Methocel™ 
E3LV 
6.2160 <0.0001 7.1784 <0.0001 45.0444 0.4778 -10.297 0.4803 
POLYOX™ 
N10 
8.7958 <0.0001 2.5032 0.0091 24.0052 0.7014 24.1370 0.1241 
Mannitol 3.0701 0.0052 9.3396 <0.0001 -227.881 0.0068 -46.418 0.0121 
Methocel™ 
E3LV-
Methocel™ 
E3LV 
2.0790 0.3042 2.3269 0.2170 -56.8848 0.7099 28.8339 0.4213 
POLYOX™ 
N10-
POLYOX™ 
N10 
2.3919 0.2428 1.1248 0.5329 -108.770 0.4829 19.3021 0.5854 
Mannitol-
Mannitol 
0.2703 0.8895 -1.202 0.5062 228.8590 0.1630 24.3909 0.4934 
Methocel™ 
E3LV-
POLYOX™ 
N10 
4.1909 0.0062 0.5789 0.5781 -100.067 0.2774 -28.138 0.1930 
Methocel™ 
E3LV-
Mannitol 
1.2777 0.2775 1.2690 0.2418 -38.0385 0.6679 25.3727 0.2352 
POLYOX™ 
N10-
Mannitol 
2.3967 0.0630 2.2597 0.0569 3.7156 0.9663 -32.526 0.1399 
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6.4.1 Formulation Viscosity 
In terms of formulation viscosity, the results (shown in Table 6.3) revealed that 
Methocel™ E3LV (p < 0.0001), Polyox™ N10 (p < 0.0001), mannitol (p < 0.01) and an 
interaction between Methocel™ E3LV and Polyox™ N10 (p < 0.01), all had a significant 
positive effect on formulation viscosity. Analysing the quantitative effect of these 
factors revealed that Polyox™ N10 had the greatest effect on formulation viscosity, 
followed by Methocel™ E3LV, an interaction between Methocel™ E3LV-Polyox™ N10, 
and finally mannitol, respectively. 
 
The ability of these factors to increase formulation viscosity upon increasing 
concentration, could possibly be attributed to an increase in the interaction between 
the formulation ingredients as their concentration were increased. The fact that 
Polyox™ N10 displayed the greatest effect on formulation viscosity highlights its 
functionality as a viscosity-increasing agent (Maximilien, 2011).  
 
Interestingly, the results also revealed that Methocel™ E3LV and Polyox™ N10 
exhibited a synergistic-interactive effect on formulation viscosity, as illustrated in Figure 
6.1, which shows that an increase in the concentrations of Methocel™ E3LV and 
Polyox™ N10 resulted in an increase in formulation viscosity. The synergistic-
interactive effect of Methocel™ E3LV and Polyox™ N10 on formulation viscosity can be 
attributed to an interaction between these two factors at a molecular level. Fuller et al. 
(2001) reported that HPMC and polyethylene oxide blends are miscible and behave 
similarly to other PEO-cellulosic blends, i.e. these polymers interact via hydrogen-
bonding between the hydroxyl groups of HPMC and the ether oxygen of PEO. 
Interactions between PEO and cellulose-based polymers have also been previously 
reported and have been attributed not only to intra- but also intermolecular interactions 
including hydrogen bonding (Kondo et al. 1994 and Kondo and Sawatari, 1994).  
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Figure 6.1 A 3D surface response plot showing the influence of varying Methocel™ 
E3LV and Polyox™ N10 levels on formulation viscosity. The different colours of the plot 
refer to contour levels, with the colour blue referring to the lowest contour level 
(response) and the colour red referring to the greatest contour level (response). The 
levels of Methocel™ E3LV and Polyox™ N10 range from -1.0 (lowest 
level/concentration) to 1.0 (greatest level/concentration).  
 
In terms of the interactions between HPMC and PEO, it has been reported that using 
these two polymers in combination, has shown to provide an innovative matrix tablet 
system that permits the adjustment of the rate of API release, in comparison with pure 
HPMC matrix tablet systems (Fuller et al. 2001). Fuller et al. (2001) reported that the 
adjustment of the rate of API release could be due to a direct interaction between 
HPMC and PEO. The application of the interaction between HPMC and PEO with 
matrix tablet systems, demonstrates the potential usefulness of this polymer:polymer 
interaction with pharmaceutical formulations. 
 
As discussed above, the results revealed that mannitol displayed the least effect on 
formulation viscosity. This could possibly be attributed to the low molecular weight and 
non-polymeric nature of mannitol, relative to Polyox™ N10 and Methocel™ E3LV, which 
possess significantly greater molecular weight and are polymeric in nature, which 
displayed more significant effect on formulation viscosity. 
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6.4.2 Tablet Hardness 
The results for tablet hardness indicated that Methocel™ E3LV (p < 0.0001), mannitol 
(p < 0.0001) and Polyox™ N10 (p < 0.01), all had a significant positive effect. An 
evaluation of the quantitative effect of these three factors revealed that mannitol 
exhibited the greatest effect on tablet hardness followed by Methocel™ E3LV and 
Polyox™ N10. Figure 6.2 illustrates the influence of mannitol and Methocel™ E3LV 
concentrations on tablet hardness.  
 
Increase in tablet hardness as a result of increasing the concentrations of these three 
factors, could possibly be attributed to the formation of a more extensive and robust 
tablet binder matrix which consequently results in an increase in tablet hardness. As 
discussed in Chapter Four (Investigating the Application of Polyox™ (Synthetic 
Polyethylene Oxide) in Freeze-Dried ODTs), mannitol has been reported to influence 
tablet hardness through a number of mechanisms including its crystalline nature 
(Sastry et al. 2000, Kearney, 2003 and Seager, 1998) and by functioning as a matrix 
supporting agent (AlHusban et al. 2010b).   
 
 
Figure 6.2 A 3D surface response plot showing the influence of varying Methocel™ 
E3LV and mannitol levels on tablet hardness. The different colours of the plot refer to 
contour levels, with the colour blue referring to the lowest contour level (response) and 
the colour red referring to the greatest contour level (response). The levels of 
Methocel™ E3LV and mannitol range from -1.0 (lowest level/concentration) to 1.0 
(greatest level/concentration).  
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In terms of Methocel™ E3LV exerting a significant effect on tablet hardness, it has 
previously been reported that the binding capacity of HPMC increases as 
concentration is increased (Ahmed et al. 2011). Additionally, as Methocel™ E3LV 
functions as a binder, its function is to convey strength and robustness to the tablets 
(Seager, 1998). The results from this DOE investigation also provide further insight into 
factors influencing tablet hardness. It is generally accepted that formulations of freeze-
dried ODTs requires the inclusion of both a binder as well as matrix supporting agents, 
with binders providing the required framework for the tablet and supporting agents 
cementing and strengthening binder scaffold. The study has shown that despite the 
formation of framework upon inclusion of Methocel™ E3LV, material properties of the 
supporting agents play a critical role in determining resultant tablet hardness. Mannitol 
in its crystalline state (which can be determined by evaluating the thermal properties of 
formulations, by using DSC) provides the necessary cementing support and ranks at 
the top in hierarchy in providing hardness to the finished dosage form which further 
suggests that two important criteria (hydrophilic nature and crystallinity) govern tablet 
properties and should be included in the development and selection of novel matrix 
supporting agents. 
 
6.4.3 Tablet Disintegration Time 
Tablet disintegration time was significantly influenced by a single factor; mannitol (p < 
0.01), which demonstrated a significant negative effect, i.e. increasing the 
concentration of mannitol resulted in a general decrease in tablet disintegration time as 
illustrated in Figure 6.3. The results reaffirmed the functionality of mannitol as a 
disintegration enhancing agent due to its highly hydrophilic nature (AlHusban et al. 
2010a), as discussed in Chapter Four (Investigating the Application of Polyox™ 
(Synthetic Polyethylene Oxide) in Freeze-Dried ODTs). 
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Figure 6.3 A main effects plot showing the influence of mannitol level on tablet 
disintegration time. The level of mannitol ranges from -1.0 (lowest level/concentration) 
to 1.0 (greatest level/concentration). 
 
6.4.4 In Vitro Oral Retention Time 
Investigation into in vitro oral retention time of the formulations showed similar trend  
as with the tablet disintegration time results, where a single factor was shown to have a 
significant effect; mannitol (p < 0.05). Mannitol exhibited a significant negative effect, 
i.e. increasing the concentration of mannitol resulted in decreasing in vitro oral 
retention time as illustrated in Figure 6.4. 
 
This trend could be attributed to mannitol being a mucoactive agent (defined as an 
agent that has the capability of modifying the nature and composition of mucus, and/or 
interactions with the mucociliary epithelium (Capri et al. 1994)), as a consequence of 
being an osmotic agent (Daviskas et al. 2008).  
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Figure 6.4 A main effects plot showing the influence of mannitol level on in vitro oral 
retention time of the formulations/tablets. The level of mannitol ranges from -1.0 
(lowest level/concentration) to 1.0 (greatest level/concentration). 
 
It can be concluded that by increasing the concentration of mannitol in the 
formulations/tablets, the nature and composition of the formulations/tablets is modified 
to such an extent that the adhesion of the formulations/tablets to the agar surface was 
reduced.  The decrease in in vitro oral retention time was possibly due to modification 
of the interactions between the formulations/tablets and the agar surface. Interestingly 
a similar observation has been reported, in that the tendency for HPMC to adhere to 
isolated porcine oesophageal tissue was reduced by the addition of sucrose to the 
formulations (Marvola et al. 1983). This was attributed to the water-soluble nature of 
sucrose, as Marvola et al. (1983) reported that the addition of sparingly water-soluble 
ingredients, such as talc, increased adherence. It therefore appeared that sucrose 
modified the nature and composition of HPMC, which resulted in a reduction in 
adherence. This observation reported by Marvola et al. (1983) has similar outcome to 
the observed results seen with mannitol in this DOE study.  
 
The results interestingly revealed that Polyox™ N10, although had a positive effect on 
in vitro oral retention time, statistical analysis of the data showed that effect was 
insignificant (p > 0.05) at the concentration values/range investigated, possibly due to 
the low viscous/low molecular weight nature of this grade of Polyox™. 
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6.5 Formulation Optimisation 
Following the preparation and characterisation of the seventeen formulations which 
were proposed as part of the DOE study, the next stage of the study involved 
formulation optimisation, which allowed identifying a formulation that exhibited desired 
properties as outlined in table 6.4. The objective of the study was to maximise tablet 
hardness with a minimum tablet hardness value of 7 N and a maximum target of 12 N. 
These values for tablet hardness were selected following macroscopic evaluation of 
the tablets of the seventeen formulations prepared as part of the DOE study, and it 
was concluded that tablets exhibiting these values for tablet hardness were sufficiently 
robust to withstand manual handling. 
 
Table 6.4 Proposed desired properties for the optimum formulation, detailing the 
acceptable and target values for; tablet hardness, tablet disintegration time and in vitro 
oral retention time. 
Response Maximise 
or 
Minimise? 
Smallest or 
Highest  
Acceptable Value 
Target 
Tablet Hardness Maximise 7 N 12 N 
Tablet Disintegration 
Time 
Minimise 30 s 10 s 
In Vitro Oral Retention 
Time 
Maximise 50 s 100 s 
 
For tablet disintegration time, the range chosen was between 10 and 30 seconds to 
comply with the criteria set by Food and Drug Administration (FDA) which stipulates 
that ODTs should disintegrate within 30s (FDA, 2008). 
 
In terms of in vitro oral retention time, it was proposed to maximise this response with a 
minimum value of 50 s and a target value of 100 s. The minimum value of 50 s was 
selected as it has been previously reported that the mean time for 50 % buccal 
clearance of a freeze-dried tablet formulation was 50 s (Wilson et al., 1987). 
 
Table 6.5 shows the composition of the optimum formulation based on the proposed 
desired properties. 
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Table 6.5 Composition of the optimum formulation, detailing the concentration of each 
of the three formulation ingredients. 
Formulation 
Ingredient 
Concentration  
(% w/w) 
Methocel™ E3LV 7.95 
Polyox™ N10 3.00 
Mannitol 28.11* 
*Mannitol concentration expressed as % w/w (of dried tablet weight), relative to 6.5% 
w/w Methocel™ E3LV. 
 
The predicted and observed responses for the optimum formulation are shown in Table 
6.6.  
 
Table 6.6 Predicted and observed responses for the optimum formulation. In terms of 
the observed responses, three measurements were performed and the mean values ± 
standard deviation are reported. 
Response Predicted Observed 
Formulation Viscosity (mPa s) 16.84 11.90 ± 0.36 
Tablet Hardness (N) 14.89 12.56 ± 2.92 
Tablet Disintegration Time (s) 27.23 46.33 ± 1.53 
In Vitro Oral Retention Time (s) 41.37 41.33 ± 2.52 
 
As Table 6.6 shows, the observed formulation viscosity was slightly less than what was 
predicted, with a difference of 4.94 mPa s. For tablet disintegration time, the observed 
value was around 20 s greater than the predicted value. Analysis of tablet hardness 
and in vitro oral retention time showed that both the tested parameters demonstrated 
comparable results between observed and predicted values. The results demonstrate 
the validity of the DOE study carried out as discussed above and provides useful 
information in formulation development of freeze dried ODT using the new combination 
of excipients. To further develop ODTs using the above strategy, the next phase of the 
investigation was focussed on formulating a tablet to deliver Nystatin. 
 
 
6.6 Assessment of the In Vitro Oral Retention of Nystatin 
One of the aims of this study was to assess if the in vitro oral retention of nystatin could 
be modified, based on the composition of the formulation, which was assessed using 
the in vitro oral retention apparatus. Two formulations were selected in order to assess 
the retention of nystatin; the optimised formulation from the DOE study and formulation 
N5 (refer to Table 6.2), also from the DOE study.  
 
These formulations were selected due to their differences in composition, as the 
optimised formulation consisted of high concentrations of Methocel™ E3LV and 
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Polyox™ N10, and a medium level of mannitol. Formulation N5 meanwhile consisted of 
a low concentration of Methocel™ E3LV and a high concentration of mannitol (this 
formulation did not consist of Polyox™ N10). 
 
The results from the assessment of the retention of nystatin (Figure 6.5) revealed that 
the retention of nystatin from the two formulations, differed greatly. With formulation 
N5, nystatin was retained up to 30s whilst with the optimised formulation, nystatin 
retention was observed up to 60s. 
 
 
Figure 6.5 An assessment of the in vitro oral retention of nystatin from formulation N5 
(shown in blue) and the optimised formulation (shown in red). Three measurements 
were taken for each formulation and the mean values ± standard deviation are shown. 
 
As discussed previously, the results from the DOE study revealed that mannitol 
exhibited a significant negative effect on in vitro oral retention time of the formulations. 
Formulation N5, which consisted of a high concentration of mannitol, exhibited a 
nystatin retention time of 30s, whilst the optimised formulation, which comprised of a 
medium level/concentration of mannitol, displayed a nystatin retention time of 60s. The 
difference in nystatin retention between the two formulations could be attributed to the 
osmotic effect which is dependent on mannitol concentration within the formulations. 
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6.7 Conclusions      
The results from the DOE study revealed that formulation viscosity was primarily 
influenced (significant positive effect) by both Polyox™ N10 and Methocel™ E3LV, and 
in fact a synergistic-interactive effect was observed with these two excipients. In terms 
of tablet hardness, mannitol and Methocel™ E3LV were shown to be most influential 
(significant positive effect). Tablet disintegration time and in vitro oral retention time 
were both significantly influenced (significant negative effect) by mannitol 
concentration. 
 
An optimised formulation was identified which exhibited desired properties/responses, 
in terms of tablet hardness, tablet disintegration time and in vitro oral retention time. 
Assessing the in vitro oral retention of nystatin demonstrated that the in vitro oral 
retention of APIs can be modified based on the composition of the formulation, with 
particular emphasis on mannitol concentration. This opens up the possibility of 
potentially optimising the retention of APIs in the oral cavity and other pre-gastric 
regions, in order to treat localised conditions such oropharyngeal candidiasis or 
encourage pre-gastric absorption of APIs.  
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7.1 Introduction 
Nanoparticles are defined as solid particles ranging in size from 10 nm to 1000 nm (1 
μm) (Kreuter, 1996). According to Bahl et al. (2011) there are only around four 
commercially available solid oral dosage formulations in the United States that contain 
nanoparticles. The first product to be approved for commercial production was 
launched in 2000; Rapamune®, which consisted of nanocrystals (the term drug 
nanocrystals refers to crystals with a size in the nanometre range) in a tablet form 
(Muller and Junghanns, 2006). 
 
The rationale for processing an active drug into nanocrystal form and subsequently 
incorporating the nanocrystals into a tablet is to increase the surface area of the drug 
particles and consequently increase drug dissolution (Muller and Junghanns, 2006). 
Processing drug particles into nanocrystals is therefore highly applicable for poorly 
water soluble drug compounds as a means of increasing solubility. 
 
It has been reported that around 40% of the APIs in development pipelines have 
solubility issues (Speiser, 1998), and that around 60% of the APIs coming from 
synthesis are currently poorly soluble (Merisko-Liversidge, 2002). This can be 
attributed to the increased use of high throughput screening methods, which results in 
the discovery of more drugs exhibiting poor water solubility (Muller and Junghanns, 
2006). It is anticipated that due to the emergence of increasing number of poorly water 
soluble drugs, an increase in drug nanocrystal-based products on the market can be 
expected (Muller and Junghanns, 2006). 
 
The incorporation of nanoparticles in freeze-dried ODTs has also been reported. Jain 
et al. (2001) investigated a rapidly disintegrating or dissolving solid oral dosage form 
comprising of a poorly soluble nanoparticulate active ingredient (on which a surface 
stabiliser is adsorbed). Jain et al. (2001) further reported that a rapidly disintegrating or 
dissolving solid oral dosage form has the advantage of combining rapid presentation of 
the poorly soluble active agent as a result of the fast disintegration and dissolution of 
the poorly soluble drug in the oral cavity. Other advantages of this type of formulation 
reported by Jain et al. (2001) included a reduction in the delay of onset of therapeutic 
action of the poorly soluble drug together with the enhanced opportunity for buccal 
absorption of the drug (Jain et al. 2001). 
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It is apparent that the rationale for Jain et al. (2001) to incorporate an API in 
nanoparticulate form in an ODT was to enhance the presentation of the poorly soluble 
API as a result of an improvement in dissolution. 
 
The incorporation of nanoparticles in freeze-dried ODTs has similarly been 
investigated by Bahl et al. (2011). Bahl et al. (2011) reported a direct method of 
preparing freeze-dried ODTs containing nanoparticles. The method involved reducing 
the particle size (by wet milling or homogenisation) of an API dispersed in a solution 
containing fish gelatin to form a nanosuspension, which is subsequently freeze-dried to 
form ODTs (Bahl et al. 2011). Fish gelatin therefore acts as a nanoparticle stabiliser 
during both the nanomilling process and freeze-drying process (Bahl et al. 2011). The 
method avoids the need to adjust excipient composition during the process steps as 
fish gelatin facilitates both the particle size reduction and freeze-drying procedures 
(Bahl et al. 2011). 
 
As with Jain et al. (2001) it is apparent that the rationale for Bahl et al. (2011) to 
incorporate nanoparticles in freeze-dried ODTs was to increase the rate and extent of 
dissolution of poorly soluble APIs.  
 
Additionally, Lai et al. (2011) reported the use of nanoparticles in freeze-dried ODTs. 
Lai et al. (2011) reported the preparation of freeze-dried ODTs using nanocrystal 
formulations, with the aim of improving the dissolution properties of piroxicam, which is 
a poorly soluble API. Lai et al. (2011) showed that ODT formulations prepared using 
piroxicam nanocrystals, exhibited a higher dissolution rate than ODT formulations 
prepared using coarse piroxicam particles, which was due to an increase in the surface 
area of the nanocrystal drug particles. 
 
Polymeric biodegradable nanoparticles have attracted attention as drug delivery 
systems due to their application in controlled release/delivery of APIs (Soppimath et al. 
2001). Nanoparticles have particular advantages over conventional drug delivery 
devices in that extended drug release rates up to days, weeks or months can be 
achieved, and biodegradable polymeric nanoparticles can be formulated (Mundargi et 
al. 2008). Another significant advantage of nanoparticles is that a wide variety of APIs 
can be delivered including hydrophilic, hydrophobic, proteins, vaccines and biological 
macromolecules (Hans and Lowman, 2002). Nanoparticles based formulations can 
also result in increase in bioavailability, solubility and permeability of many potent APIs 
which are otherwise difficult to deliver via the oral route (Kumari et al. 2010). As 
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nanoparticles can potentially provide extended drug release rates up to days, weeks or 
months, administering a drug in nanoparticulate form can reduce drug dosage 
frequency and will consequently increase patient compliance (Kumari et al. 2010). 
  
Oral dosage forms consisting of nanoparticles have been widely reported including a 
suspension in which the vehicles used for preparing the oral suspensions include 
aqueous solutions, oils, mucoadhesive gels, and microemulsions (Galindo-Rodriguez 
et al. 2005). Additionally, nanoparticles incorporated into a conventional tablet (which is 
not recommended as the integrity of the nanoparticles can be affected under high 
compression forces/pressures) have been reported, along with the filling of 
nanoparticles (in dried powder form, with excipients) into hard gelatin capsules 
(Galindo-Rodriguez et al. 2005). 
 
Oral administration of APIs in nanoparticulate form provides several advantages 
compared to single-unit oral dosage forms such as capsules (Galindo-Rodriguez et al. 
2005). Following the oral administration of nanoparticles, they distribute evenly in the 
GIT which consequently results in uniform drug absorption, extended drug release and 
a reduced risk of local irritation (Galindo-Rodriguez et al. 2005). 
 
Comparing nanoparticles with other multiparticulate carriers such as microspheres or 
pellets, studies indicate that nanoparticles are capable of penetrating the mucus layer 
to reach the apical membrane of the epithelial cells, whilst microparticles greater than 
10 μm in diameter are excluded by the viscous gel layer of the mucus (Galindo-
Rodriguez et al. 2005). Furthermore it has been reported that the number of 
nanoparticles that cross the epithelium is greater than the number of microspheres 
(Galindo-Rodriguez et al. 2005). 
 
Freeze-dried ODTs consisting of polymeric biodegradable nanoparticles have not been 
previously reported. Incorporating polymeric biodegradable nanoparticles in freeze-
dried ODTs would allow the benefits of both ODTs and polymeric biodegradable 
nanoparticles to be exploited. As ODTs provide the ease and convenience of 
administration, whilst polymeric biodegradable nanoparticles can provide extended 
drug release rates, therefore potentially reducing drug dosage frequency, which could 
increase patient compliance. 
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The conventional method of preparing polymeric nanoparticles using the 
nanoprecipitation/solvent-displacement method, which was first reported by Fessi et al. 
(1989), is summarised as a flow chart in Figure 7.1.  
 
Additionally, the method of preparing chitosan nanoparticles, using the ionic gelation 
method, is summarised as a flow chart in Figure 7.2.  
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Figure 7.1 A flow chart detailing the conventional nanoprecipitation/solvent-displacement method of preparing polymeric nanoparticles. 
 
 
Figure 7.2 A flow chart detailing the ionic gelation method of preparing chitosan nanoparticles. 
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The aim of this chapter was to incorporate polymeric biodegradable nanoparticles in 
freeze-dried ODTs using novel methods developed from the nanoprecipitation/solvent-
displacement method (shown in Figure 7.1) and ionic gelation method (shown in Figure 
7.2), respectively. 
 
The new method, based on the nanoprecipitation/solvent-displacement process, which 
allows the incorporation of polymeric nanoparticles directly in freeze-dried ODT 
formulations, is summarised as a flow chart in Figure 7.3. The method therefore 
combines the preparation of polymeric nanoparticles with the preparation of freeze-
dried ODT formulations. As Figure 7.3 shows, the first step in the process involves the 
solubilisation of the nanoparticle-forming polymer and API in a water miscible organic 
solvent, e.g. acetone. The second step involves the addition of the organic phase to an 
HPMC or suitably based ODT formulation (aqueous phase), which contains a 
surfactant/emulsifying agent. Polymeric nanoparticles are formed instantaneously in 
the ODT formulation, due to the rapid diffusion of the polymer solution in the aqueous 
phase. The next stage involves the removal of the organic phase, which is evaporated 
under reduced pressure. The formulation is then dosed and freeze-dried, which results 
in the preparation of ODTs which consist of polymeric nanoparticles. 
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Figure 7.3 A flow chart detailing the modified nanoprecipitation/solvent-displacement method, which allows the direct incorporation of polymeric 
nanoparticles in freeze-dried ODT formulations.  
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The novel method, based on the ionic gelation technique, which allows the direct 
incorporation of chitosan nanoparticles in freeze-dried ODT formulations, is 
summarised as a flow chart in Figure 7.4. The method therefore combines the 
preparation of chitosan nanoparticles with the preparation of freeze-dried ODT 
formulations. As Figure 7.4 shows, the first step involves the solubilisation of sodium 
tripolyphosphate in HPMC or suitably based ODT formulation. This solution is then 
added to an aqueous acetic acid solution, which contains dissolved chitosan. Chitosan 
nanoparticles are formed due to the complexation between oppositely charged 
species. The formulation is then dosed and freeze-dried, which results in the 
preparation of ODTs which consist of chitosan nanoparticles. 
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Figure 7.4 A flow chart detailing the modified ionic gelation method, which allows the direct incorporation of chitosan nanoparticles in freeze-
dried ODT formulations. 
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7.2 Materials 
Polyethylene oxide (Polyox™ WSR N10, Lot No.: DT353617) and hydroxypropyl 
methylcellulose (Methocel™ E3LV, Lot No.: DT220342) were supplied by Colorcon Ltd. 
(Dartford, UK). The following materials were supplied by Sigma-Aldrich (Poole, UK): 
polycaprolactone (PCL), chitosan (medium molecular weight), Pluronic® F127, sodium 
tripolyphosphate, poly(DL-lactide-co-glycolide) (50:50) (PLGA), mannitol and gelatin 
(type B, 75 bloom). The following materials were supplied by Fisher Scientific 
(Loughborough, UK): acetone, acetic acid, hydrochloric acid and methanol. The APIs: 
rizatriptan benzoate and piroxicam, were supplied by Discovery Fine Chemicals 
(Wimborne, UK) and Scientific Laboratory Supplies Ltd. (Nottingham, UK), 
respectively. 
 
7.3 Methods 
 
7.3.1 Preparation of Freeze-Dried Tablets Consisting of Nanoparticles 
For the preparation of Methocel™ E3LV-based formulations, mannitol was firstly 
dissolved in half the required amount of water which was then heated to around 90ºC 
under stirring, followed by the addition of HPMC. Cold water was then added to 
solubilise the HPMC and form the final solutions. 
 
For the preparation of the optimised formulation from the DOE study, firstly, the 
required amount of mannitol and polyethylene oxide were added to half the required 
amount of water (at ambient temperature) under stirring, until fully dissolved. These 
solutions were then heated to around 90ºC under stirring, followed by the addition of 
HPMC. Cold water was then added to solubilise the HPMC and form the final solutions. 
 
For the preparation of gelatin-based formulations, gelatin was dissolved in double-
distilled water at about 40°C under stirring, followed by the addition of mannitol to form 
a solution. 
 
In order to prepare the formulations consisting of PCL or PLGA nanoparticles, the 
required amounts of PCL or PLGA was added to the required volume of acetone, and 
was dissolved with the aid of a sonicator. This organic solution was added drop-wise 
into the appropriate ODT formulation which consisted of Pluronic® F127, under 
magnetic stirring. The organic solvent was then removed from the preparation under 
reduced pressure. 
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In order to prepare the formulations consisting of chitosan nanoparticles, the required 
amount of sodium tripolyphosphate was firstly dissolved in the appropriate ODT 
formulation. The ODT formulation was then added drop-wise into an acetic acid 
solution consisting of dissolved chitosan under magnetic stirring. 
 
1.5g of the resulting preparations were dosed into a tablet mould, frozen at -70°C for a 
minimum of sixty minutes and freeze-dried (ADVANTAGE, Freeze-Dryer, VIRTIS), 
according to the following regime; primary drying for forty eight hours at a shelf 
temperature of -40°C, secondary drying for ten hours at a shelf temperature of 20°C, 
and vacuum pressure of 6.67 Pa (50 mTorr). 
 
Using the novel method described in Figure 7.3, the following formulations were 
prepared in order to incorporate PCL and PLGA nanoparticles: 
 5 % w/w Methocel™ E3LV with 30 % w/w (of dried tablet weight) mannitol. 
 10 % w/w Methocel™ E3LV with 30 % w/w (of dried tablet weight) mannitol. 
 5 % w/w gelatin with 30 % w/w (of dried tablet weight) mannitol. 
 Optimised formulation from the DOE study. 
 
These formulations were selected in order to establish if the method shown in Figure 
7.3 could be applied with a range of different formulations, i.e. HPMC and gelatin-
based, to successfully form and incorporate PCL and PLGA nanoparticles. 
 
7.3.2 Tablet Hardness 
The hardness of the tablets was investigated using a texture analyzer (QTS 25: 
Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated 
by standard weights of 500 g and 5 kg. The tablets were placed in a holder with a 
cylindrical hole. The hardness was taken as the peak force after 1 mm penetration of a 
5 mm diameter probe at a rate of 6 mm/min. Three measurements were taken for each 
formulation, and the mean ± standard deviation is reported. 
 
7.3.3 Disintegration Time of the Tablets 
The disintegration time of the tablets was determined using a USP disintegration tester 
(Erweka, ZT3). 800 mL of double distilled water, which was kept at 37 ± 2ºC, was used 
as the medium and the basket was raised and lowered at a fixed rate of 30 rpm. Three 
tablets were evaluated from each formulation, and the mean values ± standard 
deviation is reported. 
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7.3.4 Particle Size and Zeta Potential (Particle Charge) Analysis 
Particle sizes of the formulations were determined using a ZetaPlus particle size and 
zeta potential analyser (Brookhaven Instruments Corporation, New York, USA). 50 µL 
of sample of each formulation was added to 1.5 mL of double-distilled water in a 
cuvette, and analysed for particle size. The reported particle size values are reported 
as the mean ± standard error of three measurements. 
 
Zeta potential of the formulations was determined using a ZetaPlus particle size and 
zeta potential analyser (Brookhaven Instruments Corporation, New York, USA). 50 µL 
of sample of each formulation was added to 1.5 mL of double-distilled water in a 
cuvette, followed by the insertion of a zeta potential probe. Analysis of the zeta 
potential of the formulations was then carried out. The reported zeta potential values 
are reported as the mean ± standard error of 10 measurements. 
 
7.3.5 In Vitro Tablet Dissolution Testing 
The in vitro dissolution testing of rizatriptan benzoate tablets was carried out using 
dissolution apparatus 2 (paddle apparatus) (Erweka DT600 dissolution bath, Dorset, 
UK). Dissolution testing was performed at 37ºC, in a medium consisting of 900 mL 
water (deaerated), with the paddle rotating at 50 rpm. Samples were withdrawn at 5 
minute intervals up to 30 minutes, and were analysed by UV spectroscopy (Jenway 
6405 UV/Vis. Spectrophotometer, Stone, UK) at 225 nm. The samples were then 
immediately returned to the dissolution vessel, in order to maintain sink conditions. 
Three tablets were analysed for both the nanoparticle-free and nanoparticulate 
formulations, and the mean ± standard deviation values are reported. 
 
In terms of the in vitro dissolution testing of piroxicam tablets, this too was performed 
using dissolution apparatus 2 (paddle apparatus). Dissolution testing was performed at 
37ºC, in a medium consisting of 900 mL 0.1 M hydrochloric acid, with the paddle 
rotating at 50 rpm. Samples were withdrawn at 5 minute intervals up to 90 minutes, 
and were analysed by UV spectroscopy (Jenway 6405 UV/Vis. Spectrophotometer, 
Stone, UK) at 242 nm. The samples were then immediately returned to the dissolution 
vessel, in order to maintain sink conditions. Three tablets were analysed for both the 
nanoparticle-free and nanoparticulate formulations, and the mean ± standard deviation 
values are reported. 
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7.3.6 Determination of Drug Entrapment Efficiency and Drug Recovery/Dose 
Uniformity 
The drug entrapment efficiency of rizatriptan benzoate nanoparticulate formulations 
was determined, by firstly reconstituting a tablet with double-distilled water. This 
nanosuspension underwent centrifugation (Beckman Coulter Avanti® J-E Centrifuge, 
High Wycombe, UK) at 15,000 rpm for 30 minutes, in order to separate the entrapped 
and non-entrapped drug. The resulting supernatant containing the dissolved free drug 
was analysed by UV spectroscopy (Jenway 6405 UV/Vis. Spectrophotometer, Stone, 
UK) at 225 nm. The drug entrapment efficiency was determined using Equation 7.1. 
Three tablets were analysed and the mean values ± standard deviation are reported.  
 
 
 
 
Drug Entrapment Efficiency = Total Amount of Drug – Free Amount of Drug   x 100 
          Total Amount of Drug 
 
(Equation 7.1) 
 
The drug entrapment efficiency of piroxicam nanoparticulate formulations was 
determined, by firstly reconstituting a tablet with 0.1 M HCl. This nanosuspension 
underwent centrifugation (Beckman Coulter Avanti® J-E Centrifuge, High Wycombe, 
UK) at 15,000 rpm for 30 minutes, in order to separate the entrapped and non-
entrapped drug. The resulting supernatant containing the dissolved free drug was 
analysed by UV spectroscopy (Jenway 6405 UV/Vis. Spectrophotometer, Stone, UK) 
at 242 nm. The entrapment efficiency was determined using Equation 7.1. Three 
tablets were analysed and the mean values ± standard deviation are reported.  
 
The drug recovery/dose uniformity of piroxicam tablets was determined by dissolving a 
tablet in 50 mL of methanol. A sample was taken and analysed by UV spectroscopy 
(Jenway 6405 UV/Vis. Spectrophotometer, Stone, UK) at 333 nm. Three tablets were 
analysed and the mean values ± standard deviation are reported. 
 
7.3.7 Stability Study of Piroxicam Tablets  
The stability of piroxicam tablets (both nanoparticle-free and nanoparticle-containing 
tablets) were assessed over a period of 45 days in conditions of; 25ºC/60% RH and 
40ºC/75% RH, respectively. At time points of day; 0, 30 and 45, tablets were removed 
from the Firlabo SP-BVEHF (Meyzieu, France) stability cabinets and analysed. At each 
time point, piroxicam nanoparticle-free tablets were analysed for; general appearance, 
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drug recovery/dose uniformity, tablet hardness and tablet disintegration time. Whilst for 
piroxicam nanoparticle-containing tablets, at each time point the tablets were examined 
for; general appearance, tablet hardness, tablet disintegration time, and the particle 
size and zeta potential of the nanoparticles. During the stability study, the tablets were 
packaged in 100 mL amber coloured polyethylene terephthalate (PET) screw-cap 
bottles. 
 
7.3.8 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5 statistical analysis 
software. One-way analysis of variance (ANOVA) was the statistical analysis test 
performed, using the Tukey post test. A significance level of p < 0.05 (95% confidence 
interval) was judged as being statistically significant.    
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7.4 Results and Discussion  
 
7.4.1 Incorporating PCL and PLGA Nanoparticles in Freeze-Dried ODTs 
The prepared tablets for both PCL and PLGA nanoparticles, were characterised for 
hardness and disintegration time. The particle size and zeta potential of the 
nanoparticles of the various formulations were also determined, following reconstitution 
of the tablets. The characterisation results of the formulations are shown in Table 7.1.  
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Table 7.1 Characterisation results for the four formulations, for both PCL and PLGA 
nanoparticle-containing formulations. The results shown are the mean values ± 
standard deviation, following three measurements. The zeta potential results shown 
are the mean values ± standard error, following ten measurements. 
Formulation Particle 
Size (nm) 
Zeta 
Potential 
(mV) 
Tablet 
Hardness  
(Newtons, N) 
Tablet 
Disintegration 
Time (seconds, 
s) 
5% Methocel 
with 30% 
Mannitol – PCL 
Nanoparticles 
291.6 ± 10.5 -2.73 ± 2.97 0.90 ± 0.37 66.00 ± 9.54 
10% Methocel 
with 30% 
Mannitol – PCL 
Nanoparticles 
417.5 ± 67.5 -3.96 ± 2.51 8.23 ± 3.50 55.56 ± 23.71 
5% Gelatin with 
30% Mannitol – 
PCL 
Nanoparticles 
197.9 ± 31.3 -7.04 ± 1.70 9.29 ± 5.39 76.33 ± 47.14 
Optimised 
Formulation 
from the DOE 
Study – PCL 
Nanoparticles 
383.5 ± 
129.3 
-1.70 ± 1.36 5.48 ± 2.63 65.33 ± 17.44 
     
5% Methocel 
with 30% 
Mannitol – 
PLGA 
Nanoparticles 
248.4 ± 36.7 -12.14 ± 3.76 0.98 ± 0.07 54.55 ± 25.55 
10% Methocel 
with 30% 
Mannitol – 
PLGA 
Nanoparticles 
220.4 ± 55.8 -3.36 ± 7.01 8.18 ± 0.80 103.78 ± 70.32 
5% Gelatin with 
30% Mannitol – 
PLGA 
Nanoparticles 
211.3 ± 54.8 -8.74 ± 1.39 7.67 ± 2.38 82.22 ± 9.15 
Optimised 
Formulation 
from the DOE 
Study – PLGA 
Nanoparticles 
396.7 ± 24.2 -3.06 ± 0.94 5.24 ± 2.37 86.33 ± 40.71 
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The characterisation results for the four formulations, for both PCL and PLGA 
nanoparticle-containing preparations indicated that the new method (shown in Figure 
7.3) successfully produced ODTs which consisted of polymeric nanoparticles. Intact 
and robust tablets were formulated using this method. In terms of the tablets consisting 
of PCL nanoparticles, between the four formulations, they exhibited hardness and 
disintegration time which ranged from 0.90 ± 0.37 to 9.29 ± 5.39 N and 55.56 ± 23.71 
to 76.33 ± 47.14 s, respectively.  
 
Reconstituting these tablets revealed that the nanoparticles exhibited a particle size 
which ranged in size from 197.9 ± 31.3 to 417.5 ± 67.5 nm, between the four 
formulations. In terms of the zeta potential of the nanoparticles, between the four 
formulations, values ranged from -1.70 ± 1.36 to -7.04 ± 1.70 mV.  
 
For the formulations consisting of PLGA nanoparticles, the tablets ranged in hardness 
from 0.98 ± 0.07 to 8.18 ± 0.80 N, between the four formulations. In terms of tablet 
disintegration time, the values ranged from 54.55 ± 25.55 to 103.78 ± 70.32 s.  
 
Reconstituting the tablets which consisted of PLGA nanoparticles, revealed that the 
nanoparticles exhibited particle size and zeta potential which ranged from 211.3 ± 54.8 
to 396.7 ± 24.2 nm and -12.14 ± 3.76 to -3.06 ± 0.94 mV, respectively, between the 
four formulations.    
 
The results shown in Table 7.1 revealed that with all four ODT formulations, which 
included both PCL and PLGA nanoparticles, the nanoparticles exhibited particle sizes 
in the nanometre range. This can be attributed to the rapid diffusion of the organic 
phase into the ODT formulations, which decreases the interfacial tension between 
these two components (Rao and Geckeler, 2011). This subsequently increases the 
surface area of the organic phase, which forms small droplets of organic solvent 
leading to the precipitation of PCL and PLGA resulting in nanoparticle formation (Rao 
and Geckeler, 2011). 
 
A number of formulation parameters can influence the particle size of nanoparticles, 
such as; stabiliser concentration (Hans and Lowman, 2002), polymer concentration, 
molecular weight of the polymer and the method of organic phase addition into the 
aqueous phase (Rao and Geckeler, 2011). As a result, the particle size of 
nanoparticles can be controlled by adjusting these parameters accordingly. 
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The novel method (shown in Figure 7.3) has shown to successfully form nanoparticles 
in the four formulations studied. The four formulations have shown to be compatible 
with this method, as the organic phase is capable of diffusing rapidly into the 
formulations, and subsequently form nanoparticles. 
 
Evaluating the zeta potential of the nanoparticles of the four formulations, which 
included both PCL and PLGA nanoparticles, revealed that the zeta potential of the 
nanoparticles were near neutral in charge. The zeta potential of nanoparticles is 
related to the nanoparticle-forming polymer. PCL is non-ionic in nature and therefore 
neutral charged nanoparticles were expected to be formed. However as PLGA is 
anionic, the zeta potential of the prepared nanoparticles was expected to be more 
negative in nature. In order to modify the zeta potential of PLGA nanoparticles, 
adjusting the concentration of the nanoparticle-forming polymer would be one 
formulation approach. 
 
7.4.2 Incorporating Chitosan Nanoparticles in Freeze-Dried ODTs 
Using the method described in Figure 7.4, the following formulations were prepared, in 
order to incorporate chitosan nanoparticles: 
 5 % w/w Methocel™ E3LV with 30 % w/w (of dried tablet weight) mannitol. 
 10 % w/w Methocel™ E3LV with 30 % w/w (of dried tablet weight) mannitol. 
 5 % w/w gelatin with 30 % w/w (of dried tablet weight) mannitol. 
 Optimised formulation from the DOE study. 
 
As with the formulations consisting PCL and PLGA nanoparticles, these formulations 
were selected in order to establish if the method shown in Figure 7.4 could be applied 
to a range of different formulations, to successfully form and incorporate chitosan 
nanoparticles.   
 
Of the four formulations which were attempted, only the 5% w/w Methocel™ formulation 
proved successful in preparing tablets. The prepared tablets of this formulation were 
intact, which exhibited sufficient robustness to withstand manual handling, which were 
easily removable from the tablet moulds.  
 
In terms of the 10% w/w Methocel™ formulation and the optimised formulation from the 
DOE study, these formulations proved too viscous to be added drop-wise into the 
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aqueous acetic acid solution containing dissolved chitosan, and therefore the final 
formulations could not be prepared. 
 
The 5% w/w gelatin formulation was not deemed suitable for this particular application 
due to the acidic nature of the preparation method (as chitosan is dissolved aqueous 
acetic acid), and the instability of gelatin in acidic conditions (Lund, 1994 and Northrop, 
1921). 
 
The prepared tablets of the 5% w/w Methocel™ formulation were characterised in terms 
of hardness and disintegration time. The particle size and zeta potential of the 
nanoparticles were also studied, following reconstitution of the tablets. 
 
In terms of hardness, the tablets exhibited a mean hardness of 2.34 ± 0.20 N. Tablet 
disintegration time analysis showed that the tested tablets did not disintegrate up to 
three minutes of testing possibly due to the water-insoluble nature of chitosan 
(Agnihotri et al. 2004). Consequently, the tablets could not be reconstituted in order to 
evaluate the particle size and zeta potential of the chitosan nanoparticles. However, 
prior to dosing and freeze-drying the tablets, the particle size and zeta potential of the 
nanoparticles were evaluated. The mean particle size of the nanoparticles was 428.7 ± 
23.4 nm, which displayed a mean zeta potential of 9.01 ± 1.27 mV. 
  
7.4.3 Incorporation of Rizatriptan Benzoate Nanoparticles in Freeze-Dried ODTs 
Having successfully developed a new method of preparing ODTs with in situ formation 
of nanoparticles and its suitability to a wide range of formulation excipients, the next 
phase of the investigation was to determine the impact of drug loading on formulation 
and release kinetics from the dosage form. 
 
Rizatriptan benzoate is a 5-hydroxytryptamine1 (5HT1) receptor agonist, which is used 
in the treatment of acute migraine (Joint Formulary Committee, 2003), and is available 
as a freeze-dried ODT dosage form, under the name Maxalt-MLT® (which is available 
as a 5 or 10 mg dose).  
 
In this particular study, rizatriptan benzoate was encapsulated in PCL nanoparticles, in 
order to ascertain the influence of inclusion of excipients for nanoparticle preparation 
and to provide a sustained/extended release/dissolution of the API. Both, nanoparticle-
containing and nanoparticle-free tablets were prepared (both at doses of 5 mg, in 10% 
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w/w Methocel™-based formulations), characterised and their dissolution profiles 
compared. 
 
Following the preparation of the nanoparticle-containing tablets, the tablets were 
characterised for encapsulation-efficiency of the API, particle size and zeta potential of 
the nanoparticles, and the dissolution profile of the API. 
 
The encapsulation-efficiency of the API was calculated as being 1.8 %. This low 
encapsulation-efficiency can be attributed to the highly water-soluble nature of the API 
(Avachat et al. 2012). It has been widely reported that it is difficult to encapsulate 
hydrophilic APIs using the nanoprecipitation method of preparing nanoparticles 
(Peltonen et al. 2004, Govender et al. 1999 and Barichello et al. 1999). A number of 
reasons have been reported for the poor encapsulation of hydrophilic APIs. Peltonen et 
al. (2004) reported the low affinity the hydrophilic API has for the nanoparticle-forming 
polymer which results in low diffusion of the drug into the polymeric network. Peltonen 
et al. (2004) additionally reported that interactions between the polymer and API are 
weak, and that the API has a tendency to move from the organic phase to the aqueous 
phase. Govender et al. (1999) reported that the poor encapsulation of water-soluble 
APIs is due to the rapid migration of the APIs into the aqueous phase. Reconstitution 
of the nanoparticle-containing tablets revealed that the nanoparticles exhibited a mean 
particle size of 264.8 ± 11.4 nm, with a mean zeta potential of -3.68 ± 0.48 mV. 
 
Figure 7.5, shows the dissolution profile of rizatriptan benzoate from nanoparticle-
containing and nanoparticle-free tablets. 
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Figure 7.5 A comparison of the dissolution profile of rizatriptan benzoate from 
nanoparticle-free (NP-Free, shown in blue) and nanoparticle-containing (NP, shown in 
red) tablets. Each formulation was tested three times and the mean values ± standard 
deviation is shown. 
 
The results show that after 10 minutes of dissolution testing, 101.81 ± 9.33% of 
rizatriptan benzoate dissolved from the nanoparticle-containing tablet (NP), whilst for 
the nanoparticle-free tablet (NP-Free), only 64.83 ± 7.74% of the API was released. 
The results therefore revealed that although it was hoped that attempting to 
encapsulate the API in nanoparticles would result in sustained/extended 
release/dissolution of the API, it was actually observed that the nanoparticle-containing 
tablets displayed improved/increased drug dissolution, compared to the nanoparticle-
free tablets. 
  
In an attempt to modify the release/dissolution of the API, the next stage of the 
investigation was focussed on increasing the encapsulation-efficiency of the API. The 
effects of several formulation parameters have been previously investigated/reported, 
in an effort to increase the encapsulation-efficiency of hydrophilic APIs using the 
nanoprecipitation method, such as; amount of model API, solvent selection, electrolyte 
addition, and pH modification (Peltonen et al. 2004). Similarly, Govender et al. (1999) 
reported investigating aqueous phase pH, changing the form of the API and the 
inclusion of fatty-acid excipients in the formulation to promote loading of hydrophilic 
drug candidates  
 
Peltonen et al. (2004) reported that pH adjustment was the most effective way of 
increasing drug loading of sodium cromoglycate from 10-15% (without pH change) to 
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70% (following pH adjustment). Furthermore, Govender et al. (1999) reported that 
modifying pH from 5.8 to 9.3 increased drug entrapment from 11.0 to 58.2%. 
 
In this particular study, the pH of the aqueous phase of the formulation was adjusted 
from 8.07 to 10.48, in an effort to increase the encapsulation of rizatriptan benzoate. 
The prepared pH adjusted nanoparticle-containing tablets were characterised for; 
encapsulation efficiency of the API, tablet hardness, tablet disintegration time, particle 
size and zeta potential of the nanoparticles, and the dissolution profile of the API. The 
nanoparticle-free tablets were characterised for; tablet hardness, tablet disintegration 
time, and the dissolution profile of the API. 
 
Evaluating the encapsulation-efficiency of the API from the pH adjusted nanoparticle-
containing tablets, the results revealed a mean encapsulation-efficiency of 3.30 ± 
4.10%. This value therefore showed that adjusting the pH of the aqueous phase during 
the preparation of the formulation did not result in increasing the encapsulation-
efficiency of the API, when compared to the original nanoparticle-containing 
formulation. This low value suggested that the API migrates rapidly into the aqueous 
phase, when introduced into water, during the determination of encapsulation-
efficiency (Govender et al. 1999).  
 
Assessing the hardness of the tablets from the pH adjusted nanoparticle-containing 
formulation, revealed a mean value of 11.60 ± 2.53 N, whilst the nanoparticle-free 
tablets had a hardness value of 13.70 ± 1.83 N (p > 0.05). 
 
The assessment of the dissolution profile of rizatriptan benzoate from pH adjusted 
nanoparticle-containing tablets, is shown below in Figure 7.6, and is compared with the 
dissolution profile of the API from nanoparticle-free tablets. 
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Figure 7.6 A comparison of the dissolution profile of rizatriptan benzoate from 
nanoparticle-free (NP-Free, shown in blue) and pH adjusted nanoparticle-containing 
(NP pH Adjusted, shown in red) tablets. Each formulation was tested three times and 
the mean values ± standard deviation is shown. 
 
The results show that after 10 minutes of dissolution testing, 101.01 ± 12.72% of the 
API was released from the pH adjusted nanoparticle-containing tablets, whilst only 
64.83 ± 7.74% of the API dissolved from the nanoparticle-free tablets. These results 
are in agreement with the dissolution results shown in Figure 7.5, where it was also 
shown that rizatriptan benzoate displayed increased dissolution from nanoparticle-
containing tablets, in comparison with nanoparticle-free tablets. 
 
The increased dissolution of rizatriptan benzoate from the nanoparticle-containing 
tablets, in comparison with the nanoparticle-free tablets, could be due to the presence 
of Pluronic® in the nanoparticle-containing tablet formulations. Pluronic®, which is a 
synonym for poloxamer, is a surfactant composed of a block copolymer of ethylene 
oxide and propylene oxide, and has applications in pharmaceutical formulations as a 
dispersing, emulsifying and solubilising agent (Rowe, 2012). Pluronic® was therefore 
incorporated in the nanoparticle-containing tablet formulations, to function as a 
surfactant, in the preparation of the nanoparticles.  
 
It is possible that the observed increase in dissolution of rizatriptan benzoate from the 
nanoparticle-containing tablets, compared to the nanoparticle-free tablets, could be 
attributed to the dispersing effect of Pluronic®. The dispersing effect of Pluronic® could 
also explain why the tablets of the pH adjusted nanoparticle-containing formulation, 
exhibited a shorter disintegration time than the tablets of the nanoparticle-free 
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formulation. Tablets from the nanoparticle-free formulation displayed a disintegration 
time of 79.33 ± 14.01 s, whilst tablets from the pH adjusted nanoparticle-containing 
formulation displayed a disintegration time of 47.67 ± 5.86 s (p < 0.05).  
 
7.4.4 Incorporation of Piroxicam Nanoparticles in Freeze-Dried ODTs 
Piroxicam is a non-steroidal anti-inflammatory drug, which is used in the treatment of 
rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis (Joint Formulary 
Committee, 2003). It is available as a freeze-dried ODT dosage form, under the name 
Feldene™ Melt, which is available as a 20 mg dose.  
 
In this particular study, piroxicam was studied for encapsulation in PCL nanoparticles, 
in order to assess the sustained/extended release/dissolution of the API. Both, 
nanoparticle-containing and nanoparticle-free tablets were prepared (both at doses of 
20 mg, in 10% w/w Methocel™-based formulations), in order to compare their 
dissolution profiles of the API.  
 
The encapsulation-efficiency of the API was calculated as 96.83 ± 1.61 %. This high 
encapsulation-efficiency of piroxicam was observed, as the nanoprecipitation/solvent 
displacement method is applicable to lipophilic APIs, due to the miscibility of the 
organic solvent (in which piroxicam is soluble in) with the aqueous phase (in which 
piroxicam is practically insoluble in) (Barichello et al. 1999). Reconstitution of the 
nanoparticle-containing tablets, revealed that the nanoparticles exhibited a mean 
particle size of 898.8 ± 501.7 nm, with a mean zeta potential of 4.32 ± 1.85 mV. 
 
Figure 7.7 (below), shows the dissolution profile of piroxicam from both nanoparticle-
containing and nanoparticle-free tablets. 
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Figure 7.7 A comparison of the dissolution profile of piroxicam from nanoparticle-free 
(NP-Free, shown in blue) and nanoparticle-containing (NP, shown in red) tablets. Each 
formulation was tested three times, and the mean values ± standard deviation is 
shown. 
 
The results revealed that after 90 minutes of dissolution testing, 90.40 ± 2.43% of 
piroxicam dissolved from the nanoparticle-free tablets, whilst for the nanoparticle-
containing tablets, only 58.00 ± 2.86% of the API dissolved. The results therefore 
showed that a sustained/extended release/dissolution of piroxicam was achieved, by 
incorporating piroxicam nanoparticles in freeze-dried ODTs. 
 
Tablet hardness and disintegration time of both formulations were also evaluated. In 
terms of hardness, tablets from the nanoparticle-free formulation displayed a value of 
12.34 ± 0.69 N, which was comparable to the hardness of the tablets from the 
nanoparticle-containing formulation, 12.34 ± 1.52 N (p > 0.05). These comparable 
results indicated that preparing nanoparticle-containing tablets using the method 
shown in Figure 3 did not compromise tablet hardness. 
 
Investigating tablet disintegration time, the results showed that tablets with 
nanoparticle-free formulation exhibited a value of 75.00 ± 13.34 s, whilst tablets from 
the nanoparticle-containing formulation displayed a value of 38.00 ± 3.61 s (p < 0.05). 
These results therefore showed that freeze-dried ODTs consisting of polymeric 
nanoparticles, displayed a shorter disintegration time than the conventional 
nanoparticle-free freeze-dried ODTs. 
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7.5 Stability Study of Piroxicam Tablets 
Following piroxicam demonstrating a sustained/extended release/dissolution by 
incorporating its nanoparticles in freeze-dried ODTs, both nanoparticle-free and 
nanoparticle-containing tablets of this API underwent a 45 day stability assessment to 
assess their stability. 
 
The results from the stability study for the nanoparticle-free piroxicam tablets are 
shown in Table 7.2. The results revealed that no significant change in drug 
recovery/dose uniformity occurred with the tablets stored at 25ºC/60% RH (p > 0.05). 
However, a significant change was observed with the tablets stored at 40ºC/75% RH, 
as the drug recovery/dose uniformity observed after 45 days, was significantly different 
to that observed at 0 and 30 days, respectively (p < 0.05). This could suggest that 
piroxicam was unstable in these conditions, due to the high temperature and high 
humidity of the storage conditions. The results from the stability study for the 
nanoparticle-containing piroxicam tablets are shown in Table 7.3. 
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Table 7.2 Stability study results of the characterisation of the nanoparticle-free 
piroxicam tablets, stored at 25ºC/60% RH and 40ºC/75% RH, respectively. The results 
shown are the mean values ± standard deviation, following three measurements. 
 Time Point (Days) 
 0 30 45 
Parameter 25ºC/75
% RH 
40ºC/75
% RH 
25ºC/75
% RH 
40ºC/75
% RH 
25ºC/75
% RH 
40ºC/75
% RH 
Drug 
Recovery/Do-
se Uniformity 
(%) 
92.71 ± 
5.09 
90.21 ± 
4.69 
101.04 ± 
18.31 
93.13 ± 
4.37 
90.42 ± 
3.77 
107.50 ± 
3.80 
Tablet 
Hardness (N) 
18.34 ± 
3.13 
15.74 ± 
1.47 
9.37 ± 
2.30 
10.80 ± 
0.91 
12.41 ± 
2.97 
6.62 ± 
0.39 
Tablet 
Disintegratio
n Time (s) 
55.33 ± 
20.60 
61.00 ± 
6.00 
34.00 ± 
6.56 
42.33 ± 
5.69 
166.33 ± 
184.87 
81.33 ± 
84.68 
 
 
Table 7.3 Stability study results of the characterisation of the nanoparticle-containing 
piroxicam tablets, stored at 25ºC/60% RH and 40ºC/75% RH, respectively. The results 
shown are the mean values ± standard deviation, following three measurements. The 
zeta potential results shown are the mean values ± standard error, following ten 
measurements. 
 Time Point (Days) 
 0 30 45 
Parameter 25ºC/60
% RH 
40ºC/75
% RH 
25ºC/60
% RH 
40ºC/75
% RH 
25ºC/60
% RH 
40ºC/75
% RH 
Tablet 
Hardness 
(N) 
19.37 ± 
2.76 
15.93 ± 
5.32 
7.73 ± 
1.67 
7.00 ± 
3.73 
16.95 ± 
1.11 
9.42 ± 
1.85 
Tablet 
Disintegrati
-on Time (s) 
41.33 ± 
0.58 
45.00 ± 
3.61 
10.67 ± 
1.53 
9.67 ± 
0.58 
14.67 ± 
1.53 
14.33 ± 
1.15 
Particle 
Size (nm) 
727.3 ± 
127.5 
715.2 ± 
119.0 
615.9 ± 
32.9 
397.3 ± 
58.8 
472.0 ± 
26.1 
508.4 ± 
25.7 
Zeta 
Potential 
(mV) 
-4.70 ± 
0.90 
-4.39 ± 
1.16 
-11.05 ± 
2.12 
-3.00 ± 
1.04 
-9.43 ± 
0.63 
-11.17 ± 
2.25 
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In terms of tablet hardness, the results revealed that this property changed significantly 
during the 45 days of stability assessment, for both the tablets stored at 25ºC/60% RH 
and 40ºC/75% RH, respectively (p < 0.05). As with the tablets stored at 25ºC/60% RH, 
the hardness of the tablets after 0 days were significantly greater to those after 30 days 
(p < 0.05). Whilst with the tablets stored at 40ºC/75% RH, the hardness of the tablets 
decreased over time (p < 0.05), suggesting deterioration in the physical stability of the 
tablets. The deterioration in the physical stability of the tablets over time could possibly 
be attributed to the high humidity, plasticising the tablet which results in the 
deterioration of the physical properties of the tablets. It has been reported previously 
that once tablets reach a certain level of moisture content, the physical properties of 
the tablets can deteriorate (Nakabayashi et al. 1980).   
 
The tablet disintegration time results revealed that no significant change was observed 
after 45 days of storage, for the tablets stored at both conditions (p > 0.05). 
 
No noticeable change in the general appearance of the nanoparticle-free tablets was 
observed, during and after the stability study, for the tablets stored at both conditions. 
 
The results from the stability study for the nanoparticle-containing piroxicam tablets, 
shown in Table 7.3, revealed that in terms of the hardness of the tablets stored at 
25ºC/60% RH, this property changed significantly during the 45 days of stability 
assessment (p < 0.05). The tablets analysed after 30 days of storage exhibited a 
significantly lower hardness than those analysed after 0 and 45 days, respectively (p < 
0.05). As the hardness of the tablets did not deteriorate over time, i.e. the hardness of 
the tablets analysed after 45 days were not lower than those after 30 days, it appeared 
that there was no physical stability issue with these tablets.  
 
No significant change in the hardness of the tablets stored at 40ºC/75% RH was 
observed after 45 days of stability assessment (p > 0.05).  
 
The results for the disintegration time of the tablets stored at both storage conditions 
indicated that this property changed significantly during the 45 day stability study (p < 
0.05) as the disintegration time of the tablets analysed after 30 and 45 days, 
respectively, were significantly lower than those analysed at day 0 (p < 0.05). As tablet 
disintegration testing involves human judgment to determine when a tablet has 
disintegrated, variability in the results will exist. For this reason, it appeared that the 
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significant changes observed with tablet disintegration time during the stability study, 
was not related to the stability of the tablets.    
 
In relation to the particle size of the nanoparticles of the tablets stored at both storage 
conditions, this property displayed significant changes during the 45 days of stability 
assessment (p < 0.05) as the particle size of the nanoparticles of the tablets analysed 
after 45 days of storage, were significantly smaller than those analysed at day 0 (p < 
0.05). As discussed earlier, one factor which influences the particle size of 
nanoparticles is the method of organic phase addition into the aqueous phase. As the 
preparation of these formulations was performed manually, the rate of organic phase 
addition was not constant. Consequently, variability in the particle size of the 
nanoparticles was expected. Therefore the significant changes observed with the 
particle sizes of the nanoparticles in the stability study, appeared not be related to the 
stability of the nanoparticles.  
 
This could possibly be related to the zeta potential results, where it was found that 
analysing the zeta potential of the nanoparticles for the tablets stored at both storage 
conditions, revealed that this property changed significantly during the stability study (p 
< 0.05).  
 
No noticeable change in the general appearance of the nanoparticle-containing tablets 
was observed, during and after the stability study, for the tablets stored at both 
conditions.  
 
 
7.6 Conclusions 
A novel method has been developed, which is based on the nanoprecipitation/solvent-
displacement method of preparing polymeric nanoparticles, which allows the direct 
incorporation of polymeric nanoparticles in freeze-dried ODT formulations. The method 
was used to prepare PCL (non-ionic) and PLGA (anionic) nanoparticles, which were 
subsequently incorporated in both Methocel™ and gelatin-based freeze-dried ODT 
formulations, forming intact and robust tablets. 
 
A novel method has also been developed, which is based on the ionic gelation method 
of preparing chitosan (cationic) nanoparticles, which allows the direct incorporation of 
these nanoparticles in freeze-dried ODT formulations. The new method produced 
chitosan nanoparticles, which were subsequently incorporated in a 5% w/w Methocel™-
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based freeze-dried ODT formulation, forming intact tablets. However, due to the water-
insoluble nature of chitosan, the prepared tablets did not show signs of disintegration 
during testing. A potential formulation strategy to overcome this, could involve 
investigating water-soluble forms of chitosan. 
 
The APIs; rizatriptan benzoate (water-soluble) and piroxicam (practically insoluble in 
water), were encapsulated in PCL nanoparticles, in order to develop a 
sustained/extended release/dissolution of the API from ODTs. Due to the water-soluble 
nature of rizatriptan benzoate, a very low encapsulation-efficiency of the API was 
observed (< 5 %), and as a result a sustained/extended release/dissolution of the API 
was not observed. In fact an increase in drug dissolution was observed with the 
nanoparticle-containing formulation tablets, compared to the nanoparticle-free 
formulation tablets. Tablet hardness was comparable between the two formulations, 
and in terms of tablet disintegration time, nanoparticle-containing tablets exhibited a 
shorter disintegration time. 
 
Piroxicam on the other hand had a high encapsulation-efficiency (> 95 %) and the 
dissolution results of the nanoparticle-containing tablets revealed a sustained/extended 
release/dissolution of the API, compared to the tablets of the nanoparticle-free 
formulation. Tablet hardness was comparable between the two formulations, and in 
terms of tablet disintegration time, nanoparticle-containing tablets exhibited a shorter 
disintegration time. 
 
The stability study results for the nanoparticle-free piroxicam tablets revealed potential 
API and physical stability issues with the tablets stored at 40ºC/75% RH. 
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8.1 The Influence of Formulation and Manufacturing Process Parameters on the 
Characteristics of Lyophilised Orally Disintegrating Tablets 
Gelatin is a widely-studied excipient used in the formulation of freeze-dried ODTs. 
Studies have shown that the swelling behaviour and solubility of gelatin are pH-
dependent. Additionally, the swelling behaviour of gelatin is influenced by ionic 
strength. Despite the extensive literature on the properties of gelatin, no work has been 
reported previously which attempted to exploit its properties in order to modify the 
behaviour of freeze-dried ODTs. The aim of this study was to further understand the 
properties of gelatin, and its implications on the performance of freeze-dried ODTs. 
 
The results from the study revealed that the disintegration time of gelatin-based freeze-
dried ODTs can be reduced by adjusting the pH of the formulation. This was likely due 
to an increase in tablet porosity (possibly due to the swelling behaviour gelatin) and an 
improvement in gelatin solubility. Meanwhile, adjusting the ionic strength of gelatin-
based formulations has shown to influence tablet porosity, again this was possibly 
attributed to the swelling behaviour of gelatin. 
 
This study has shown than an appreciation and understanding of the properties of 
gelatin has allowed the formulation and process of preparing gelatin-based 
formulations to be modified, in order to exploit the properties of gelatin and 
subsequently adjust the characteristics of the tablets. 
 
8.2 Investigating the Application of Methocel™ (Hydrophilic Cellulose Ethers) as 
Binders in Freeze-Dried ODTs 
As discussed earlier, gelatin is used extensively in the preparation of freeze-dried 
ODTs. As gelatin is derived from animal-sources a number of ethical issues surround 
its use as an excipient in pharmaceutical preparations. Consequently, certain groups of 
the population restrict gelatin from their diet, including when gelatin is used in their 
medication. For this reason extensive research has been published, investigating 
alternative materials to use as a replacement to gelatin. Certain grades of Methocel™ 
have been reported to be used as binders in the preparation of freeze-dried ODTs, 
however, an extensive and comprehensive evaluation of the use of Methocel™ has not 
been previously reported. 
 
The aim of this investigation therefore was to undertake a systematic and 
comprehensive evaluation of Methocel™ as a binder in freeze-dried ODTs. Both low 
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and high viscosity grades of Methocel™ were evaluated, together with both 
methylcellulose and HPMC grades.  
 
The results from the study revealed that low viscosity grades, in particular; Methocel™ 
E3LV and K3LV, appeared most suitable as binders in freeze-dried ODTs, as high 
concentrations could be used to form robust tablets. It was found that increasing 
Methocel™ concentration resulted in a general increase in tablet hardness and 
disintegration time, respectively. The higher viscosity grades did not appear suitable as 
binders, as only low concentrations could be used, and as a result robust tablets were 
not prepared. Performing a systematic and comprehensive evaluation identified which 
grades were most suitable and also which concentrations were appropriate.  
 
8.3 Investigating the Application of Polyox™ (Synthetic Polyethylene Oxide) in 
Freeze-Dried ODTs  
Polyox™ is a highly versatile polymer, as it is available in a number of grades which 
differ in molecular weight. Consequently, Polyox™ has a number of applications in 
pharmaceutical preparations, such as a tablet binder, viscosity increasing agent and 
mucoadhesive agent. Due to the tremendous versatility of Polyox™, a systematic and 
comprehensive evaluation of its applications as an excipient in freeze-dried ODTs was 
conducted.  
 
The results from the study revealed that the lowest viscosity grade, Polyox™ N10, was 
most suitable as a binder, as tablets were produced of satisfactory hardness and 
disintegration time. The higher viscosity grades, due to their highly viscous and 
cohesive nature, appeared potentially suitable as excipients which could increase the 
retention of ODT formulations in pre-gastric regions. By increasing the retention of 
ODT formulations in the pre-gastric regions, this opens up the possibility for pre-gastric 
absorption of APIs, which could provide clinical/therapeutic benefits to patients. 
 
8.4 Investigating the Application of Kollicoat® IR as a Binder in Freeze-Dried 
ODTs 
Kollicoat® IR as a co-polymer, has been reported widely as a versatile material able to 
fulfil various functions, such as a binder, and as a hydrophilic excipient in solid 
dispersions preparations. Additionally, Kollicoat® IR displays a number of physico 
chemical properties which could be utilised in order for it to function as a binder in 
freeze-dried ODTs, such as its high aqueous solubility and low viscosity. For this 
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reason, a systematic and comprehensive evaluation of Kollicoat® IR was performed in 
order to exploit its favourable properties. 
 
Data from the study indicated that Kollicoat® IR functions as a binder, and its function is 
concentration dependent. Kollicoat® IR at concentrations above 10% w/w, forms robust 
tablets which demonstrate satisfactory disintegration times. In fact it was found that 
increasing Kollicoat® IR concentration, resulted in an increase in tablet hardness and 
disintegration time, respectively. Additionally, Kollicoat® IR-based formulations can be 
prepared at room/ambient temperature, which makes formulation preparation highly 
efficient and convenient.    
 
8.5 A Design of Experiments (DOE) Study Evaluating the Role of Excipients on 
the Properties of Freeze-Dried ODTs 
The use of DOE – factorial design is a highly useful tool in the development of 
pharmaceutical formulations. Using DOE – factorial design in the development of 
pharmaceutical formulations provides a wealth of information about the formulation 
excipients, and their role, both individually and interactively, on the properties of the 
formulation. Additionally, formulations can be optimised in order for the formulation to 
exhibit desired properties. A DOE study was conducted in order investigate the role of; 
Methocel™ E3LV, Polyox™ N10 and mannitol concentrations, on; formulation viscosity, 
tablet hardness, tablet disintegration time and in vitro oral retention time. 
 
The results from the study revealed that formulation viscosity was primarily influenced 
(significant positive effect) by Polyox™ N10 and Methocel™ E3LV, and in fact a 
synergistic-interactive effect was observed between these two excipients. Methocel™ 
E3LV and mannitol were most influential (significant positive effect) on tablet hardness. 
In terms of tablet disintegration time and in vitro oral retention time, mannitol was found 
to exhibit a significant negative effect. 
 
An optimised formulation was identified which exhibited desired properties, relating to 
tablet hardness, tablet disintegration time and in vitro oral retention time. Assessing the 
in vitro oral retention of nystatin, demonstrated that the in vitro oral retention of APIs 
can be modified based on the composition of the formulation. 
 
The results from this study suggest that the retention of formulations in the mouth and 
other pre-gastric regions could potentially be optimised, in order to treat localised 
medical conditions or encourage pre-gastric absorption of APIs. 
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8.6 Incorporation of Nanoparticles in Freeze-Dried ODTs  
Polymeric nanoparticles possess a number of unique properties as drug delivery 
systems. Polymeric nanoparticles have the capability of releasing APIs over extended 
periods of time, and the ability of encapsulating a wide range of APIs. Incorporating 
polymeric nanoparticles in freeze-dried ODTs would allow the benefits of both ODTs as 
a dosage form and polymeric nanoparticles as drug delivery devices to be experienced 
by patients, simultaneously. The aim of this study was to formulate ODTs consisting of 
polymeric nanoparticles, using novel methods. 
 
The results from the study revealed that novel methods have been developed, that 
allows the direct incorporation of polymeric nanoparticles in freeze-dried ODTs. A 
method based on the nanoprecipitation/solvent-displacement method of preparing 
polymeric nanoparticles has shown to incorporate PCL and PLGA nanoparticles, 
directly into gelatin and Methocel™-based ODT formulations, forming intact and robust 
tablets. A novel method based on the ionic gelation method of preparing chitosan 
nanoparticles, has shown to incorporate these nanoparticles directly into a Methocel™-
based ODT formulation, forming intact tablets. However, due to the water-insoluble 
nature of chitosan, the tablets did not disintegrate during testing. Further research is 
required in this area. 
 
The APIs; rizatriptan benzoate and piroxicam were studied as model drugs for 
encapsulation in PCL nanoparticles in order to exhibit a sustained release of the API. 
Due to the water-soluble nature of rizatriptan benzoate, a low encapsulation-efficiency 
was observed, consequently, a sustained release of this API was not observed. 
Further research is required to increase the encapsulation-efficiency of water-soluble 
APIs. 
 
In terms of piroxicam, a high encapsulation-efficiency was observed. The formulation 
displayed a sustained release of the API, additionally, the disintegration time of the 
formulation was shorter than that of the nanoparticle-free formulation. 
 
The stability study results for the nanoparticle-free tablets revealed potential API and 
physical stability issues with the tablets stored at 40ºC/75% RH. 
 
The results from this study are significant, as freeze-dried ODTs have been developed 
which consist of polymeric nanoparticles, prepared using novel methods. The method 
based on the nanoprecipitation/solvent-displacement technique, has shown to produce 
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a sustained release formulation of piroxicam. A sustained release ODT formulation 
could potentially improve patient compliance with their medication programs, due to a 
reduction in the frequency of medication administration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References  
 
220 
 
References 
ABDELBARY, G., PRINDERRE, P., EOUANI, C., JOACHIM, J., REYNIER, J.P. and 
PICCEREELLE, Ph. (2004) The preparation of orally disintegrating tablets using a 
hydrophilic waxy binder. International Journal of Pharmaceutics, 278, pp. 423-433. 
 
ABDELBARY, G.; EOUANI, C.; PRINDERRE, P.; JOACHIM, J.; REYNIER, J.P. AND 
PICCERELLE, P.H. (2005) Determination of the in vitro disintegration profile of rapidly 
disintegrating tablets and correlation with oral disintegration. International Journal of 
Pharmaceutics, 292, pp. 29-41. 
 
AGNIHOTRI, S.A., MALLIKARJUNA, N.N. and AMINABHAVI, T.M. (2004) Recent 
advances on chitosan-based micro- and nanoparticles in drug delivery. Journal of 
Controlled Release, 100, pp. 5-28. 
 
AHMED, I.S., SHAMMA, R.N. and SHOUKRI, R.A. (2011) Development and 
optimization of lyophilized orally disintegrating tablets using factorial design. 
Pharmaceutical Development and Technology, 2011, pp. 1-9.  
 
ALDERBORN, G. (2007) Tablets and Compaction. In: AULTON, M.E. (ed.) Aulton’s 
Pharmaceutics: The Design and Manufacture of Medicines. 3rd ed. Edinburgh: 
Churchill Livingstone Elsevier. 
 
ALHUSBAN, F.A., ELSHAER, A.M., JONES, R.J. and MOHAMMED, A.R. (2010a) 
Recent patents and trends in orally disintegrating tablets. Recent Patents on Drug 
Delivery & Formulation, 4 (3), pp. 178-197. 
 
ALHUSBAN, F., PERRIE, Y. and MOHAMMED, A.R. (2010b) Formulation and 
characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix 
forming agents. European Journal of Pharmaceutics and Biopharmaceutics, 75, pp. 
254-262. 
 
ALHUSBAN, F., ELSHAER, A.M., KANSARA, J.H., SMITH, A.M., GROVER, L.M., 
PERRIE, Y. and MOHAMMED, A.R. (2010c) Investigation of Formulation and Process 
of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid 
Combination. Pharmaceutics, 2, pp. 1-17. 
 
References  
 
221 
 
ALHUSBAN, F., PERRIE, Y. and MOHAMMED, A. (2010d) Preparation, optimisation 
and characterisation of lyophilised rapid disintegrating tablets based on gelatin and 
saccharide. Current Drug Delivery, 7, pp. 65-75.  
 
ALHUSBAN, F. and MOHAMMED, A.R. (2011) Novel Zero-Saccharide Orally 
Disintegrating Tablets. European Industrial Pharmacy, 9, pp. 15-17. 
 
ALHUSBAN, F., PERRIE, Y. and MOHAMMED, A.R. (2011) Formulation of 
multiparticulate systems as lyophilised orally disintegrating tablets. European Journal 
of Pharmaceutics and Biopharmaceutics, 79 (3), pp. 627-634. 
 
ALLEN Jr, L.V. (2012) Methylcellulose [WWW] Medicines Complete – Pharmaceutical 
Excipient. Available from: 
http://www.medicinescomplete.com/mc/excipients/current/1001941845.htm [Accessed 
04/10/12]. 
 
ANSEL, H. C., ALLEN, L. V. and POPOVICH, N. G. (2011) Ansel’s Pharmaceutical 
Dosage Forms and Drug Delivery Systems. 9th ed. Philadelphia, USA: Lippincott 
Williams & Wilkins. 
 
ARMSTRONG, N.A. and JAMES, K.C. (1996) Pharmaceutical Experimental Design 
and Interpretation. London: Taylor & Francis. 
 
ASHFORD, M. (2002a) Bioavailability – Physicochemical and Dosage Form Factors. 
In: AULTON, M.E., ed. Pharmaceutics: The Science of Dosage Form Design. 2nd ed. 
Edinburgh: Churchill Livingstone, pp. 234-252.  
 
ASHFORD, M. (2002b) The Gastrointestinal Tract – Physiology and Drug Absorption. 
In: AULTON, M.E., ed. Pharmaceutics: The Science of Dosage Form Design. 2nd ed. 
Edinburgh: Churchill Livingstone, pp. 217-233. 
 
AULTON, M.E. (2002) Drying. In: AULTON, M.E., ed. Pharmaceutics: The Science of 
Dosage Form Design. 2nd ed. Edinburgh: Churchill Livingstone, pp. 390-393. 
 
AVACHAT, A.M., GUJAR, K.N. and WAGH, K.V. (2012) Development and evaluation 
of tamarind seed xyloglucan based mucoadhesive buccal films of rizatriptan benzoate. 
Carbohydrate Polymers, doi: 10.1016/j.carbpol.2012.08.062. 
References  
 
222 
 
 
BADGUJAR, B.P. and MUNDADA, A.S. (2011) The technologies used for developing 
orally disintegrating tablets: A review. Acta Pharmaceutica, 61, pp. 117-139. 
 
BAHL, D., CROWLEY, K.J. and YU, D. Oral Solid Dosage Form Containing 
Nanoparticles and Process of Formulating the Same Using Fish Gelatin. United States 
patent application 0064812 A1, 2011. 
 
BAILEY, F.E. and KOLESKY, J.V. (1976) Poly(ethylene oxide). London: Academic 
Press. 
 
BARICHELLO, J.M., MORISHITA, M., TAKAYAMA, K. and NAGAI, T. (1999) 
Encapsulation of Hydrophilic and Lipophilic Drugs in PLGA Nanoparticles by the 
Nanoprecipitation Method. Drug Development and Industrial Pharmacy, 25 (4), pp. 
471-476. 
 
BASF SE (2010) Kollicoat® IR Technical Information. 
 
BATCHELOR, H.K., BANNING, D., DETTMAR, P.W., HAMPSON, F.C., JOLLIFFE, 
I.G. and CRAIG, D.Q.M. (2002) An in vitro mucosal model for prediction of the 
bioadhesion of alginate solutions to the oesophagus. International Journal of 
Pharmaceutics, 238, pp. 123-132. 
 
BAUER, K.H. (2007) A partially freeze-dried lyophilisation technique for producing fast-
melting tablets. Pharmaceutical Technology Europe, September, pp. 63-69. 
 
BAUER, K.H. and ROHRER, H.P. (2007) Fast-disintegrating tablets. US Patent: 
20070148231. 
 
BENJAKUL, S.; OUNGBHO, K.; VISESSANGUAN, W.; THIANSILAKUL, Y. and 
ROYTRAKUL, S. (2009) Characteristics of gelatin from the skins of bigeye snapper, 
Priacanthus tayenus and Priacanthus macracanthus. Food Chemistry, 116, pp. 445-
451. 
 
BERTRAM, U. and BODMEIER, R. (2006) In situ gelling, bioadhesive nasal inserts for 
extended drug delivery: In vitro characterisation of a new nasal dosage form. European 
Journal of Pharmaceutical Sciences, 27, pp. 62-71. 
References  
 
223 
 
 
BI, Y., SUNADA, H., YONEZAWA, Y., DANJO, K., OTSUKA, A. and IIDA, K. (1996) 
Preparation and Evaluation of a Compressed Tablet Rapidly Disintegrating in the Oral 
Cavity. Chemical and Pharmaceutical Bulletin, 44 (11), pp. 2121-2127. 
 
BIGUCCI, F., LUPPI, B., MONACO, L., CERCHIARA, T. and ZECCHI, V. (2008) 
Pectin-based microspheres for colon-specific delivery of vancomycin. Journal of 
Pharmacy and Pharmacology, 61, pp. 41-46. 
 
BOTTENBERG, P., CLEYMAET, R., DE MUYNCK, C., REMON, J.P., COOMANS, D., 
MICHOTTE, Y. and SLOP, D. (1991) Development and testing of bioadhesive, 
fluoride-containing slow-release tablets for oral use. Journal of Pharmacy and 
Pharmacology, 43, pp. 457-464. 
 
BRITISH PHARMACOPOEIA COMISSION (2011) British Pharmacopoeia, Volume I 
and II, Monographs: Medicinal and Pharmaceutical Substances: Hypromellose. 
London: Stationery Office. 
 
BRITISH PHARMACOPOEIA COMISSION (2012) British Pharmacopoeia, Volume I 
and II, Monographs: Medicinal and Pharmaceutical Substances: Methylcellulose. 
London: Stationery Office. 
 
BRUST, J.C.M. (ed.) (1993) Neurological Aspects of Substance Abuse. London: 
Butterworth-Heineman. 
 
CAPRI, S., GALLUS, G., GRASSI, C., HUCHON, G.J., IRVINE, S.H., LOPEZ-
VIDRIERO, M.T., LUISETTI, M., LUNGARELLA, G., MARRIOTT, C., MARSAC, J., 
MATTHYS, H., RENNARD, S.I., TABUSSO, G. and TORRENT, J. (1994) 
Recommendations for Guidelines on Clinical Trials of Mucoactive Drugs in Chronic 
Bronchitis and Chronic Obstructive Pulmonary Disease. Chest, 106, pp. 1532-1537. 
 
CAVATUR, R.K., VEMURI, N.M., PYNE, A., CHRZAN, Z., TOLEDO-VELASQUEZ, D. 
and SURYANARAYANAN, R. (2002) Crystallisation behaviour of mannitol in frozen 
aqueous solutions. Pharmaceutical Research, 19 (6), pp. 894-900. 
 
CHANDRASEKHAR, R., HASSAN, Z., ALHUSBAN, F., SMITH, A.M. and 
MOHAMMED, A.R. (2009) The role of formulation excipients in the development of 
References  
 
224 
 
lyophilised fast-disintegrating tablets. European Journal of Pharmaceutics and 
Biopharmaceutics, 72, pp. 119-129. 
 
CHOWHAN, Z.T. (1980) Role of binders in moisture-induced hardness increase in 
compressed tablets and its effect on in vitro disintegration and dissolution. Journal of 
Pharmaceutical Sciences, 69, pp.1-4. 
 
CHURCHYARD, A., MATHIAS, C.J., BOONKONGCHUEN, P. and LEES, A.J. (1997) 
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. 
Journal of Neurology Neurosurgery and Psychiatry, 63, pp. 228-234.  
 
CLARKE, A., JOHNSON, E.S., MALLARD, N., CORN, T.H., JOHNSTON, A., BOYCE, 
M., WARRINGTON, S. and MACMAHON, D.G. (2003) A new low-dose formulation of 
selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. 
Journal of Neural Transmission, 110, pp. 1257-1271. 
 
COLLETT, J. and MORETON, C. (2002) Modified-release peroral dosage form. In 
Pharmaceutics – the Science of Dosage Form Design, 2nd ed.; AULTON, M.E., Ed.; 
Churchill Livingstone: Edinburgh, Scotland, pp. 289-305. 
 
CORNISH, P. (2005) Avoid the crush: hazards of medication administration in patients 
with dysphagia or a feeding tube. Canadian Medical Association Journal, 172, pp. 871-
872. 
 
CORTESI, R.; ESPOSITO, E.; OSTI, M.; SQUARZONI, G.; MENEGATTI, E.; DAVIS, 
S.S. and NASTRUZZI, C. (1999) Dextran cross-linked gelatin microspheres as a drug 
delivery system. European Journal of Pharmaceutics and Biopharmaceutics, 47, pp. 
153-160. 
 
CORVELEYN, S. and REMON, J.P. (1997) Formulation and production of rapidly 
disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug. 
International Journal of Pharmaceutics, 152, pp. 215-225. 
 
CORVELEYN, S. and REMON, J.P. (1998) Formulation of a lyophilised dry emulsion 
tablet for the delivery of poorly soluble drugs. International Journal of Pharmaceutics, 
166, pp. 65-74. 
 
References  
 
225 
 
COUNCIL OF EUROPE (2002) European Pharmacopoeia: published in accordance 
with the Convention on the Elaboration of a European Pharmacopoeia (European 
Treaty series no. 50). Strasbourg: Council of Europe. 
 
DAHL, T.C., CALDERWOOD, T., BORMETH, A., TRIMBLE, K. and PIEPMEIER, E. 
(1990) Influence of physico-chemical properties of hydroxypropyl methylcellulose on 
naproxen release from sustained release matrix tablets. Journal of Controlled Release, 
14, pp. 1-10. 
 
DALAL, P.S. and NARURKAR, M.M. (1991) In vitro and in vivo evaluation of sustained 
release suspensions of ibuprofen. International Journal of Pharmaceutics, 73, pp. 157-
162. 
 
DAVISKAS, E., ANDERSON, S.D., EBERL, S. and YOUNG, I.H. (2008) Effect of 
increasing doses of mannitol on mucus clearance in patients with bronchiectasis. 
European Respiratory Journal, 31, pp. 765-772. 
 
DAWSON, P.J. and HOCKLEY, D.J. (1991) Scanning electron microscopy of freeze-
dried preparations: relationship of morphology to freeze-drying parameters. 
Developments in Biological Standardization, 74, pp. 185-192. 
 
DOW CHEMICAL COMPANY (2002) METHOCEL Cellulose Ethers: Technical 
Handbook. U.S.A. 
 
DOW CHEMICAL COMPANY (2002) POLYOX Water-Soluble Resins. U.S.A. 
 
EDWARDS, L.L., PFEIFFER, R.F., QUIGLEY, E.M. HOFMAN, R. and BALLUFF, M. 
(1991) Gastrointestinal symptoms in Parkinson’s disease. Movement Disorders, 6 (2), 
pp. 151-156. 
 
EL-BADRY, M., ALANAZI, F.K., MAHROUS, G.M. and ALSARRA, I.A. (2010) Effects 
of Kollicoat IR and hydroxypropyl-beta-cyclodextrin on the dissolution rate of 
omeprazole from its microparticles and enteric-coated capsules. Pharmaceutical 
Development and Technology, 15 (5), pp. 500-510. 
 
References  
 
226 
 
ESEZOBO, S. (1989) Disintegrants: effects of interacting variables on the tensile 
strengths and dissolution times of sulfaguanidine tablets. International Journal of 
Pharmaceutics, 56, pp. 207-211. 
 
FESSI, H., PUISIEUX, F., DEVISSAGUET, J.PH., AMMOURY, N. and BENITA, S. 
(1989) Nanocapsule formation by interfacial polymer deposition following solvent 
displacement. International Journal of Pharmaceutics, 55, R1-R4. 
 
FOOD AND DRUG ADMINISTRATION (2008) Guidance for Industry: Orally 
Disintegrating Tablets. Rockville, MD: United States Pharmacopoeial Convention. 
 
FOOD AND DRUG ADMINISTRATION (2009) International Conference on 
Harmonisation Q8 (R2) Pharmaceutical Development – Guidance for Industry. 
Maryland, USA: Food and Drug Administration, Revision 2. 
 
FOOD AND DRUG ADMINISTRATION (2011) Inactive Ingredient Search for Approved 
Drug Products – Hypromellose [WWW] Available from: 
http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm [Accessed 04/11/11]. 
 
FOUAD, E.A., EL-BADRY, M., NEAU, S.H., ALANAZI, F.K. and ALSARRA, I.A. (2011) 
Technology evaluation: Kollicoat IR. Expert Opinion on Drug Delivery, 8 (5), pp. 693-
703. 
 
FOUGERA, E. and CO. (2005) Nystatin Suspension Prescribing Information. Mellville, 
New York. 
 
FU, Y., YANG, S., JEONG, S., KIMURA, S. and PARK, K. (2004) Orally Fast 
Disintegrating Tablets: Developments, Technologies, Taste-Masking and Clinical 
Studies. Critical Reviews in Therapeutic Drug Carrier Systems, 21 (6), pp. 433-475. 
 
FULLER, C.S., MACRAE, R.J., WALTHER, M. and CAMERON, R.E. (2001) 
Interactions in poly(ethylene oxide)-hydroxypropyl methylcellulose blends. Polymer, 42, 
pp. 9583-9592. 
 
GALINDO-RODRIGUEZ, S.A., ALLEMANN, E., FESSI, H. and DOELKER, E. (2005) 
Polymeric Nanoparticles for Oral Delivery of Drugs and Vaccines: A Critical Evaluation 
References  
 
227 
 
of In Vivo Studies. Critical Reviews in Therapeutic Drug Carrier Systems, 22 (5), pp. 
419-463. 
 
GERBINO, P.P. (2005) Topical Products. In: TROY, D.B. (ed.) Remington: The 
Science and Practice of Pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams and 
Wilkins, p. 1280. 
 
GHOSH, S. and COUPLAND, J.N. (2008) Factors affecting the freeze-thaw stability of 
emulsions. Food Hydrocolloids, 22, pp. 105-111. 
 
GOLE, D.J., LEVINSON, R.S., CARBONE, J. and DAVIES, J.D. Preparation of 
pharmaceutical and other matrix systems by solid-state dissolution. US5215756 
(1993).  
 
GOVENDER, T., STOLNIK, S., GARNETT, M.C., ILLUM, L. and DAVIS, S.S. (1999) 
PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of 
a water soluble drug. Journal of Controlled Release, 57 (2), pp. 171-185. 
 
GRAHAM, N.B., ZULFIQAR, M., NWACHUKU, N.E. and RASHID, A. (1990) 
Interaction of Poly(ethylene oxide) with Solvents: 4. Interaction of Water with 
Poly(ethylene oxide) crosslinked hydrogels. Polymer, 31, pp. 909-916. 
 
HAMLEN, S. and MACGREGOR, K. Patient Compliance Study – New Data Shows 
Drug Delivery Has Positive Impact on Patient Compliance. Drug Development and 
Delivery, 11 (7), pp. 30-33. 
 
HANS, M.L. and LOWMAN, A.M. (2002) Biodegradable nanoparticles for drug delivery 
and targeting. Current Opinion in Solid State and Materials Science, 6, pp. 319-327. 
 
HARRIS, J.M. (ed.) (1992) Poly(ethylene glycol) Chemistry: Biotechnical and 
Biomedical Applications. New York: Plenum Press. 
 
HE, X.; BARONE, M.R.; MARSAC, P.J. and SPERRY, D.C. (2008) Development of a 
rapidly dispersing tablet of a poorly wettable compound – formulation DOE and 
mechanistic study of effect of formulation excipients on wetting of celecoxib. 
International Journal of Pharmaceutics, 353, pp. 176-186. 
 
References  
 
228 
 
HOLM, P. and SLOT, L. (2009) Disintegrating loadable tablets. US Patent: 
20090186081. 
 
HOUWINK, R. and DE DECKER, H.K. (eds.) (1971) Elasticity, Plasticity and Structure 
of Matter. 3rd ed. London: Cambridge University Press. 
 
HUANG, Z.-Q.; XIE, X.-L.; CHEN, Y.; LU, J.-P. and TONG, Z.-F. (2008) Ball-milling 
treatment effect on physicochemical properties and features for cassava and maize 
starches. Competes Rendus Chimie, 11, pp. 73-79. 
 
ITIOLA, O.A. and PILPEL, N. (1991) Formulation effects on the Mechanical Properties 
of metronidazole tablets. Journal of Pharmacy and Pharmacology, 43, pp. 145-147. 
 
JAIN, R.A., RUDDY, S.B., CUMMING, K.I., CLANCY, M.J.A. and CODD, J.A. Rapidly 
disintegrating solid oral dosage form. US6316029 (2001). 
 
JOHNSON, E., CLARKE, A. and GREEN, R. (2002) Oral fast-dissolving compositions 
for dopamine agonists. US Patent: 20020156056. 
 
JOINT FORMULARY COMMITTEE (2003) British National Formulary. 45th ed. London: 
British Medical Association and the Royal Pharmaceutical Society of Great Britain. 
 
KEARNEY, P. (2003) The zydis oral fast-dissolving dosage form. In: RATHBONE, M., 
HADGRAFT, J. and ROBERTS, M. eds. Modified-release drug delivery technology. 
New York: Marcel Dekker, pp. 191-201. 
 
KELLY, J., D’CRUZ, G. and WRIGHT, D. (2009) A qualitative study of the problems 
surrounding medicine administration to patients with dysphagia. Dysphagia, 24, pp. 49-
56. 
 
KELLY, J., D’CRUZ, G. and WRIGHT, D. (2010) Patients with dysphagia: experiences 
of taking medication. Journal of Advanced Nursing, 66, pp. 82-91. 
 
KIM, A.I., AKERS, M.J. and NAIL, S.L. (1998) The physical state of mannitol after 
freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing 
cosolute. Journal of Pharmaceutical Sciences, 87 (8), pp. 931-935. 
 
References  
 
229 
 
KIM, M.S., KIM, J.S. and HWANG, S.J. (2010) Enhancement of wettability and 
dissolution properties of cilostazol using the supercritical antisolvent process: effect of 
various additives. Chemical & Pharmaceutical Bulletin, 58, pp. 230-233. 
 
KOCKISCH, S., REES, G.D., YOUNG, S.A., TSIBOUKLIS, J. and SMART, J.D. 
Polymeric microspheres for drug delivery to the oral cavity: An in vitro evaluation of 
mucoadhesive potential. Journal of Pharmaceutical Sciences, 92, pp. 1614-1623. 
 
KONDO, T. and SAWATARI, C. (1994) Intermolecular hydrogen bonding in 
cellulose/poly(ethylene oxide) blends: thermodynamic examination using 2,3-di-O- and 
6-O-methylcelluloses as cellulose model compounds. Polymer, 35 (20), pp. 4423-4428. 
 
KONDO, T., SAWATARI, C., MANLEY, R.S. and GRAY, D.G. (1994) Characterization 
of hydrogen bonding in cellulose-synthetic polymer blend systems with regioselectively 
substituted methylcellulose. Macromolecules, 27 (1), pp. 210-215. 
 
KRAMER, W. and INGLOTT, A. (1971) Some physical and chemical incompatibilities 
of drugs for i.v. administration. Drug Intelligence & Clinical Pharmacy, 5, pp. 211-228. 
 
KREUTER, J. (1996) Nanoparticles and microparticles for drug and vaccine delivery. 
Journal of Anatomy, 189, pp. 503-505. 
 
KUMARI, A., YADAV, S.K. and YADAV, S.C. (2010) Biodegradable polymeric 
nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75, 
pp. 1-18. 
 
KURIHARA, K., KITA, K., HIRAYAMA, K. and HARA, T. (1993) Dysphagia in 
Parkinson’s disease. Clinical Neurology, 33 (2), pp. 150-154. 
 
KUROYA, T. and INOUE, Y. (1992) Film applicable to oral mucosa and drug 
preparation comprising the same. US Patent: 5166233. 
 
LAFON, L. Galenic form for oral administration and its method of preparation by 
lyophilisation of an oil-in-water emulsion. US4616047 (1986).  
 
LAI, F., PINI, E., ANGIONI, G., MANCA, M.L., PERRICCI, J., SINICO, C. and FADDA, 
A.M. (2011) Nanocrystals as tool to improve piroxicam dissolution rate in novel orally 
References  
 
230 
 
disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 79, 
pp. 552-558. 
 
LEE, C.H., WOO, J.S. and CHANG, H.C. Rapidly disintegrating tablet and process for 
the manufacture thereof. US20020001617 (2002). 
 
LEFORT, R.; DE GUSSEME, A.; WILLART, J.-F.; DANEDE, F. and DESCAMPS, M. 
(2004) Solid state NMR and DSC methods for quantifying the amorphous content in 
solid dosage forms: an application to ball-milling of trehalose. International Journal of 
Pharmaceutics, 280, pp. 209-219. 
 
LEOPOLD, N.A. and KAGEL, M.C. (1996) Prepharyngeal dysphagia in Parkinson’s 
disease. Dysphagia, 11 (1), pp. 14-22. 
 
LI, H., WANG, H., WANG, M. and WANG, L. (2007) Orally distintegrating formulation 
and process for preparing the same. US Patent: 20070092564.  
 
LIN, W.; YAN, L.; MU, C.; LI, W.; ZHANG, M. and ZHU, Q. (2002) Effect of pH on 
gelatin self-association investigated by laser light scattering and atomic force 
microscopy. Polymer International, 51, pp. 233-238. 
 
LIVERSIDGE, G.G. and CUNDY, K.C. (1995) Particle size reduction for improvement 
of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of 
nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics, 125, 
pp. 91-97. 
 
LUND, W. (1994) Ed. The Pharmaceutical Codex, 12th ed.; Pharmaceutical Press: 
London, England, p.79. 
 
MACKENZIE, A.P. (1966) Basic principles of freeze-drying for pharmaceuticals. 
Bulletin of the Parenteral Drug Association, 20, pp. 101-130. 
 
MALLICK, S.; PATTNAIK, S.; SWAIN, K.; DE, P.K.; SAHA, A.; GHOSHAL, G. and 
MONDAL, A. (2008) Formation of physically stable amorphous phase of ibuprofen by 
solid state milling with kaolin. European Journal of Pharmaceutics and 
Biopharmaceutics, 68, pp. 346-351. 
 
References  
 
231 
 
MARVOLA, M., RAJANIEMI, M., MARTTILA, E., VAHERVUO, K. and SOTHMANN, A. 
(1983) Effect of Dosage Form and Formulation Factors on the Adherence of Drugs to 
the Esophagus. Journal of Pharmaceutical Sciences, 72 (9), pp. 1034-1036. 
 
MAXIMILIEN, J.S. (2011) Polyethylene Oxide [WWW] Medicines Complete – 
Pharmaceutical Excipients. Available from: 
http://www.medicinescomplete.com/mc/excipients/current/1001943596.htm [Accessed 
14/11/11]. 
 
MCCLEMENTS, D.J. (2004) Protein-stabilized emulsions. Current Opinion in Colloid & 
Interface Science, 9, pp. 305-313. 
 
MERISKO-LIVERSIDGE, E. (2002) Nanocrystals: Resolving Pharmaceutical 
Formulation Issues Associated with Poorly Water-Soluble Compounds in Particles. 
Orlando: Marcel Dekker. 
 
MIMURA, K., TAKEDA, Y. and KANADA, K. (2009) Oral disintegrating tablet having 
masked bitter taste and method for production thereof. US Patent: 20090311321. 
 
MIYAWAKI, O., NORIMATSU, Y., KUMAGAI, H., IRIMOTO, Y., KUMAGAI, H. and 
SAKURAI, H. (2003) Effect of water potential on sol-gel transition and intermolecular 
interaction of gelatin near the transition temperature. Biopolymers, 70 (4), pp. 482-491. 
 
MOHAMMED, A.R., ELSHAER, A.M., JONES, R.J., KHAN, S. and RUSSELL, C.A. 
(2011) Drug Bioavailability and Gene Profiling: Challenges and Opportunities for 
Pharmaceutics and Personalised Medicine. In: VIZIRIANAKIS, I.S. ed. Handbook of 
Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy. In 
Press.  
 
MULLER, R.H. and JUNGHANNS, J-U.A.H. (2006) Drug 
Nanocrystals/Nanosuspensions for the Delivery of Poorly Soluble Drugs. In: 
TORCHILIN, V.P. (ed.). Nanoparticulates as Drug Carriers. London: Imperial College 
Press, pp. 307-328. 
 
MUNDARGI, R.C., BABU, V.M., RANGASWAMY, V., PATEL, P. and AMINABHAVI, 
T.M. (2008) Nano/micro technologies for delivering macromolecular therapeutics using 
References  
 
232 
 
poly(D,L-lactide-co-glycolide) and its derivatives. Journal of Controlled Release, 125, 
pp. 193-209. 
 
MURRAY, O.J., GREEN, R., KEARNEY, P. and GROTHER, L.P. (2003) Fast 
dispersing dosage forms essentially free of mammalian gelatin. US Patent: 6509040. 
 
MYERS, G.L., BATTIST, G.E. and FUISZ, R.C. (1999) Apparatus for making rapidly-
dissolving dosage units. US Patent: 5871781. 
 
NAKABAYASHI, K., SHIMAMOTO, T. and MIMA, H. (1980) Stability of packaged solid 
dosage forms. I. Shelf-life prediction for packaged tablets liable to moisture damage. 
Chemical and Pharmaceutical Bulletin (Tokyo), 28 (4), pp. 1090-1098. 
 
NAKAMURA, F., OHTA, R., MACHIDA, Y. and NAGAI, T. (1996) In vitro and in vivo 
nasal mucoadhesion of some water-soluble polymers. International Journal of 
Pharmaceutics, 134, pp. 173-181. 
 
NESARIKAR, V.V. and NASSAR, M.N. (2007) Effect of cations and anions on glass 
transition temperatures in excipient solutions. Pharmaceutical Development and 
Technology, 12, pp. 259-264. 
 
NORTHROP, J.H. (1921) Comparative hydrolysis of gelatin by pepsin, trypsin, acid, 
and alkali. The Journal of General Physiology, 4, pp. 57-71. 
 
OHTA, M., YOSHIMOTO, H., SAITO, N., WATANABE, Y. and MORIMOTO, K. (2004) 
Amino acid-containing tablets quickly disintegrating in the oral cavity and process for 
producing the same. US Patent: 20040047904. 
 
OUALI, A. Fast-melt tablet and method of making same. (1998) US Patent: 5807577. 
 
PAYOT, V., CORDONIER, A.-C., MARQUIS, J., BUGNON, O., HERSBERGER, K.E., 
SCHNEIDER, M.-P. and ARNET, I. (2011) Prevalence of patient’s difficulties in 
swallowing solid SODF. International Journal of Clinical Pharmacology, 33, pp. 402.   
 
PELTONEN, L., AITTA, J., HYVONEN, S., KARJALAINEN, M. and HIRVONEN, J. 
(2004) Improved entrapment efficiency of hydrophilic drug substance during 
References  
 
233 
 
nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech, 5 (1), pp. 115-
120. 
 
PEPPAS, P.G., KAUFFMAN, C.A., ANDES, D., BENJAMIN, D.K., CALANDRA, T.F., 
EDWARDS, J.E., FILLER, S.G., FISHER, J.F., KULLBERG, B-J., OSTROSKY-
ZEICHNER, L., REBOLI, A.C., REX, J.H., WALSH, T.J. and SOBEL, J.D. (2009) 
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the 
Infectious Diseases Society of America. Clinical Infectious Diseases, 48 (5), pp. 503-
535. 
 
PIKAL, M.J. (1990a) Freeze-drying of proteins. Part I: process design. BioPharm, 3, 
pp. 14-26. 
 
PIKAL, M.J. (1990b) Freeze-drying of proteins. Part II: formulation selection. 
BioPharm, 3, pp. 26-30. 
 
PIKAL, M.J. and SHAH, S. (1990) The collapse temperature in freeze-drying: 
dependence on measurement methodology and rate of water removal from the glassy 
phase. International Journal of Pharmaceutics, 62, pp. 165-186. 
 
PICKAR, D., COHEN, R.M., JIMERSON, D.C., RAYMOND-LAKE, C. and MURPHY, 
D.L. (1981) Tyramine infusions and selective monoamine oxidase inhibitor treatment II. 
Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and 
plasma MHPG reduction. Psychopharmacology, 74, pp. 8-12. 
 
POLYPARADIGM (2006) Freeze-drying [WWW] Available from: 
en.wikipedia.org/wiki/Freeze-drying [Accessed 08/12/12]. 
 
QIAO, X., TANG, Z. and SUN, K. (2011) Plasticization of corn starch by polyol 
mixtures. Carbohydrate Polymers, 83 (2), pp. 659-664. 
 
RAMALHO, M.J.C. and  MULCHANDE, M.C. (2006) Fast water-dispersible 
domperidone tablets. US Patent: 20060051414. 
 
RAO, J.P. and GECKELER, K.E. (2011) Polymer nanoparticles: preparation 
techniques and size-control parameters. Progress in Polymer Science, 36, pp. 887-
913. 
References  
 
234 
 
 
REMON, J. and CORVELEYN, S. (2000) Freeze-dried disintegrating tablets. US 
Patent: 6010719. 
 
ROGERS, T.L. (2009) Hypromellose [WWW] Medicines Complete – Pharmaceutical 
Excipients. Available from: 
http://www.medicinescomplete.com/mc/excipients/current/1001939693.htm [Accessed 
14/11/11]. 
 
ROWE, R.C., SHESKEY, P.J. and QUINN, M.E. (2009) Eds. Handbook of 
Pharmaceutical Excipients, 6th ed.; Pharmaceutical Press: London, England. 
 
ROWE, R.C., SHESKEY, P.J., COOK, W.G. and FENTON, M.E. (eds.) (2012) 
Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press. 
 
SANGHAVI, N.M., KAMATH, P.R. and AMIN, D.S. (1990) Sustained release tablets of 
theophylline. Drug Development and Industrial Pharmacy, 16 (11), pp. 1843-1848. 
 
SASTRY, S.V.; NYSHADHAM, J.R. and FIX, J.A. (2000) Recent technological 
advances in oral drug delivery – a review. Pharmaceutical Science & Technology 
Today, 3, pp. 138-145. 
 
SATTAR, S.P., AHMED, M.S., MAJEED, F. and PETTY, F. (2004) Inert Medication 
Ingredients Causing Nonadherence Due to Religious Beliefs. The Annals of 
Pharmacotherapy, 38, pp. 621-624. 
 
SCHWARTZ, J.I., YEH, K.C., BERGER, M.L., TOMASKO, L., HOOVER, M.E., EBEL, 
D.L., STAUFFER, L.A., HAN, R. and BJORNSSON, T.D. (1995) Novel oral medication 
delivery system for famotidine. Journal of Clinical Pharmacology, 35, pp. 362-367. 
 
SEAGER, H. (1998) Drug delivery products and the Zydis fast dissolving dosage form. 
Journal of Pharmacy and Pharmacology, 50, pp. 375-383. 
 
SHEPPARD, S.E.; HOUCK, R.C. and DITTMAR, C. (1942) The sorption of soluble 
dyes by gelatin. The Journal of Physical Chemistry, 46, pp. 158-176. 
 
References  
 
235 
 
SHIMIZU, T., MORIMOTO, S. and TABATA, T. (2001) Orally disintegrable tablets. US 
Patent: 6328994. 
 
SIEPMANN, F., HOFFMANN, A., LECLERCQ, B., CARLIN, B. and SIEPMANN, J. 
(2007) How to adjust desired drug release patterns from ethylcellulose-coated dosage 
forms. Journal of Controlled Release, 119 (2), pp. 182-189. 
 
SINGER, C., WEINER, W.J. and SANCHEZ-RAMOS, J.R. (1992) Autonomic 
dysfunction in men with Parkinson’s disease. European Neurology, 32 (3), pp. 134-
140. 
 
SOPPIMATH, K.S, AMINABHAVI, T.J., KULKARNI, A.R. and RUDZINSKI, W.E. 
(2001) Biodegradable polymeric nanoparticles as drug delivery devices. Journal of 
Controlled Release, 70, pp. 1-20. 
 
SPEISER, P.P. (1998) Poorly Soluble Drugs, a Challenge in Drug Delivery. In: 
MULLER, R.H., BENITA, S. and BOHM, B. (eds.). Emulsions and Nanosuspensions 
for the Formulation of Poorly Soluble Drugs. Stuttgart: Medpharm Scientific Publishers. 
 
STANIFORTH, J. (2002) Powder flow. In Pharmaceutics: The Science of Dosage Form 
Design, 2nd ed.; AULTON, M.E., Ed.; Churchill Livingstone: Edinburgh, Scotland, pp. 
197-210. 
 
STEGEMANN, S., GOSCH, M. and BREITKREUTZ, J. (2012) Swallowing dysfunction 
and dysphagia is an unrecognised challenge for oral drug therapy. International 
Journal of Pharmaceutics, 430, pp. 197-206. 
 
STRACHAN, I. and GREENER, M. (2005) Medication related swallowing difficulties 
may be more common than we realize. Pharmacy in Practice, 15, pp. 411-414. 
 
SUNADA, H. and BI, Y. (2002) Preparation, evaluation and optimization of rapidly 
disintegrating tablets. Powder Technology, 122, pp. 188-198. 
 
TAKAISHI, Y., MIZUMOTO, T. and MASUDA, Y. (2005) Quick-disintegrating tablet in 
buccal cavity and manufacturing method thereof. US Patent: 6872405. 
 
References  
 
236 
 
TAKEI, T., KUROSAKI, K. NISHIMOTO, Y. and SUGITANI, Y. (2002) Behaviour of 
Bound Water in Polyethylene Oxide Studied by DSC and High-Frequency 
Spectroscopy. Analytical Sciences, 18, pp. 681-684. 
 
TANG, X. and PIKAL, M.J. (2004) Design of Freeze-Drying Processes for 
Pharmaceuticals: Practical Advice. Pharmaceutical Research, 21 (2), pp. 191-200. 
 
TIROSH, O., BARENHOLZ, Y., KATZHENDLER, J. and PRIEV, A. (1998) Hydration of 
Polyethylene Glycol-Grafted Liposomes. Biophysical Journal, 74, pp. 1371-1379. 
 
UEMURA, K., SUGIMOTO, M., TAKATSUKA, S. and KOMORI, T. (2009) Rapidly 
disintergrating tablet in oral cavity. US Patent: 20090136569. 
 
UNITED NATIONS DEPARTMENT OF ECONOMIC AND SOCIAL AFFAIRS (2011) 
World Population Prospects: The 2010 Revision. New York: United Nations. 
 
UNITED STATES PHARMACOPEIAL CONVENTION (2003) The United States 
Pharmacopeia, twenty-sixth revision: the National Formulary twenty-first edition. 
Rockville, MD: United States Pharmacopeial Convention, pp. 2814-2815.  
 
VAN EERDENBRUGH, B.; FROYEN, L.; MARTENS, J.A.; BLATON, N.; 
AUGUSTIJNS, P.; BREWSTER, M. and VAN DEN MOOTER, G. (2007) 
Characterization of physico-chemical properties and pharmaceutical performance of 
sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride 
prepared by media milling. International Journal of Pharmaceutics, 338, pp. 198-206. 
 
VISSAMSETTI, B., PAYNE, M. and PAYNE, S. (2012) Inadvertent prescription of 
gelatin-containing oral medication: its acceptability to patients. Postgraduate Medical 
Journal, 88, pp. 499-502. 
 
WAN, L.S.C. and PRASAD, K.P.P. (1989) Uptake of water by excipients in tablets. 
International Journal of Pharmaceutics, 50, pp. 147-153). 
 
WASHINGTON, N., WILSON, C.G., GREAVES, J.L., NORMAN, S. PEACH, J.M. and 
PUGH, K.A. (1989) A gamma scintigraphic study of gastric coating by Expidet, tablet 
and liquid formulations. International Journal of Pharmaceutics, 57, pp. 17-22. 
 
References  
 
237 
 
WEN, H. and PARK, K. (2010) eds. Oral Controlled Release Formulation Design and 
Drug Delivery – Theory to Practice. New Jersey: John Wiley & Sons. 
 
WIDMAIER, E. P., RAFF, H. and STRANG, K. T. (2011) Vander’s Human Physiology: 
The Mechanisms of Body Function. 12th ed. New York, USA: McGraw-Hill. 
 
WILSON, C.G., WASHINGTON, N., PEACH, J., MURRAY, G.R. and KENNERLEY, J. 
(1987) The behaviour of a fast-dissolving dosage form (Expidet) followed by γ-
scintigraphy. International Journal of Pharmaceutics, 40, pp. 119-123.   
 
XIAO, L., YU, Z-Y., YANG, C., ZHU, H-Y. and DU, Y-M. (2004) Swelling studies of 
chitosan-gelatin films cross-linked by sulfate. Wuhan University Journal of Natural 
Sciences, 9, pp. 247-251. 
 
YORK, P. (2007) Design of Dosage Forms. In: AULTON, M.E. (ed.) Aulton’s 
Pharmaceutics: The Design and Manufacture of Medicines. 3rd ed. Edinburgh: 
Churchill Livingstone Elsevier. 
 
YOUNG, S.A. and SMART, J.D. (1998) A novel in-vitro apparatus for evaluating the 
mucoadhesion of liquid and semi-solid formulations. Journal of Pharmacy and 
Pharmacology, 50 (Supplement), p. 167. 
 
ZAHRANI, E.M. and FATHI, M.H. (2009) The effect of high-energy ball milling 
parameters on the preparation and characterization of fluorapatite nanocrystalline 
powder. Ceramics International, 35, pp. 2311-2323. 
 
ZHANG, L. (2008) Strategies for local drug delivery targeting the oesophagus. 
Published thesis (PhD), Aston University. 
 
